User login
‘I’ve been abducted by aliens’
CASE: ’I’m not crazy’
Ms. S, age 55, presents for treatment because she is feeling depressed and anxious. Her symptoms include decreased concentration, intermittent irritability, hoarding, and difficulty starting and completing tasks. She also has chronic sleep difficulties that often keep her awake until dawn.
Fatigue, lack of focus, and poor comprehension and motivation have left her unemployed. She and her teenage daughter live with Ms. S’s elderly mother. Ms. S feels tremendous guilt because she cannot be the mother and daughter she wants to be.
Initially, I (PK) diagnose Ms. S with major depressive disorder and prescribe sertraline, 100 mg/d, which improves her mood and energy. However, her inability to stay organized results in her being “let go” from job training.
Ms. S reports similar difficulties in school as a child. I determine that she meets DSM-IV-TR criteria for attention-deficit/hyperactivity disorder (ADHD). Adding methylphenidate, 10 mg bid, improves her concentration and ability to complete tasks. It also reduces the impulsivity that has disrupted her relationships.
Despite a strong desire to normalize her sleep schedule, Ms. S continues to have difficulty falling asleep, so I add melatonin, 3 to 6 mg at bedtime. Her sleeping pattern is improved, but still variable. She also tries quetiapine, 25 mg at bedtime, but soon discontinues it due to intolerance.
As our rapport strengthens, Ms. S reveals that she has had multiple encounters with aliens beginning at age 3. Although she has not had an “alien experience” for about 5 years, she does not feel safe sleeping at night and instead sleeps during the day. Her efforts to stay awake at night strain her relationship with her mother.
The authors’ observations
Approximately 1% of the U.S. population report alien abduction experiences (AAE)—an umbrella term that includes alleged contact with aliens ranging from sightings to abductions.1 Patients rarely report AAE to mental health professionals. In our society, claiming to be an “abductee” implies that one might be insane. A survey of 398 Canadian students that assessed attitudes, beliefs, and experiences regarding alien abductions found that 79% of respondents believed they would have mostly negative consequences—such as being laughed at or socially isolated—if they claimed to have encountered aliens.1
Persons who have AAE may attend support groups of fellow “abductees” to accumulate behavior-consonant information (hearing other people’s abduction stories) and reduce dissonance by being surrounded by others who share a questionable belief.2 A survey of “abductees” found that 88% report at least some positive aspects of the experience, such as a sense of importance or feeling as though they were chosen to bridge communication between extraterrestrials and humans.3
- high levels of psychic energy
- self-sufficiency
- resourcefulness
- a tendency to question authority and to be exposed to situational conflicts.1
After Ms. S reveals her alien experiences, I reassure her in a nonjudgmental manner that we will explore her experiences and determine ways to help her cope with them.
HISTORY: Terrifying experiences
Ms. S elaborates on her alien experiences, relating a particularly terrifying example from her teen years. She was lying awake in bed, looking at the ceiling, where she saw a jeweled spider with a drill. As the spider descended from the ceiling and spread its legs, she recalled a noise like a dentist’s drill. As the spider neared her face, it grew larger and larger. Terrified, Ms. S was unable to scream for help or move anything except her eyes as the spider clamped its legs around her head and bored into her skull. She reported that although she could feel the drill go in, it wasn’t painful.
Other experiences included giving birth, undergoing examinations or probes, and communicating with aliens. Although she is very distressed by most memories, she feels she benefited from others. For example, as a child, Ms. S’s math skills improved dramatically after an AAE episode; she believes this was a gift from the aliens. Ms. S’s AAE memories are as vivid to her as memories of her college graduation. She had been reluctant to discuss these events with anyone outside her family out of fear of being perceived as “crazy.”
Ms. S says she was a shy child who had difficulty making friends. She was plagued with fatigue and worry about family members. She believed that aliens might attack her sisters and felt obligated to stay awake at night to protect them. Aside from alien experiences, Ms. S reports a happy childhood.
She has always been an avid reader. At age 8 or 9, after reading a book on alien abduction, she concluded that she had been abducted. Later, she joined a group of professed alien abductees. She feels accepted and validated by this group and has a forum for discussing her experiences without fear of ridicule or rejection.
Ms. S remains frightened by things that remind her of aliens. Although she wrote a summary of her alien experiences, she cannot draw a picture of an alien, and thoughts or images of the prototypical “grey” alien trigger panic. She also feels somewhat “different,” nervous, and distant from others.
The authors’ observations
Reviewing AAE literature led me to consider several diagnoses, including:
- psychosis
- seizures
- false memory (sexual abuse, trauma)
- narcolepsy
- sleep paralysis.
Electroencephalography (during drowsiness) revealed abnormal activity (occurrences of widely scattered bursts of nonspecific, round, sharply contoured slow waves in the left frontal region) only in the F7 electrode. In the absence of clinical symptoms and when found in a single lead, this is considered a normal variant.
Diagnostic testing ruled out hallucinosis related to seizures. I also ruled out false memory related to sexual abuse or trauma, which is commonly found in patients who present with AAE.
Collaborative information from relatives did not uncover a history of psychosis. She and family members reported, however, that Ms. S’s father and 1 sister had periodic sleep disturbances with associated hallucinations. I began to suspect sleep paralysis.
The authors’ observations
Full-body paralysis normally accompanies rapid eye movement (REM) sleep, which occurs several times a night.4 Sleep paralysis is a transient state that occurs when an individual becomes conscious of this immobility, typically while falling asleep or awakening.5 These experiences can be accompanied by hypnagogic (while falling asleep) or hypnopompic (while awakening) hallucinations. An estimated 30% of the population has had at least one sleep paralysis episode.6 In one study, 5% of sleep paralysis patients had episodes that were accompanied by hallucinations.7
Although individuals cannot make gross body movements during sleep paralysis, they can open their eyes and are able to report events that occurred around them during the episode.8 Patients interpret sleep paralysis experiences in subjective terms. Common descriptions include intense fear, breathing difficulties, feeling of bodily pressure—especially on the chest—and sensations of floating, flying, or falling (Table 1).7,9
During sleep paralysis episodes, individuals typically sense a threatening presence.6 Patients have reported beastly and demonic figures of doom: devils, demons, witches, aliens, and even cinematic villains such as Darth Vader and Freddy Kruger.6 Others have described this presence in terms of alien visitations or abductions.
Table 1
4 types of sleep paralysis-related hallucinations
Intruder | Vague sense of a threatening presence accompanied by visual, auditory, and tactile hallucinations—noises, footsteps, gibbering voices, humanoid apparitions, and sensation of being touched or grabbed |
Incubus | Breathing difficulties, feelings of suffocation, bodily pressure (particularly on the chest, as if someone were sitting or standing on it), pain, and thoughts of impending death |
Vestibular-motor | Sensations of floating (levitation), flying, and falling |
Other | Out-of-body experiences, autoscopy (seeing oneself from an external point), and fictive motor movements, ranging from simple arm movements to sitting up to apparent locomotion through the environment |
Source: References 7,9 |
A Harvard University study of 11 individuals who reported alien abductions found that all participants experienced a similar sequence of events:
- They suspected abduction after sleep episodes characterized by awakening, full-body paralysis, intense fear, and a feeling of a presence. Several reported tactile or visual sensations strikingly similar to descriptions of sleep paralysis, such as levitating, being touched, and seeing shadowy figures.
- They sought explanations for what they perceived as anomalous experiences.
- They “recovered” abduction memories in therapy (with the help of techniques such as hypnosis) or spontaneously (after reading books or seeing movies or television shows depicting similar episodes).4
Ms. S reported no daytime sleep attacks, cataplexy, or rapid onset of dreaming. Because her reported AAEs were spread out and the last occurred approximately 5 years ago, I decided against conducting a sleep study because it likely would be low yield and costly. I reached a diagnosis of sleep paralysis-familial type, chronic based on:
- an absence of organic or psychiatric dysfunction
- a familial pattern of sleep disturbances
- the temporal pattern and description of her symptoms (Table 2).11
Table 2
Diagnostic criteria for sleep paralysis
A. Patient complains of inability to move the trunk or limbs at sleep onset or upon awakening |
B. Brief episodes of partial or complete skeletal muscle paralysis |
C. Episodes can be associated with hypnagogic (preceding sleep) hallucinations or dreamlike mentation |
D. Polysomnographic monitoring demonstrates at least 1 of the following:
|
E. Symptoms are not associated with other medical or mental disorders, such as hysteria or hypokalemic paralysis |
Minimal criteria are A plus B plus E |
Note: If symptoms are associated with a familial history, the diagnosis is sleep paralysis-familial type. If symptoms are not associated with a familial history, the diagnosis is sleep paralysis-isolated type |
Severity criteria Mild: Moderate: >1 episode per month but Severe: ≥1 episode per week |
Duration criteria Acute: ≤1 month Subacute: >1 month but Chronic: ≥6 months |
REM: rapid eye movement |
Source: Reference 11 |
TREATMENT: Reassurance, therapy
Effective treatment for Ms. S required helping her to understand that an organic condition was the foundation of her experiences. I began by conveying the sleep paralysis diagnosis and my understanding of the occupational and personal consequences that this condition had had for her. I explained the physiology of sleep paralysis and that memories or hallucinations (dreamlike mentation) are preserved in an extremely vivid fashion because her eyes are open. I acknowledged the realistic character of her experiences and the resulting symptoms of posttraumatic stress disorder (PTSD).
I refer Ms. S to a therapist for psychotherapy. The therapist begins by using trauma informed techniques to address Ms. S’s PTSD. As she improves, her therapy evolves into a combination of narrative and supportive psychotherapy, and then family systems therapy to address issues with her daughter and mother.
In a follow-up visit 1 year after beginning treatment, Ms. S cites multiple improvements, with no recurrence of sleep paralysis episodes. She continues to take sertraline, which relieves her depression and anxiety, and methylphenidate to improve her attention and concentration. She has taken on more responsibility at home, cleaning, preparing meals, helping her daughter choose a college, and attending to her mother’s health issues. Ms. S still has difficulties with her sleep patterns, and her new psychiatrist is exploring the possibility of a bipolar component to her mood disorder.
The authors’ observations
Like other traumas, AAE can induce symptoms of acute or chronic PTSD. The various psychoses, personality disorders, and dissociative disorders that could account for abduction experiences are characterized by delusions, so conduct ongoing assessment for these conditions in patients who report AAE. However, evidence suggests that serious psychopathology is no more common among “abductees” than among the general population.12
Persons reporting AAE exhibit physiologic reactivity as profound as that of survivors of combat or sexual assault.13 This reactivity confirms that the emotional power of the memory is as evocative and problematic as the physiologic reactions attributable to genuine (documented) traumatic events. Because patients have difficulty differentiating these hallucinations from actual events, they experience emotional pain and suffering. Fifty-seven percent of sleep paralysis patients who report AAE attempt suicide.14
There are no FDA-approved medications for treating sleep paralysis. Pharmacotherapy can be used to address psychiatric symptoms such as the depression and anxiety Ms. S exhibited.
Related resources
- American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001:166-9.
- Cheyne JA. Sleep paralysis and associated hypnagogic and hypnopompic experiences. http://watarts.uwaterloo.ca/~acheyne/S_P.html.
- Methylphenidate • Ritalin
- Quetiapine • Seroquel
- Sertraline • Zoloft
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Patry AL, Pelletier LG. Extraterrestrial beliefs and experiences: an application of the theory of reasoned action. J Soc Psychol 2001;141(2):199-217.
2. Newman LS, Baumeister RF. Toward an explanation of the UFO abduction phenomenon: hypnotic elaboration, extraterrestrial sadomasochism, and spurious memories. Psychol Inq 1996;7(2):99-126.
3. Bader CD. Supernatural support groups: who are the UFO abductees and ritual-abuse survivors? J Sci Study Relig 2003;42(4):669-78.
4. Clancy SA, McNally RJ, Schacter DL, et al. Memory distortion in people reporting abduction by aliens. J Abnorm Psychol 2002;111(3):455-61.
5. Girard TA, Cheyne JA. Individual differences in lateralization of hallucinations associated with sleep paralysis. Laterality 2004;9(1):93-111.
6. Cheyne JA. The ominous numinous: sensed presence and “other” hallucinations. Journal of Consciousness Studies 2001;8(5-7):133-50.
7. Cheyne JA, Newby-Clark IR, Rueffer SD. Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res 1999;8:313-7.
8. Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn 1999;8(3):319-37.
9. Cheyne JA. Sleep paralysis and the structure of waking-nightmare hallucinations. Dreaming 2003;13(3):163-79.
10. Spanos NP, Cross PA, Dickson K, et al. Close encounters: an examination of UFO experiences. J Abnorm Psychol 1993;102(4):624-32.
11. American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine. 2001;166-9.
12. Holden KJ, French CC. Alien abduction experiences: some clues from neuropsychology and neuropsychiatry. Cognit Neuropsychiatry 2002;7(3):163-78.
13. McNally RJ. Applying biological data in forensic and policy arenas. Ann N Y Acad Sci 2006;1071:267-76.
14. Stone-Carmen J. A descriptive study of people reporting abduction by unidentified flying objects (UFOs). In: Pritchard A, Pritchard DE, Mack JE, et al, eds. Alien discussions: proceedings of the abduction study conference held at MIT. Cambridge, MA: North Cambridge Press; 1994:309-15
CASE: ’I’m not crazy’
Ms. S, age 55, presents for treatment because she is feeling depressed and anxious. Her symptoms include decreased concentration, intermittent irritability, hoarding, and difficulty starting and completing tasks. She also has chronic sleep difficulties that often keep her awake until dawn.
Fatigue, lack of focus, and poor comprehension and motivation have left her unemployed. She and her teenage daughter live with Ms. S’s elderly mother. Ms. S feels tremendous guilt because she cannot be the mother and daughter she wants to be.
Initially, I (PK) diagnose Ms. S with major depressive disorder and prescribe sertraline, 100 mg/d, which improves her mood and energy. However, her inability to stay organized results in her being “let go” from job training.
Ms. S reports similar difficulties in school as a child. I determine that she meets DSM-IV-TR criteria for attention-deficit/hyperactivity disorder (ADHD). Adding methylphenidate, 10 mg bid, improves her concentration and ability to complete tasks. It also reduces the impulsivity that has disrupted her relationships.
Despite a strong desire to normalize her sleep schedule, Ms. S continues to have difficulty falling asleep, so I add melatonin, 3 to 6 mg at bedtime. Her sleeping pattern is improved, but still variable. She also tries quetiapine, 25 mg at bedtime, but soon discontinues it due to intolerance.
As our rapport strengthens, Ms. S reveals that she has had multiple encounters with aliens beginning at age 3. Although she has not had an “alien experience” for about 5 years, she does not feel safe sleeping at night and instead sleeps during the day. Her efforts to stay awake at night strain her relationship with her mother.
The authors’ observations
Approximately 1% of the U.S. population report alien abduction experiences (AAE)—an umbrella term that includes alleged contact with aliens ranging from sightings to abductions.1 Patients rarely report AAE to mental health professionals. In our society, claiming to be an “abductee” implies that one might be insane. A survey of 398 Canadian students that assessed attitudes, beliefs, and experiences regarding alien abductions found that 79% of respondents believed they would have mostly negative consequences—such as being laughed at or socially isolated—if they claimed to have encountered aliens.1
Persons who have AAE may attend support groups of fellow “abductees” to accumulate behavior-consonant information (hearing other people’s abduction stories) and reduce dissonance by being surrounded by others who share a questionable belief.2 A survey of “abductees” found that 88% report at least some positive aspects of the experience, such as a sense of importance or feeling as though they were chosen to bridge communication between extraterrestrials and humans.3
- high levels of psychic energy
- self-sufficiency
- resourcefulness
- a tendency to question authority and to be exposed to situational conflicts.1
After Ms. S reveals her alien experiences, I reassure her in a nonjudgmental manner that we will explore her experiences and determine ways to help her cope with them.
HISTORY: Terrifying experiences
Ms. S elaborates on her alien experiences, relating a particularly terrifying example from her teen years. She was lying awake in bed, looking at the ceiling, where she saw a jeweled spider with a drill. As the spider descended from the ceiling and spread its legs, she recalled a noise like a dentist’s drill. As the spider neared her face, it grew larger and larger. Terrified, Ms. S was unable to scream for help or move anything except her eyes as the spider clamped its legs around her head and bored into her skull. She reported that although she could feel the drill go in, it wasn’t painful.
Other experiences included giving birth, undergoing examinations or probes, and communicating with aliens. Although she is very distressed by most memories, she feels she benefited from others. For example, as a child, Ms. S’s math skills improved dramatically after an AAE episode; she believes this was a gift from the aliens. Ms. S’s AAE memories are as vivid to her as memories of her college graduation. She had been reluctant to discuss these events with anyone outside her family out of fear of being perceived as “crazy.”
Ms. S says she was a shy child who had difficulty making friends. She was plagued with fatigue and worry about family members. She believed that aliens might attack her sisters and felt obligated to stay awake at night to protect them. Aside from alien experiences, Ms. S reports a happy childhood.
She has always been an avid reader. At age 8 or 9, after reading a book on alien abduction, she concluded that she had been abducted. Later, she joined a group of professed alien abductees. She feels accepted and validated by this group and has a forum for discussing her experiences without fear of ridicule or rejection.
Ms. S remains frightened by things that remind her of aliens. Although she wrote a summary of her alien experiences, she cannot draw a picture of an alien, and thoughts or images of the prototypical “grey” alien trigger panic. She also feels somewhat “different,” nervous, and distant from others.
The authors’ observations
Reviewing AAE literature led me to consider several diagnoses, including:
- psychosis
- seizures
- false memory (sexual abuse, trauma)
- narcolepsy
- sleep paralysis.
Electroencephalography (during drowsiness) revealed abnormal activity (occurrences of widely scattered bursts of nonspecific, round, sharply contoured slow waves in the left frontal region) only in the F7 electrode. In the absence of clinical symptoms and when found in a single lead, this is considered a normal variant.
Diagnostic testing ruled out hallucinosis related to seizures. I also ruled out false memory related to sexual abuse or trauma, which is commonly found in patients who present with AAE.
Collaborative information from relatives did not uncover a history of psychosis. She and family members reported, however, that Ms. S’s father and 1 sister had periodic sleep disturbances with associated hallucinations. I began to suspect sleep paralysis.
The authors’ observations
Full-body paralysis normally accompanies rapid eye movement (REM) sleep, which occurs several times a night.4 Sleep paralysis is a transient state that occurs when an individual becomes conscious of this immobility, typically while falling asleep or awakening.5 These experiences can be accompanied by hypnagogic (while falling asleep) or hypnopompic (while awakening) hallucinations. An estimated 30% of the population has had at least one sleep paralysis episode.6 In one study, 5% of sleep paralysis patients had episodes that were accompanied by hallucinations.7
Although individuals cannot make gross body movements during sleep paralysis, they can open their eyes and are able to report events that occurred around them during the episode.8 Patients interpret sleep paralysis experiences in subjective terms. Common descriptions include intense fear, breathing difficulties, feeling of bodily pressure—especially on the chest—and sensations of floating, flying, or falling (Table 1).7,9
During sleep paralysis episodes, individuals typically sense a threatening presence.6 Patients have reported beastly and demonic figures of doom: devils, demons, witches, aliens, and even cinematic villains such as Darth Vader and Freddy Kruger.6 Others have described this presence in terms of alien visitations or abductions.
Table 1
4 types of sleep paralysis-related hallucinations
Intruder | Vague sense of a threatening presence accompanied by visual, auditory, and tactile hallucinations—noises, footsteps, gibbering voices, humanoid apparitions, and sensation of being touched or grabbed |
Incubus | Breathing difficulties, feelings of suffocation, bodily pressure (particularly on the chest, as if someone were sitting or standing on it), pain, and thoughts of impending death |
Vestibular-motor | Sensations of floating (levitation), flying, and falling |
Other | Out-of-body experiences, autoscopy (seeing oneself from an external point), and fictive motor movements, ranging from simple arm movements to sitting up to apparent locomotion through the environment |
Source: References 7,9 |
A Harvard University study of 11 individuals who reported alien abductions found that all participants experienced a similar sequence of events:
- They suspected abduction after sleep episodes characterized by awakening, full-body paralysis, intense fear, and a feeling of a presence. Several reported tactile or visual sensations strikingly similar to descriptions of sleep paralysis, such as levitating, being touched, and seeing shadowy figures.
- They sought explanations for what they perceived as anomalous experiences.
- They “recovered” abduction memories in therapy (with the help of techniques such as hypnosis) or spontaneously (after reading books or seeing movies or television shows depicting similar episodes).4
Ms. S reported no daytime sleep attacks, cataplexy, or rapid onset of dreaming. Because her reported AAEs were spread out and the last occurred approximately 5 years ago, I decided against conducting a sleep study because it likely would be low yield and costly. I reached a diagnosis of sleep paralysis-familial type, chronic based on:
- an absence of organic or psychiatric dysfunction
- a familial pattern of sleep disturbances
- the temporal pattern and description of her symptoms (Table 2).11
Table 2
Diagnostic criteria for sleep paralysis
A. Patient complains of inability to move the trunk or limbs at sleep onset or upon awakening |
B. Brief episodes of partial or complete skeletal muscle paralysis |
C. Episodes can be associated with hypnagogic (preceding sleep) hallucinations or dreamlike mentation |
D. Polysomnographic monitoring demonstrates at least 1 of the following:
|
E. Symptoms are not associated with other medical or mental disorders, such as hysteria or hypokalemic paralysis |
Minimal criteria are A plus B plus E |
Note: If symptoms are associated with a familial history, the diagnosis is sleep paralysis-familial type. If symptoms are not associated with a familial history, the diagnosis is sleep paralysis-isolated type |
Severity criteria Mild: Moderate: >1 episode per month but Severe: ≥1 episode per week |
Duration criteria Acute: ≤1 month Subacute: >1 month but Chronic: ≥6 months |
REM: rapid eye movement |
Source: Reference 11 |
TREATMENT: Reassurance, therapy
Effective treatment for Ms. S required helping her to understand that an organic condition was the foundation of her experiences. I began by conveying the sleep paralysis diagnosis and my understanding of the occupational and personal consequences that this condition had had for her. I explained the physiology of sleep paralysis and that memories or hallucinations (dreamlike mentation) are preserved in an extremely vivid fashion because her eyes are open. I acknowledged the realistic character of her experiences and the resulting symptoms of posttraumatic stress disorder (PTSD).
I refer Ms. S to a therapist for psychotherapy. The therapist begins by using trauma informed techniques to address Ms. S’s PTSD. As she improves, her therapy evolves into a combination of narrative and supportive psychotherapy, and then family systems therapy to address issues with her daughter and mother.
In a follow-up visit 1 year after beginning treatment, Ms. S cites multiple improvements, with no recurrence of sleep paralysis episodes. She continues to take sertraline, which relieves her depression and anxiety, and methylphenidate to improve her attention and concentration. She has taken on more responsibility at home, cleaning, preparing meals, helping her daughter choose a college, and attending to her mother’s health issues. Ms. S still has difficulties with her sleep patterns, and her new psychiatrist is exploring the possibility of a bipolar component to her mood disorder.
The authors’ observations
Like other traumas, AAE can induce symptoms of acute or chronic PTSD. The various psychoses, personality disorders, and dissociative disorders that could account for abduction experiences are characterized by delusions, so conduct ongoing assessment for these conditions in patients who report AAE. However, evidence suggests that serious psychopathology is no more common among “abductees” than among the general population.12
Persons reporting AAE exhibit physiologic reactivity as profound as that of survivors of combat or sexual assault.13 This reactivity confirms that the emotional power of the memory is as evocative and problematic as the physiologic reactions attributable to genuine (documented) traumatic events. Because patients have difficulty differentiating these hallucinations from actual events, they experience emotional pain and suffering. Fifty-seven percent of sleep paralysis patients who report AAE attempt suicide.14
There are no FDA-approved medications for treating sleep paralysis. Pharmacotherapy can be used to address psychiatric symptoms such as the depression and anxiety Ms. S exhibited.
Related resources
- American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001:166-9.
- Cheyne JA. Sleep paralysis and associated hypnagogic and hypnopompic experiences. http://watarts.uwaterloo.ca/~acheyne/S_P.html.
- Methylphenidate • Ritalin
- Quetiapine • Seroquel
- Sertraline • Zoloft
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: ’I’m not crazy’
Ms. S, age 55, presents for treatment because she is feeling depressed and anxious. Her symptoms include decreased concentration, intermittent irritability, hoarding, and difficulty starting and completing tasks. She also has chronic sleep difficulties that often keep her awake until dawn.
Fatigue, lack of focus, and poor comprehension and motivation have left her unemployed. She and her teenage daughter live with Ms. S’s elderly mother. Ms. S feels tremendous guilt because she cannot be the mother and daughter she wants to be.
Initially, I (PK) diagnose Ms. S with major depressive disorder and prescribe sertraline, 100 mg/d, which improves her mood and energy. However, her inability to stay organized results in her being “let go” from job training.
Ms. S reports similar difficulties in school as a child. I determine that she meets DSM-IV-TR criteria for attention-deficit/hyperactivity disorder (ADHD). Adding methylphenidate, 10 mg bid, improves her concentration and ability to complete tasks. It also reduces the impulsivity that has disrupted her relationships.
Despite a strong desire to normalize her sleep schedule, Ms. S continues to have difficulty falling asleep, so I add melatonin, 3 to 6 mg at bedtime. Her sleeping pattern is improved, but still variable. She also tries quetiapine, 25 mg at bedtime, but soon discontinues it due to intolerance.
As our rapport strengthens, Ms. S reveals that she has had multiple encounters with aliens beginning at age 3. Although she has not had an “alien experience” for about 5 years, she does not feel safe sleeping at night and instead sleeps during the day. Her efforts to stay awake at night strain her relationship with her mother.
The authors’ observations
Approximately 1% of the U.S. population report alien abduction experiences (AAE)—an umbrella term that includes alleged contact with aliens ranging from sightings to abductions.1 Patients rarely report AAE to mental health professionals. In our society, claiming to be an “abductee” implies that one might be insane. A survey of 398 Canadian students that assessed attitudes, beliefs, and experiences regarding alien abductions found that 79% of respondents believed they would have mostly negative consequences—such as being laughed at or socially isolated—if they claimed to have encountered aliens.1
Persons who have AAE may attend support groups of fellow “abductees” to accumulate behavior-consonant information (hearing other people’s abduction stories) and reduce dissonance by being surrounded by others who share a questionable belief.2 A survey of “abductees” found that 88% report at least some positive aspects of the experience, such as a sense of importance or feeling as though they were chosen to bridge communication between extraterrestrials and humans.3
- high levels of psychic energy
- self-sufficiency
- resourcefulness
- a tendency to question authority and to be exposed to situational conflicts.1
After Ms. S reveals her alien experiences, I reassure her in a nonjudgmental manner that we will explore her experiences and determine ways to help her cope with them.
HISTORY: Terrifying experiences
Ms. S elaborates on her alien experiences, relating a particularly terrifying example from her teen years. She was lying awake in bed, looking at the ceiling, where she saw a jeweled spider with a drill. As the spider descended from the ceiling and spread its legs, she recalled a noise like a dentist’s drill. As the spider neared her face, it grew larger and larger. Terrified, Ms. S was unable to scream for help or move anything except her eyes as the spider clamped its legs around her head and bored into her skull. She reported that although she could feel the drill go in, it wasn’t painful.
Other experiences included giving birth, undergoing examinations or probes, and communicating with aliens. Although she is very distressed by most memories, she feels she benefited from others. For example, as a child, Ms. S’s math skills improved dramatically after an AAE episode; she believes this was a gift from the aliens. Ms. S’s AAE memories are as vivid to her as memories of her college graduation. She had been reluctant to discuss these events with anyone outside her family out of fear of being perceived as “crazy.”
Ms. S says she was a shy child who had difficulty making friends. She was plagued with fatigue and worry about family members. She believed that aliens might attack her sisters and felt obligated to stay awake at night to protect them. Aside from alien experiences, Ms. S reports a happy childhood.
She has always been an avid reader. At age 8 or 9, after reading a book on alien abduction, she concluded that she had been abducted. Later, she joined a group of professed alien abductees. She feels accepted and validated by this group and has a forum for discussing her experiences without fear of ridicule or rejection.
Ms. S remains frightened by things that remind her of aliens. Although she wrote a summary of her alien experiences, she cannot draw a picture of an alien, and thoughts or images of the prototypical “grey” alien trigger panic. She also feels somewhat “different,” nervous, and distant from others.
The authors’ observations
Reviewing AAE literature led me to consider several diagnoses, including:
- psychosis
- seizures
- false memory (sexual abuse, trauma)
- narcolepsy
- sleep paralysis.
Electroencephalography (during drowsiness) revealed abnormal activity (occurrences of widely scattered bursts of nonspecific, round, sharply contoured slow waves in the left frontal region) only in the F7 electrode. In the absence of clinical symptoms and when found in a single lead, this is considered a normal variant.
Diagnostic testing ruled out hallucinosis related to seizures. I also ruled out false memory related to sexual abuse or trauma, which is commonly found in patients who present with AAE.
Collaborative information from relatives did not uncover a history of psychosis. She and family members reported, however, that Ms. S’s father and 1 sister had periodic sleep disturbances with associated hallucinations. I began to suspect sleep paralysis.
The authors’ observations
Full-body paralysis normally accompanies rapid eye movement (REM) sleep, which occurs several times a night.4 Sleep paralysis is a transient state that occurs when an individual becomes conscious of this immobility, typically while falling asleep or awakening.5 These experiences can be accompanied by hypnagogic (while falling asleep) or hypnopompic (while awakening) hallucinations. An estimated 30% of the population has had at least one sleep paralysis episode.6 In one study, 5% of sleep paralysis patients had episodes that were accompanied by hallucinations.7
Although individuals cannot make gross body movements during sleep paralysis, they can open their eyes and are able to report events that occurred around them during the episode.8 Patients interpret sleep paralysis experiences in subjective terms. Common descriptions include intense fear, breathing difficulties, feeling of bodily pressure—especially on the chest—and sensations of floating, flying, or falling (Table 1).7,9
During sleep paralysis episodes, individuals typically sense a threatening presence.6 Patients have reported beastly and demonic figures of doom: devils, demons, witches, aliens, and even cinematic villains such as Darth Vader and Freddy Kruger.6 Others have described this presence in terms of alien visitations or abductions.
Table 1
4 types of sleep paralysis-related hallucinations
Intruder | Vague sense of a threatening presence accompanied by visual, auditory, and tactile hallucinations—noises, footsteps, gibbering voices, humanoid apparitions, and sensation of being touched or grabbed |
Incubus | Breathing difficulties, feelings of suffocation, bodily pressure (particularly on the chest, as if someone were sitting or standing on it), pain, and thoughts of impending death |
Vestibular-motor | Sensations of floating (levitation), flying, and falling |
Other | Out-of-body experiences, autoscopy (seeing oneself from an external point), and fictive motor movements, ranging from simple arm movements to sitting up to apparent locomotion through the environment |
Source: References 7,9 |
A Harvard University study of 11 individuals who reported alien abductions found that all participants experienced a similar sequence of events:
- They suspected abduction after sleep episodes characterized by awakening, full-body paralysis, intense fear, and a feeling of a presence. Several reported tactile or visual sensations strikingly similar to descriptions of sleep paralysis, such as levitating, being touched, and seeing shadowy figures.
- They sought explanations for what they perceived as anomalous experiences.
- They “recovered” abduction memories in therapy (with the help of techniques such as hypnosis) or spontaneously (after reading books or seeing movies or television shows depicting similar episodes).4
Ms. S reported no daytime sleep attacks, cataplexy, or rapid onset of dreaming. Because her reported AAEs were spread out and the last occurred approximately 5 years ago, I decided against conducting a sleep study because it likely would be low yield and costly. I reached a diagnosis of sleep paralysis-familial type, chronic based on:
- an absence of organic or psychiatric dysfunction
- a familial pattern of sleep disturbances
- the temporal pattern and description of her symptoms (Table 2).11
Table 2
Diagnostic criteria for sleep paralysis
A. Patient complains of inability to move the trunk or limbs at sleep onset or upon awakening |
B. Brief episodes of partial or complete skeletal muscle paralysis |
C. Episodes can be associated with hypnagogic (preceding sleep) hallucinations or dreamlike mentation |
D. Polysomnographic monitoring demonstrates at least 1 of the following:
|
E. Symptoms are not associated with other medical or mental disorders, such as hysteria or hypokalemic paralysis |
Minimal criteria are A plus B plus E |
Note: If symptoms are associated with a familial history, the diagnosis is sleep paralysis-familial type. If symptoms are not associated with a familial history, the diagnosis is sleep paralysis-isolated type |
Severity criteria Mild: Moderate: >1 episode per month but Severe: ≥1 episode per week |
Duration criteria Acute: ≤1 month Subacute: >1 month but Chronic: ≥6 months |
REM: rapid eye movement |
Source: Reference 11 |
TREATMENT: Reassurance, therapy
Effective treatment for Ms. S required helping her to understand that an organic condition was the foundation of her experiences. I began by conveying the sleep paralysis diagnosis and my understanding of the occupational and personal consequences that this condition had had for her. I explained the physiology of sleep paralysis and that memories or hallucinations (dreamlike mentation) are preserved in an extremely vivid fashion because her eyes are open. I acknowledged the realistic character of her experiences and the resulting symptoms of posttraumatic stress disorder (PTSD).
I refer Ms. S to a therapist for psychotherapy. The therapist begins by using trauma informed techniques to address Ms. S’s PTSD. As she improves, her therapy evolves into a combination of narrative and supportive psychotherapy, and then family systems therapy to address issues with her daughter and mother.
In a follow-up visit 1 year after beginning treatment, Ms. S cites multiple improvements, with no recurrence of sleep paralysis episodes. She continues to take sertraline, which relieves her depression and anxiety, and methylphenidate to improve her attention and concentration. She has taken on more responsibility at home, cleaning, preparing meals, helping her daughter choose a college, and attending to her mother’s health issues. Ms. S still has difficulties with her sleep patterns, and her new psychiatrist is exploring the possibility of a bipolar component to her mood disorder.
The authors’ observations
Like other traumas, AAE can induce symptoms of acute or chronic PTSD. The various psychoses, personality disorders, and dissociative disorders that could account for abduction experiences are characterized by delusions, so conduct ongoing assessment for these conditions in patients who report AAE. However, evidence suggests that serious psychopathology is no more common among “abductees” than among the general population.12
Persons reporting AAE exhibit physiologic reactivity as profound as that of survivors of combat or sexual assault.13 This reactivity confirms that the emotional power of the memory is as evocative and problematic as the physiologic reactions attributable to genuine (documented) traumatic events. Because patients have difficulty differentiating these hallucinations from actual events, they experience emotional pain and suffering. Fifty-seven percent of sleep paralysis patients who report AAE attempt suicide.14
There are no FDA-approved medications for treating sleep paralysis. Pharmacotherapy can be used to address psychiatric symptoms such as the depression and anxiety Ms. S exhibited.
Related resources
- American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001:166-9.
- Cheyne JA. Sleep paralysis and associated hypnagogic and hypnopompic experiences. http://watarts.uwaterloo.ca/~acheyne/S_P.html.
- Methylphenidate • Ritalin
- Quetiapine • Seroquel
- Sertraline • Zoloft
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Patry AL, Pelletier LG. Extraterrestrial beliefs and experiences: an application of the theory of reasoned action. J Soc Psychol 2001;141(2):199-217.
2. Newman LS, Baumeister RF. Toward an explanation of the UFO abduction phenomenon: hypnotic elaboration, extraterrestrial sadomasochism, and spurious memories. Psychol Inq 1996;7(2):99-126.
3. Bader CD. Supernatural support groups: who are the UFO abductees and ritual-abuse survivors? J Sci Study Relig 2003;42(4):669-78.
4. Clancy SA, McNally RJ, Schacter DL, et al. Memory distortion in people reporting abduction by aliens. J Abnorm Psychol 2002;111(3):455-61.
5. Girard TA, Cheyne JA. Individual differences in lateralization of hallucinations associated with sleep paralysis. Laterality 2004;9(1):93-111.
6. Cheyne JA. The ominous numinous: sensed presence and “other” hallucinations. Journal of Consciousness Studies 2001;8(5-7):133-50.
7. Cheyne JA, Newby-Clark IR, Rueffer SD. Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res 1999;8:313-7.
8. Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn 1999;8(3):319-37.
9. Cheyne JA. Sleep paralysis and the structure of waking-nightmare hallucinations. Dreaming 2003;13(3):163-79.
10. Spanos NP, Cross PA, Dickson K, et al. Close encounters: an examination of UFO experiences. J Abnorm Psychol 1993;102(4):624-32.
11. American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine. 2001;166-9.
12. Holden KJ, French CC. Alien abduction experiences: some clues from neuropsychology and neuropsychiatry. Cognit Neuropsychiatry 2002;7(3):163-78.
13. McNally RJ. Applying biological data in forensic and policy arenas. Ann N Y Acad Sci 2006;1071:267-76.
14. Stone-Carmen J. A descriptive study of people reporting abduction by unidentified flying objects (UFOs). In: Pritchard A, Pritchard DE, Mack JE, et al, eds. Alien discussions: proceedings of the abduction study conference held at MIT. Cambridge, MA: North Cambridge Press; 1994:309-15
1. Patry AL, Pelletier LG. Extraterrestrial beliefs and experiences: an application of the theory of reasoned action. J Soc Psychol 2001;141(2):199-217.
2. Newman LS, Baumeister RF. Toward an explanation of the UFO abduction phenomenon: hypnotic elaboration, extraterrestrial sadomasochism, and spurious memories. Psychol Inq 1996;7(2):99-126.
3. Bader CD. Supernatural support groups: who are the UFO abductees and ritual-abuse survivors? J Sci Study Relig 2003;42(4):669-78.
4. Clancy SA, McNally RJ, Schacter DL, et al. Memory distortion in people reporting abduction by aliens. J Abnorm Psychol 2002;111(3):455-61.
5. Girard TA, Cheyne JA. Individual differences in lateralization of hallucinations associated with sleep paralysis. Laterality 2004;9(1):93-111.
6. Cheyne JA. The ominous numinous: sensed presence and “other” hallucinations. Journal of Consciousness Studies 2001;8(5-7):133-50.
7. Cheyne JA, Newby-Clark IR, Rueffer SD. Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res 1999;8:313-7.
8. Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn 1999;8(3):319-37.
9. Cheyne JA. Sleep paralysis and the structure of waking-nightmare hallucinations. Dreaming 2003;13(3):163-79.
10. Spanos NP, Cross PA, Dickson K, et al. Close encounters: an examination of UFO experiences. J Abnorm Psychol 1993;102(4):624-32.
11. American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine. 2001;166-9.
12. Holden KJ, French CC. Alien abduction experiences: some clues from neuropsychology and neuropsychiatry. Cognit Neuropsychiatry 2002;7(3):163-78.
13. McNally RJ. Applying biological data in forensic and policy arenas. Ann N Y Acad Sci 2006;1071:267-76.
14. Stone-Carmen J. A descriptive study of people reporting abduction by unidentified flying objects (UFOs). In: Pritchard A, Pritchard DE, Mack JE, et al, eds. Alien discussions: proceedings of the abduction study conference held at MIT. Cambridge, MA: North Cambridge Press; 1994:309-15
The patient who ‘spilled salt’
HISTORY: ‘They’re out to get me’
Mrs. V, age 64, tells her primary care physician she has felt “bad” for 2 weeks. She complains of depressed mood, middle insomnia, diminished appetite, poor concentration, and poor energy. She denies suicidal thoughts but reports feeling alone, overwhelmed, and unable to manage her daily life.
Mrs. V is very concerned about losing her job because she cannot function at work. She believes her coworkers may be plotting to get her fired. The primary care physician refers Mrs. V to us to evaluate her mood.
According to her daughter, Mrs. V has had multiple psychiatric hospitalizations; the most recent occurred 2 years ago when she was admitted for paranoia and disorganized behavior. The daughter also mentions that her mother has a remote history of daily alcohol use, drinking until she was intoxicated. Mrs. V says she occasionally drinks beer and she scores 2 out of 4 on the CAGE questionnaire, which may indicate alcohol dependence.
During mental status examination, Mrs. V is alert and oriented to person, place, and date. She is pleasant and cooperative but shows apparent thought blocking and some tangentiality. She has substantial difficulty answering questions and articulating symptoms. Speech is slow in rate and rhythm. Mrs. V’s mood is severely depressed and her affect constricted.
She denies suicidal or homicidal ideations or visual or auditory hallucinations. Cognitive testing reveals mild deficits in recall memory and poor concentration. Her insight is limited and her judgment fair.
Her medical history includes hypertension, hyperlipidemia, coronary artery disease, cardiac catheterization, and hyponatremia. Her medication regimen consists of aripiprazole, 15 mg/d; diltiazem, 180 mg/d; atenolol, 25 mg/d; aspirin, 325 mg/d; atorvastatin, 10 mg/d; sertraline, 50 mg/d; and ibuprofen, 600 mg as needed for hip pain. She also reports taking diuretics in the past.
Vital signs include blood pressure, 125/95 mm Hg; respirations, 16/min; temperature, 98.2° F; and pulse rate, 72/min. Serum investigations reveal sodium, 119 mEq/L (normal range: 135 to 145 mEq/L) and random blood sugar, 160 mg/dL (normal range: 60 to 114 mg/dL).
The authors’ observations
The combination of major depression with psychosis and hyponatremia makes Mrs. V’s case challenging. Hyponatremia in psychiatric inpatients can prompt medical consultation, thus possibly halting or delaying psychiatric treatment.
Hyponatremia has been associated with the use of:
- diuretics
- selective serotonin reuptake inhibitors (SSRIs)
- serotonin-norepinephrine reuptake inhibitors (SNRIs)
- tricyclic antidepressants
- calcium antagonists.
Among psychiatric inpatients, the risk of hyponatremia is doubled in women.1 It is unclear, however, if female gender is an independent risk factor for hyponatremia. Sharabi et al2 reported that patients of both sexes age >65 have a 9-fold greater risk of developing hyponatremia than younger counterparts.
In addition, hyponatremia risk during any antidepressant treatment is highest:
- in the summer
- during the first weeks of treatment
- with concomitant drug use, especially with diuretics.3
The authors’ observations
Based on Mrs. V’s initial lab results (Table 1), we classify her hyponatremia as euvolemic, with high urine osmolarity (≥100 mOsm/L). That helps narrow our differential diagnosis to glucocorticoid deficiency, hypothyroidism, and SIADH (Table 2).5 We exclude psychogenic polydipsia, “tea and toast” syndrome, or beer potomania because they usually present as euvolemic hyponatremia with low urinary osmolality.
SSRI use in elderly persons has been associated with hyponatremia, which in some cases may be consistent with SIADH. Unfortunately, few psychiatrists are aware of this potentially fatal side effect.
SIADH occurs in association with reduced serum osmolality. It is characterized by:
- hypotonic hyponatremia (serum sodium
- inappropriately elevated urine osmolarity (>200 mOsm/L) relative to plasma osmolarity
- elevated urine sodium (typically >20 mEq/L).4
The key to the pathophysiology, signs, symptoms, and treatment of SIADH is understanding that the hyponatremia is a result of excess water and not a sodium deficiency. Hyponatremia’s signs and symptoms primarily are related to CNS dysfunction and correlate with how rapidly and severely the condition develops.
We monitor Mrs. V for anorexia, nausea, and malaise because they would be the earliest findings, followed by headache, irritability, confusion, muscle cramps, weakness, obtundation, seizures, and coma. These occur as osmotic fluid shifts and results in cerebral edema and increased intracranial pressure. When sodium concentration drops below 105 mEq/L, life-threatening complications are likely.
Table 1
Mrs. V’s laboratory results
Mrs. V’s results | |||
---|---|---|---|
Normal range | Before Tx | After Tx | |
Serum sodium (mEq/L) | 135 to 145 | 119 | 127 |
Serum potassium (mEq/L) | 3.5 to 5.0 | 3.6 | 3.8 |
Creatinine (mg/dL) | 0.5 to 1.7 | 0.74 | 0.84 |
Glucose (mg/dL) | 60 to 114 | 160 | 150 |
Osmolarity | |||
Serum (measured; mOsm/L) | 275 to 300 | 258 | 242 |
Urine (mOsm/L) | 257 | 180 | |
Urine sodium (mEq/L) | 20 to 40 | 48 | 42 |
Mrs. V’s laboratory results
Hypovolemic hyponatremia | Euvolemic hyponatremia | Hypervolemic hyponatremia |
---|---|---|
Vomiting Diarrhea Laxative abuse Renal disease Nasogastric suction Salt-wasting nephropathy Addison’s disease | Normal urinary sodium Glucocorticoid deficiency Hypothyroidism Certain drugs SIADH | Congestive heart failure Nephrotic syndrome Cirrhosis |
Low urinary osmolality Psychogenic polydipsia ‘Tea and toast’ syndrome Beer potomania | ||
SIADH: syndrome of inappropriate antidiuretic hormone | ||
Source: Reference 5 |
SSRIs and SIADH
Bouman et al6 estimated that the incidence of SSRI-induced SIADH in elderly patients is 12%. Liu et al7 described 706 cases of hyponatremia associated with SSRI use in unpublished reports. Fluoxetine was most commonly the cause (75.3% cases), followed by paroxetine (12.4%), sertraline (11.7%), and fluvoxamine (1.5%). Resuming the same drug resulted in hyponatremia in 16 of 24 of these cases (66.7%).
Kirby et al,8 however, found no clear advantages in different SSRIs’ propensity to cause hyponatremia. Seventy-one percent of patients treated with the SNRI venlafaxine developed hyponatremia, compared with 32% taking paroxetine and 29% receiving sertraline. It is unclear whether a specific SSRI or venlafaxine has a stronger association with hyponatremia than any other antidepressant.
Hyponatremia’s nonspecific symptoms and wide range of time to detection (1 to 253 days) suggest clinicians usually detect the condition by chance rather than specifically assessing for it.9
TREATMENT: Medication change?
Coordinating Mrs. V’s depression and hyponatremia treatment is critical. We propose discontinuing sertraline and treating Mrs. V’s symptoms with electroconvulsive therapy (ECT). She refuses ECT, stating “I don’t feel that bad. My father was treated with ECT and I am scared of it.”
The authors’ observations
SSRI-induced hyponatremia can be transient or persistent and recurrent. The usual approach is to discontinue the SSRI and try a different antidepressant. Because hyponatremia has been associated with all SSRIs and SNRIs, it would be prudent to choose an alternate antidepressant agent outside these classes. If patients must continue taking an antidepressant that causes hyponatremia, avoid concurrent use of drugs that cause hyponatremia, restrict fluid intake, and consider adding a medication that prevents hyponatremia, such as demeclocycline or fludrocortisone.
SSRI-induced hyponatremia may resolve:
- with SSRI discontinuation alone11
- with fluid restriction and without discontinuation of the SSRI11
- with drug discontinuation, fluid restriction, and sodium chloride and potassium supplementation.12
FOLLOW-UP: Analysis error?
Despite modifications to Mrs. V’s diet, her fasting serum glucose level remains >100. She is diagnosed with diabetes mellitus type 2 and treated with metformin. We continue mirtazapine, which has successfully controlled Mrs. V’s depressive symptoms. Her serum sodium levels start normalizing.
The authors’ observations
Related resources
- Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008;16(1):13-24.
- Atalay A, Turhan N, Aki OE. A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J 2007;100(8):832-3.
- Aripiprazole • Abilify
- Atenolol • Tenormin
- Atorvastatin • Lipitor
- Demeclocycline • Declomycin, Declostatin, others
- Diltiazem • Cardizem, Dilacor, others
- Fludrocortisone • Florinef
- Fluvoxamine • Luvox
- Ibuprofen • Advil, Motrin, others
- Metformin • Glucophage, Diabex, others
- Mirtazapine • Remeron
- Paroxetine • Paxil
- Sertraline • Zoloft
- Venlafaxine • Effexor
Disclosures
Dr. Romanowicz reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Ramaswamy receives research support from Bristol-Myers Squibb, Shire, and Forest Pharmaceuticals and is a consultant to Dainippon Sumitomo Pharma.
Dr. Wilson receives research support from the National Institute of Mental Health, the Veterans Administration, the State of Nebraska, Health Futures Foundation, Inc., AstraZeneca, Dainippon Sumitomo Pharma, Eli Lilly and Company, and Pfizer Inc. and serves as a consultant to the Substance Abuse and Mental Health Services Administration and the State of Nebraska.
Reference
1. Siegler EL, Tamres D, Berlin JA, et al. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155(9):953-7.
2. Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 2002;16(9):631-5.
3. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327(2):109-11.
4. Buff DD, Markowitz S. Hyponatremia in the psychiatric patient: a review of diagnostic and management strategies. Psychiatr Ann 2003;33(5):318-25.
5. Levitan A. Hyponatremia: how to recognize the cause promptly—and avoid treatment pitfalls. Consultant 2003;43(7):861-70.
6. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998;13(1):12-5
7. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996;155(5):519-27
8. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001;16(5):484-93
9. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998;12(4):396-400.
10. Jagsch C, Marksteiner J, Seiringer E, Windhager E. Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion. Pharmacopsychiatry 2007;40(3):129-31.
11. Bigaillon C, El Jahiri Y, Garcia C, et al. Inappropriate ADH secretion-induced hyponatremia and associated with paroxetine use. Rev Med Interne 2007;28(9):642-4.
12. Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 1993;27(6):723-4.
HISTORY: ‘They’re out to get me’
Mrs. V, age 64, tells her primary care physician she has felt “bad” for 2 weeks. She complains of depressed mood, middle insomnia, diminished appetite, poor concentration, and poor energy. She denies suicidal thoughts but reports feeling alone, overwhelmed, and unable to manage her daily life.
Mrs. V is very concerned about losing her job because she cannot function at work. She believes her coworkers may be plotting to get her fired. The primary care physician refers Mrs. V to us to evaluate her mood.
According to her daughter, Mrs. V has had multiple psychiatric hospitalizations; the most recent occurred 2 years ago when she was admitted for paranoia and disorganized behavior. The daughter also mentions that her mother has a remote history of daily alcohol use, drinking until she was intoxicated. Mrs. V says she occasionally drinks beer and she scores 2 out of 4 on the CAGE questionnaire, which may indicate alcohol dependence.
During mental status examination, Mrs. V is alert and oriented to person, place, and date. She is pleasant and cooperative but shows apparent thought blocking and some tangentiality. She has substantial difficulty answering questions and articulating symptoms. Speech is slow in rate and rhythm. Mrs. V’s mood is severely depressed and her affect constricted.
She denies suicidal or homicidal ideations or visual or auditory hallucinations. Cognitive testing reveals mild deficits in recall memory and poor concentration. Her insight is limited and her judgment fair.
Her medical history includes hypertension, hyperlipidemia, coronary artery disease, cardiac catheterization, and hyponatremia. Her medication regimen consists of aripiprazole, 15 mg/d; diltiazem, 180 mg/d; atenolol, 25 mg/d; aspirin, 325 mg/d; atorvastatin, 10 mg/d; sertraline, 50 mg/d; and ibuprofen, 600 mg as needed for hip pain. She also reports taking diuretics in the past.
Vital signs include blood pressure, 125/95 mm Hg; respirations, 16/min; temperature, 98.2° F; and pulse rate, 72/min. Serum investigations reveal sodium, 119 mEq/L (normal range: 135 to 145 mEq/L) and random blood sugar, 160 mg/dL (normal range: 60 to 114 mg/dL).
The authors’ observations
The combination of major depression with psychosis and hyponatremia makes Mrs. V’s case challenging. Hyponatremia in psychiatric inpatients can prompt medical consultation, thus possibly halting or delaying psychiatric treatment.
Hyponatremia has been associated with the use of:
- diuretics
- selective serotonin reuptake inhibitors (SSRIs)
- serotonin-norepinephrine reuptake inhibitors (SNRIs)
- tricyclic antidepressants
- calcium antagonists.
Among psychiatric inpatients, the risk of hyponatremia is doubled in women.1 It is unclear, however, if female gender is an independent risk factor for hyponatremia. Sharabi et al2 reported that patients of both sexes age >65 have a 9-fold greater risk of developing hyponatremia than younger counterparts.
In addition, hyponatremia risk during any antidepressant treatment is highest:
- in the summer
- during the first weeks of treatment
- with concomitant drug use, especially with diuretics.3
The authors’ observations
Based on Mrs. V’s initial lab results (Table 1), we classify her hyponatremia as euvolemic, with high urine osmolarity (≥100 mOsm/L). That helps narrow our differential diagnosis to glucocorticoid deficiency, hypothyroidism, and SIADH (Table 2).5 We exclude psychogenic polydipsia, “tea and toast” syndrome, or beer potomania because they usually present as euvolemic hyponatremia with low urinary osmolality.
SSRI use in elderly persons has been associated with hyponatremia, which in some cases may be consistent with SIADH. Unfortunately, few psychiatrists are aware of this potentially fatal side effect.
SIADH occurs in association with reduced serum osmolality. It is characterized by:
- hypotonic hyponatremia (serum sodium
- inappropriately elevated urine osmolarity (>200 mOsm/L) relative to plasma osmolarity
- elevated urine sodium (typically >20 mEq/L).4
The key to the pathophysiology, signs, symptoms, and treatment of SIADH is understanding that the hyponatremia is a result of excess water and not a sodium deficiency. Hyponatremia’s signs and symptoms primarily are related to CNS dysfunction and correlate with how rapidly and severely the condition develops.
We monitor Mrs. V for anorexia, nausea, and malaise because they would be the earliest findings, followed by headache, irritability, confusion, muscle cramps, weakness, obtundation, seizures, and coma. These occur as osmotic fluid shifts and results in cerebral edema and increased intracranial pressure. When sodium concentration drops below 105 mEq/L, life-threatening complications are likely.
Table 1
Mrs. V’s laboratory results
Mrs. V’s results | |||
---|---|---|---|
Normal range | Before Tx | After Tx | |
Serum sodium (mEq/L) | 135 to 145 | 119 | 127 |
Serum potassium (mEq/L) | 3.5 to 5.0 | 3.6 | 3.8 |
Creatinine (mg/dL) | 0.5 to 1.7 | 0.74 | 0.84 |
Glucose (mg/dL) | 60 to 114 | 160 | 150 |
Osmolarity | |||
Serum (measured; mOsm/L) | 275 to 300 | 258 | 242 |
Urine (mOsm/L) | 257 | 180 | |
Urine sodium (mEq/L) | 20 to 40 | 48 | 42 |
Mrs. V’s laboratory results
Hypovolemic hyponatremia | Euvolemic hyponatremia | Hypervolemic hyponatremia |
---|---|---|
Vomiting Diarrhea Laxative abuse Renal disease Nasogastric suction Salt-wasting nephropathy Addison’s disease | Normal urinary sodium Glucocorticoid deficiency Hypothyroidism Certain drugs SIADH | Congestive heart failure Nephrotic syndrome Cirrhosis |
Low urinary osmolality Psychogenic polydipsia ‘Tea and toast’ syndrome Beer potomania | ||
SIADH: syndrome of inappropriate antidiuretic hormone | ||
Source: Reference 5 |
SSRIs and SIADH
Bouman et al6 estimated that the incidence of SSRI-induced SIADH in elderly patients is 12%. Liu et al7 described 706 cases of hyponatremia associated with SSRI use in unpublished reports. Fluoxetine was most commonly the cause (75.3% cases), followed by paroxetine (12.4%), sertraline (11.7%), and fluvoxamine (1.5%). Resuming the same drug resulted in hyponatremia in 16 of 24 of these cases (66.7%).
Kirby et al,8 however, found no clear advantages in different SSRIs’ propensity to cause hyponatremia. Seventy-one percent of patients treated with the SNRI venlafaxine developed hyponatremia, compared with 32% taking paroxetine and 29% receiving sertraline. It is unclear whether a specific SSRI or venlafaxine has a stronger association with hyponatremia than any other antidepressant.
Hyponatremia’s nonspecific symptoms and wide range of time to detection (1 to 253 days) suggest clinicians usually detect the condition by chance rather than specifically assessing for it.9
TREATMENT: Medication change?
Coordinating Mrs. V’s depression and hyponatremia treatment is critical. We propose discontinuing sertraline and treating Mrs. V’s symptoms with electroconvulsive therapy (ECT). She refuses ECT, stating “I don’t feel that bad. My father was treated with ECT and I am scared of it.”
The authors’ observations
SSRI-induced hyponatremia can be transient or persistent and recurrent. The usual approach is to discontinue the SSRI and try a different antidepressant. Because hyponatremia has been associated with all SSRIs and SNRIs, it would be prudent to choose an alternate antidepressant agent outside these classes. If patients must continue taking an antidepressant that causes hyponatremia, avoid concurrent use of drugs that cause hyponatremia, restrict fluid intake, and consider adding a medication that prevents hyponatremia, such as demeclocycline or fludrocortisone.
SSRI-induced hyponatremia may resolve:
- with SSRI discontinuation alone11
- with fluid restriction and without discontinuation of the SSRI11
- with drug discontinuation, fluid restriction, and sodium chloride and potassium supplementation.12
FOLLOW-UP: Analysis error?
Despite modifications to Mrs. V’s diet, her fasting serum glucose level remains >100. She is diagnosed with diabetes mellitus type 2 and treated with metformin. We continue mirtazapine, which has successfully controlled Mrs. V’s depressive symptoms. Her serum sodium levels start normalizing.
The authors’ observations
Related resources
- Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008;16(1):13-24.
- Atalay A, Turhan N, Aki OE. A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J 2007;100(8):832-3.
- Aripiprazole • Abilify
- Atenolol • Tenormin
- Atorvastatin • Lipitor
- Demeclocycline • Declomycin, Declostatin, others
- Diltiazem • Cardizem, Dilacor, others
- Fludrocortisone • Florinef
- Fluvoxamine • Luvox
- Ibuprofen • Advil, Motrin, others
- Metformin • Glucophage, Diabex, others
- Mirtazapine • Remeron
- Paroxetine • Paxil
- Sertraline • Zoloft
- Venlafaxine • Effexor
Disclosures
Dr. Romanowicz reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Ramaswamy receives research support from Bristol-Myers Squibb, Shire, and Forest Pharmaceuticals and is a consultant to Dainippon Sumitomo Pharma.
Dr. Wilson receives research support from the National Institute of Mental Health, the Veterans Administration, the State of Nebraska, Health Futures Foundation, Inc., AstraZeneca, Dainippon Sumitomo Pharma, Eli Lilly and Company, and Pfizer Inc. and serves as a consultant to the Substance Abuse and Mental Health Services Administration and the State of Nebraska.
HISTORY: ‘They’re out to get me’
Mrs. V, age 64, tells her primary care physician she has felt “bad” for 2 weeks. She complains of depressed mood, middle insomnia, diminished appetite, poor concentration, and poor energy. She denies suicidal thoughts but reports feeling alone, overwhelmed, and unable to manage her daily life.
Mrs. V is very concerned about losing her job because she cannot function at work. She believes her coworkers may be plotting to get her fired. The primary care physician refers Mrs. V to us to evaluate her mood.
According to her daughter, Mrs. V has had multiple psychiatric hospitalizations; the most recent occurred 2 years ago when she was admitted for paranoia and disorganized behavior. The daughter also mentions that her mother has a remote history of daily alcohol use, drinking until she was intoxicated. Mrs. V says she occasionally drinks beer and she scores 2 out of 4 on the CAGE questionnaire, which may indicate alcohol dependence.
During mental status examination, Mrs. V is alert and oriented to person, place, and date. She is pleasant and cooperative but shows apparent thought blocking and some tangentiality. She has substantial difficulty answering questions and articulating symptoms. Speech is slow in rate and rhythm. Mrs. V’s mood is severely depressed and her affect constricted.
She denies suicidal or homicidal ideations or visual or auditory hallucinations. Cognitive testing reveals mild deficits in recall memory and poor concentration. Her insight is limited and her judgment fair.
Her medical history includes hypertension, hyperlipidemia, coronary artery disease, cardiac catheterization, and hyponatremia. Her medication regimen consists of aripiprazole, 15 mg/d; diltiazem, 180 mg/d; atenolol, 25 mg/d; aspirin, 325 mg/d; atorvastatin, 10 mg/d; sertraline, 50 mg/d; and ibuprofen, 600 mg as needed for hip pain. She also reports taking diuretics in the past.
Vital signs include blood pressure, 125/95 mm Hg; respirations, 16/min; temperature, 98.2° F; and pulse rate, 72/min. Serum investigations reveal sodium, 119 mEq/L (normal range: 135 to 145 mEq/L) and random blood sugar, 160 mg/dL (normal range: 60 to 114 mg/dL).
The authors’ observations
The combination of major depression with psychosis and hyponatremia makes Mrs. V’s case challenging. Hyponatremia in psychiatric inpatients can prompt medical consultation, thus possibly halting or delaying psychiatric treatment.
Hyponatremia has been associated with the use of:
- diuretics
- selective serotonin reuptake inhibitors (SSRIs)
- serotonin-norepinephrine reuptake inhibitors (SNRIs)
- tricyclic antidepressants
- calcium antagonists.
Among psychiatric inpatients, the risk of hyponatremia is doubled in women.1 It is unclear, however, if female gender is an independent risk factor for hyponatremia. Sharabi et al2 reported that patients of both sexes age >65 have a 9-fold greater risk of developing hyponatremia than younger counterparts.
In addition, hyponatremia risk during any antidepressant treatment is highest:
- in the summer
- during the first weeks of treatment
- with concomitant drug use, especially with diuretics.3
The authors’ observations
Based on Mrs. V’s initial lab results (Table 1), we classify her hyponatremia as euvolemic, with high urine osmolarity (≥100 mOsm/L). That helps narrow our differential diagnosis to glucocorticoid deficiency, hypothyroidism, and SIADH (Table 2).5 We exclude psychogenic polydipsia, “tea and toast” syndrome, or beer potomania because they usually present as euvolemic hyponatremia with low urinary osmolality.
SSRI use in elderly persons has been associated with hyponatremia, which in some cases may be consistent with SIADH. Unfortunately, few psychiatrists are aware of this potentially fatal side effect.
SIADH occurs in association with reduced serum osmolality. It is characterized by:
- hypotonic hyponatremia (serum sodium
- inappropriately elevated urine osmolarity (>200 mOsm/L) relative to plasma osmolarity
- elevated urine sodium (typically >20 mEq/L).4
The key to the pathophysiology, signs, symptoms, and treatment of SIADH is understanding that the hyponatremia is a result of excess water and not a sodium deficiency. Hyponatremia’s signs and symptoms primarily are related to CNS dysfunction and correlate with how rapidly and severely the condition develops.
We monitor Mrs. V for anorexia, nausea, and malaise because they would be the earliest findings, followed by headache, irritability, confusion, muscle cramps, weakness, obtundation, seizures, and coma. These occur as osmotic fluid shifts and results in cerebral edema and increased intracranial pressure. When sodium concentration drops below 105 mEq/L, life-threatening complications are likely.
Table 1
Mrs. V’s laboratory results
Mrs. V’s results | |||
---|---|---|---|
Normal range | Before Tx | After Tx | |
Serum sodium (mEq/L) | 135 to 145 | 119 | 127 |
Serum potassium (mEq/L) | 3.5 to 5.0 | 3.6 | 3.8 |
Creatinine (mg/dL) | 0.5 to 1.7 | 0.74 | 0.84 |
Glucose (mg/dL) | 60 to 114 | 160 | 150 |
Osmolarity | |||
Serum (measured; mOsm/L) | 275 to 300 | 258 | 242 |
Urine (mOsm/L) | 257 | 180 | |
Urine sodium (mEq/L) | 20 to 40 | 48 | 42 |
Mrs. V’s laboratory results
Hypovolemic hyponatremia | Euvolemic hyponatremia | Hypervolemic hyponatremia |
---|---|---|
Vomiting Diarrhea Laxative abuse Renal disease Nasogastric suction Salt-wasting nephropathy Addison’s disease | Normal urinary sodium Glucocorticoid deficiency Hypothyroidism Certain drugs SIADH | Congestive heart failure Nephrotic syndrome Cirrhosis |
Low urinary osmolality Psychogenic polydipsia ‘Tea and toast’ syndrome Beer potomania | ||
SIADH: syndrome of inappropriate antidiuretic hormone | ||
Source: Reference 5 |
SSRIs and SIADH
Bouman et al6 estimated that the incidence of SSRI-induced SIADH in elderly patients is 12%. Liu et al7 described 706 cases of hyponatremia associated with SSRI use in unpublished reports. Fluoxetine was most commonly the cause (75.3% cases), followed by paroxetine (12.4%), sertraline (11.7%), and fluvoxamine (1.5%). Resuming the same drug resulted in hyponatremia in 16 of 24 of these cases (66.7%).
Kirby et al,8 however, found no clear advantages in different SSRIs’ propensity to cause hyponatremia. Seventy-one percent of patients treated with the SNRI venlafaxine developed hyponatremia, compared with 32% taking paroxetine and 29% receiving sertraline. It is unclear whether a specific SSRI or venlafaxine has a stronger association with hyponatremia than any other antidepressant.
Hyponatremia’s nonspecific symptoms and wide range of time to detection (1 to 253 days) suggest clinicians usually detect the condition by chance rather than specifically assessing for it.9
TREATMENT: Medication change?
Coordinating Mrs. V’s depression and hyponatremia treatment is critical. We propose discontinuing sertraline and treating Mrs. V’s symptoms with electroconvulsive therapy (ECT). She refuses ECT, stating “I don’t feel that bad. My father was treated with ECT and I am scared of it.”
The authors’ observations
SSRI-induced hyponatremia can be transient or persistent and recurrent. The usual approach is to discontinue the SSRI and try a different antidepressant. Because hyponatremia has been associated with all SSRIs and SNRIs, it would be prudent to choose an alternate antidepressant agent outside these classes. If patients must continue taking an antidepressant that causes hyponatremia, avoid concurrent use of drugs that cause hyponatremia, restrict fluid intake, and consider adding a medication that prevents hyponatremia, such as demeclocycline or fludrocortisone.
SSRI-induced hyponatremia may resolve:
- with SSRI discontinuation alone11
- with fluid restriction and without discontinuation of the SSRI11
- with drug discontinuation, fluid restriction, and sodium chloride and potassium supplementation.12
FOLLOW-UP: Analysis error?
Despite modifications to Mrs. V’s diet, her fasting serum glucose level remains >100. She is diagnosed with diabetes mellitus type 2 and treated with metformin. We continue mirtazapine, which has successfully controlled Mrs. V’s depressive symptoms. Her serum sodium levels start normalizing.
The authors’ observations
Related resources
- Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008;16(1):13-24.
- Atalay A, Turhan N, Aki OE. A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J 2007;100(8):832-3.
- Aripiprazole • Abilify
- Atenolol • Tenormin
- Atorvastatin • Lipitor
- Demeclocycline • Declomycin, Declostatin, others
- Diltiazem • Cardizem, Dilacor, others
- Fludrocortisone • Florinef
- Fluvoxamine • Luvox
- Ibuprofen • Advil, Motrin, others
- Metformin • Glucophage, Diabex, others
- Mirtazapine • Remeron
- Paroxetine • Paxil
- Sertraline • Zoloft
- Venlafaxine • Effexor
Disclosures
Dr. Romanowicz reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Ramaswamy receives research support from Bristol-Myers Squibb, Shire, and Forest Pharmaceuticals and is a consultant to Dainippon Sumitomo Pharma.
Dr. Wilson receives research support from the National Institute of Mental Health, the Veterans Administration, the State of Nebraska, Health Futures Foundation, Inc., AstraZeneca, Dainippon Sumitomo Pharma, Eli Lilly and Company, and Pfizer Inc. and serves as a consultant to the Substance Abuse and Mental Health Services Administration and the State of Nebraska.
Reference
1. Siegler EL, Tamres D, Berlin JA, et al. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155(9):953-7.
2. Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 2002;16(9):631-5.
3. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327(2):109-11.
4. Buff DD, Markowitz S. Hyponatremia in the psychiatric patient: a review of diagnostic and management strategies. Psychiatr Ann 2003;33(5):318-25.
5. Levitan A. Hyponatremia: how to recognize the cause promptly—and avoid treatment pitfalls. Consultant 2003;43(7):861-70.
6. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998;13(1):12-5
7. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996;155(5):519-27
8. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001;16(5):484-93
9. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998;12(4):396-400.
10. Jagsch C, Marksteiner J, Seiringer E, Windhager E. Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion. Pharmacopsychiatry 2007;40(3):129-31.
11. Bigaillon C, El Jahiri Y, Garcia C, et al. Inappropriate ADH secretion-induced hyponatremia and associated with paroxetine use. Rev Med Interne 2007;28(9):642-4.
12. Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 1993;27(6):723-4.
Reference
1. Siegler EL, Tamres D, Berlin JA, et al. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155(9):953-7.
2. Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 2002;16(9):631-5.
3. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327(2):109-11.
4. Buff DD, Markowitz S. Hyponatremia in the psychiatric patient: a review of diagnostic and management strategies. Psychiatr Ann 2003;33(5):318-25.
5. Levitan A. Hyponatremia: how to recognize the cause promptly—and avoid treatment pitfalls. Consultant 2003;43(7):861-70.
6. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998;13(1):12-5
7. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996;155(5):519-27
8. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001;16(5):484-93
9. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998;12(4):396-400.
10. Jagsch C, Marksteiner J, Seiringer E, Windhager E. Successful mirtazapine treatment of an 81-year-old patient with syndrome of inappropriate antidiuretic hormone secretion. Pharmacopsychiatry 2007;40(3):129-31.
11. Bigaillon C, El Jahiri Y, Garcia C, et al. Inappropriate ADH secretion-induced hyponatremia and associated with paroxetine use. Rev Med Interne 2007;28(9):642-4.
12. Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 1993;27(6):723-4.
A Reverend’s tale: Too tragic to be true?
CASE: A tragic tale
Reverend R, a 62-year-old Methodist minister, is admitted to a general surgical service for abdominal pain secondary to a recurring bowel obstruction. While there, he learns that his pregnant 24-year-old fiancée was struck and killed by a drunk driver as she was driving to visit him. Her medical team was not able to save her child. The surgical service requests a psychiatric consultation for Reverend R to assist him with grieving.
Our team interviews Reverend R 3 days after his fiancée’s death. We did not have access to his psychiatric records before our evaluation, but his chart indicates Reverend R had been hospitalized for nearly 3 months after being transferred from another hospital. He has a history of colon cancer and cerebral palsy and has struggled with depression since college. He had 1 psychiatric hospitalization 26 years earlier and no history of suicide attempts. He has responded to pharmacotherapy and is taking sertraline, 100 mg daily.
Reverend R expresses grief, stating he has lost the love of his life. With prompting, he provides a few details about his fiancée but does not say much about the accident. He says he feels guilty and frustrated that he can’t attend his fiancée’s funeral because “I have a nasogastric tube.” He claims he has cried excessively in the last few days, repeatedly stating, “I soaked 4 towels.” He is profusely apologetic for expressing his grief, as if doing so was inappropriate.
Reverend R acknowledges feeling sad but denies pervasively depressed mood or anhedonia, excessive guilt, or feelings of hopelessness, helplessness, or worthlessness. His affect ranges from mildly dysphoric to jovial and witty. His thought form and content are logical, linear, and goal-oriented. He denies having preoccupations, obsessions, delusions, or hallucinations. Attention and concentration are intact without evidence of waxing and waning. Cognition and memory also are intact. His Folstein Mini-Mental State Exam (MMSE) score is 29/30. Insight and judgment are assessed to be good, and intellect is above average.
We end our interview by asking Reverend R for permission to contact his psychiatrist for additional information. He stops making eye contact, begins to stammer, and tells us he is acutely short of breath. We seek out his nurse to check him, and within a few minutes his shortness of breath resolves without intervention.
The authors’ observations
Reverend R’s presentation does not suggest that his fiancée died 3 days ago. Without prompting, he says little about her or the accident, but he provides a great deal of information about himself. He clearly enjoys our attention, several times enthusiastically asking, “What else would you like to know about me?” At times he focuses on irrelevant topics.
He does not appear depressed and, although Reverend R’s voice breaks at times, we do not observe tears. His intermittent jovial, witty manner is inappropriate, but he is oriented and his MMSE provides no evidence of delirium. He does not elaborate on his frustration at being unable to attend the funeral and seems satisfied with the possibility of watching a video of the service.
Reverend R does not meet DSM-IV-TR criteria for major depressive disorder. We feel his emotions and conduct are unusual in response to the stress and therefore, based on what we have learned so far, we believe he best meets criteria for an adjustment disorder.
HISTORY: A series of traumas
During our initial interview, Reverend R explains that his life has been characterized by a series of traumatic events (Table 1). He had been sexually assaulted twice: by an uncle during childhood and by a male nurse while hospitalized for depression 26 years ago. The nurse had HIV, but the Reverend tested negative.
The day before our visit was not only the Reverend’s birthday but also was to be his wedding day. The Reverend had met his fiancée, a nurse, at the nursing home where he lives. At times, she took him on outings for dinner and other activities.
We ask the Reverend precisely why he needed 24-hour care and why he had been in the nursing home for 15 years. He is not able to provide a reasonable explanation.
Table 1
Reverend R’s life story: A series of traumatic events
Period | Event |
---|---|
Childhood | Sexually assaulted by an uncle |
Young adulthood | Develops depression; 1 hospitalization in his 30s; sexually assaulted by male nurse while hospitalized |
Adulthood | Motor vehicle accident results in traumatic brain injury and leads to nursing home placement in his late 40s |
3 months ago | Hospitalized for abdominal pain secondary to recurring bowel obstruction; medical history includes colon cancer, cerebral palsy |
Presently | Loses pregnant, 24-year-old fiancée in a traffic accident |
The authors’ observations
Reverend R talks almost incessantly about the atrocities he suffered throughout his life. Times of happiness and success are the exception.
We begin to doubt the veracity of certain details of his story. We question the plausibility of a young nurse having an intimate relationship with and becoming pregnant by a 62-year-old nursing home patient who was an ordained minister. Reverend R’s claim of being the nursing home’s public relations director and performing sermons there seems unlikely. His stories are inconsistent; whenever we question him, he creates a reply that he is convinced seems believable. A collateral history is imperative for us to establish a diagnosis.
FOLLOW-UP: His story starts to fray
At a follow-up visit the next day, the Reverend states that he has been sad and at times he will “fall apart” in response to his fiancée’s death. He says that a video of the memorial service his fiancée’s father gave him had been “hard to watch.” We ask if he has the video; he says that he sent it back to the nursing home.
The authors’ observations
It seems strange that Reverend R is concerned that talking with us could compromise his return to the nursing home. His questions and behavior are paranoid; we did not observe this type of behavior during our initial interview.
We investigate Reverend R’s claims. A hospital dismissal summary from 13 years ago documents that Reverend R had been caught pulling out his NG tube. Additionally, he was observed drinking out of the sink when he was advised to take nothing by mouth.
Within days of that hospitalization, he presented to our outpatient gastrointestinal clinic for a second opinion regarding his abdominal pain. His father demanded that the Reverend be admitted. When told that hospitalization was not warranted, Reverend R and his father became angry and abruptly left the office.
Our hospital’s nursing staff is a vital source of information because they observed Reverend R often during his 3-month stay. They are suspicious of his history because they noticed discrepancies, such as Reverend R telling one nurse his fiancée died on a Thursday and another she died on a Friday. He spoke of people visiting him, but the staff never saw any visitors.
The nursing staff reports that at times he would use profanity and was quite hostile. A member of our team saw him yelling at a female chaplain. In our initial interview he told our team that the chaplain had reprimanded him for having premarital relations with his fiancée.
We find no evidence of an accident that resulted in the death of a 24-year-old pregnant female. Obviously, there was never a funeral or visits from the fictitious fiancée’s father. The sexual assault by the male nurse while hospitalized is possible but not probable, given the other falsehoods Reverend R told.
The seminary Reverend R told us he attended exists, but we are not able to determine if he was educated there. He told some staff members he had obtained a Master’s degree and others a PhD.
Reverend R refuses to sign a release of information form for the nursing home. We speak with the nurse who worked with Reverend R’s psychiatrist, who confirms that the patient’s diagnosis was depression. She tells us that the Reverend said he relocated to that area to live closer to a man with whom he had a romantic relationship. Reverend R confided to her that his father never approved of the relationship, but his mother accepted it.
DIAGNOSIS: A rarely seen symptom
Reverend R meets the DSM-IV-TR criteria for factitious disorder (Table 2).1 The presentation of a patient with this disorder may include:
- fabrication of subjective complaints
- self-inflicted conditions
- exaggeration or exacerbation of pre-existing conditions
- any combination of these.
Differential diagnosis for pseudologia fantastica includes dementia, delusional disorder, antisocial personality disorder, borderline personality disorder, factitious disorder, malingering, hypochondriasis, substance abuse/dependence, and schizophrenia/schizophreniform disorder.3
Table 2
DSM-IV-TR criteria for factitious disorder*
Intentional production or feigning of physical or psychological signs and symptoms |
Motivation for the behavior is to assume the sick role |
External incentives such as economic gain, avoiding legal responsibility, or improving physical well-being are absent |
* Specifiers include with predominantly psychological signs and symptoms, with predominantly physical signs and symptoms, or a combination of both |
Source: Reference 1 |
Characteristics of stories told by patients with pseudologia fantastica
|
|
|
|
|
Source: Reference 2 |
Because of an unstable self image, the pseudologia fantastica patient constantly battles to regulate his or her sense of self. The dramatic production of symptoms due to this constant battle is thought to be a way for the patient to stabilize the self by making the experience of distress concrete and legitimate.5 It was fascinating to see Reverend R’s defense mechanisms work.
Confronting patients such as Reverend R likely is not the best approach. Showing them respect and empathy is important. Creating a safe, supportive environment in which they can express themselves will encourage them to consider ongoing psychiatric care.3,6
OUTCOME: Return to nursing home
Approximately 1 week after our follow-up visit, Reverend R was discharged to the nursing home where he had resided prior to the hospitalization. Several attempts to contact him to obtain additional information and collateral history were unsuccessful, but clearly we had enough information to refute the reason we were asked to evaluate him.
Related resources
- Epstein LA, Stern TA. Factitious illness: a 3-step consultation-liaison approach. Current Psychiatry 2007;6(4):54-58.
- Birch CD, Kelln BRC, Aquino EPB. A review and case report of pseudologia fantastica. Journal of Forensic Psychiatry and Psychology 2006;17(2):299-320.
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
2. King BH, Ford CV. Pseudologia fantastica. Acta Psychiatr Scand 1988;77(1):1-6.
3. Newmark N, Adityanjee, Kay J. Pseudologia fantastica and factitious disorder: review of the literature and a case report. Compr Psychiatry 1999;40(2):89-95.
4. Levenson JL. Deception syndromes: factitious disorders and malingering. In: Ford CV, ed. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing; 2005:297-309.
5. Spivak H, Rodin G, Sutherland A. The psychology of factitious disorders. A reconsideration. Psychosomatics 1994;35:25-34.
6. Hoyer TV. Pseudologia fantastica: a consideration of “the lie” and a case presentation. Psychiatr Q 1959;33:203-20.
CASE: A tragic tale
Reverend R, a 62-year-old Methodist minister, is admitted to a general surgical service for abdominal pain secondary to a recurring bowel obstruction. While there, he learns that his pregnant 24-year-old fiancée was struck and killed by a drunk driver as she was driving to visit him. Her medical team was not able to save her child. The surgical service requests a psychiatric consultation for Reverend R to assist him with grieving.
Our team interviews Reverend R 3 days after his fiancée’s death. We did not have access to his psychiatric records before our evaluation, but his chart indicates Reverend R had been hospitalized for nearly 3 months after being transferred from another hospital. He has a history of colon cancer and cerebral palsy and has struggled with depression since college. He had 1 psychiatric hospitalization 26 years earlier and no history of suicide attempts. He has responded to pharmacotherapy and is taking sertraline, 100 mg daily.
Reverend R expresses grief, stating he has lost the love of his life. With prompting, he provides a few details about his fiancée but does not say much about the accident. He says he feels guilty and frustrated that he can’t attend his fiancée’s funeral because “I have a nasogastric tube.” He claims he has cried excessively in the last few days, repeatedly stating, “I soaked 4 towels.” He is profusely apologetic for expressing his grief, as if doing so was inappropriate.
Reverend R acknowledges feeling sad but denies pervasively depressed mood or anhedonia, excessive guilt, or feelings of hopelessness, helplessness, or worthlessness. His affect ranges from mildly dysphoric to jovial and witty. His thought form and content are logical, linear, and goal-oriented. He denies having preoccupations, obsessions, delusions, or hallucinations. Attention and concentration are intact without evidence of waxing and waning. Cognition and memory also are intact. His Folstein Mini-Mental State Exam (MMSE) score is 29/30. Insight and judgment are assessed to be good, and intellect is above average.
We end our interview by asking Reverend R for permission to contact his psychiatrist for additional information. He stops making eye contact, begins to stammer, and tells us he is acutely short of breath. We seek out his nurse to check him, and within a few minutes his shortness of breath resolves without intervention.
The authors’ observations
Reverend R’s presentation does not suggest that his fiancée died 3 days ago. Without prompting, he says little about her or the accident, but he provides a great deal of information about himself. He clearly enjoys our attention, several times enthusiastically asking, “What else would you like to know about me?” At times he focuses on irrelevant topics.
He does not appear depressed and, although Reverend R’s voice breaks at times, we do not observe tears. His intermittent jovial, witty manner is inappropriate, but he is oriented and his MMSE provides no evidence of delirium. He does not elaborate on his frustration at being unable to attend the funeral and seems satisfied with the possibility of watching a video of the service.
Reverend R does not meet DSM-IV-TR criteria for major depressive disorder. We feel his emotions and conduct are unusual in response to the stress and therefore, based on what we have learned so far, we believe he best meets criteria for an adjustment disorder.
HISTORY: A series of traumas
During our initial interview, Reverend R explains that his life has been characterized by a series of traumatic events (Table 1). He had been sexually assaulted twice: by an uncle during childhood and by a male nurse while hospitalized for depression 26 years ago. The nurse had HIV, but the Reverend tested negative.
The day before our visit was not only the Reverend’s birthday but also was to be his wedding day. The Reverend had met his fiancée, a nurse, at the nursing home where he lives. At times, she took him on outings for dinner and other activities.
We ask the Reverend precisely why he needed 24-hour care and why he had been in the nursing home for 15 years. He is not able to provide a reasonable explanation.
Table 1
Reverend R’s life story: A series of traumatic events
Period | Event |
---|---|
Childhood | Sexually assaulted by an uncle |
Young adulthood | Develops depression; 1 hospitalization in his 30s; sexually assaulted by male nurse while hospitalized |
Adulthood | Motor vehicle accident results in traumatic brain injury and leads to nursing home placement in his late 40s |
3 months ago | Hospitalized for abdominal pain secondary to recurring bowel obstruction; medical history includes colon cancer, cerebral palsy |
Presently | Loses pregnant, 24-year-old fiancée in a traffic accident |
The authors’ observations
Reverend R talks almost incessantly about the atrocities he suffered throughout his life. Times of happiness and success are the exception.
We begin to doubt the veracity of certain details of his story. We question the plausibility of a young nurse having an intimate relationship with and becoming pregnant by a 62-year-old nursing home patient who was an ordained minister. Reverend R’s claim of being the nursing home’s public relations director and performing sermons there seems unlikely. His stories are inconsistent; whenever we question him, he creates a reply that he is convinced seems believable. A collateral history is imperative for us to establish a diagnosis.
FOLLOW-UP: His story starts to fray
At a follow-up visit the next day, the Reverend states that he has been sad and at times he will “fall apart” in response to his fiancée’s death. He says that a video of the memorial service his fiancée’s father gave him had been “hard to watch.” We ask if he has the video; he says that he sent it back to the nursing home.
The authors’ observations
It seems strange that Reverend R is concerned that talking with us could compromise his return to the nursing home. His questions and behavior are paranoid; we did not observe this type of behavior during our initial interview.
We investigate Reverend R’s claims. A hospital dismissal summary from 13 years ago documents that Reverend R had been caught pulling out his NG tube. Additionally, he was observed drinking out of the sink when he was advised to take nothing by mouth.
Within days of that hospitalization, he presented to our outpatient gastrointestinal clinic for a second opinion regarding his abdominal pain. His father demanded that the Reverend be admitted. When told that hospitalization was not warranted, Reverend R and his father became angry and abruptly left the office.
Our hospital’s nursing staff is a vital source of information because they observed Reverend R often during his 3-month stay. They are suspicious of his history because they noticed discrepancies, such as Reverend R telling one nurse his fiancée died on a Thursday and another she died on a Friday. He spoke of people visiting him, but the staff never saw any visitors.
The nursing staff reports that at times he would use profanity and was quite hostile. A member of our team saw him yelling at a female chaplain. In our initial interview he told our team that the chaplain had reprimanded him for having premarital relations with his fiancée.
We find no evidence of an accident that resulted in the death of a 24-year-old pregnant female. Obviously, there was never a funeral or visits from the fictitious fiancée’s father. The sexual assault by the male nurse while hospitalized is possible but not probable, given the other falsehoods Reverend R told.
The seminary Reverend R told us he attended exists, but we are not able to determine if he was educated there. He told some staff members he had obtained a Master’s degree and others a PhD.
Reverend R refuses to sign a release of information form for the nursing home. We speak with the nurse who worked with Reverend R’s psychiatrist, who confirms that the patient’s diagnosis was depression. She tells us that the Reverend said he relocated to that area to live closer to a man with whom he had a romantic relationship. Reverend R confided to her that his father never approved of the relationship, but his mother accepted it.
DIAGNOSIS: A rarely seen symptom
Reverend R meets the DSM-IV-TR criteria for factitious disorder (Table 2).1 The presentation of a patient with this disorder may include:
- fabrication of subjective complaints
- self-inflicted conditions
- exaggeration or exacerbation of pre-existing conditions
- any combination of these.
Differential diagnosis for pseudologia fantastica includes dementia, delusional disorder, antisocial personality disorder, borderline personality disorder, factitious disorder, malingering, hypochondriasis, substance abuse/dependence, and schizophrenia/schizophreniform disorder.3
Table 2
DSM-IV-TR criteria for factitious disorder*
Intentional production or feigning of physical or psychological signs and symptoms |
Motivation for the behavior is to assume the sick role |
External incentives such as economic gain, avoiding legal responsibility, or improving physical well-being are absent |
* Specifiers include with predominantly psychological signs and symptoms, with predominantly physical signs and symptoms, or a combination of both |
Source: Reference 1 |
Characteristics of stories told by patients with pseudologia fantastica
|
|
|
|
|
Source: Reference 2 |
Because of an unstable self image, the pseudologia fantastica patient constantly battles to regulate his or her sense of self. The dramatic production of symptoms due to this constant battle is thought to be a way for the patient to stabilize the self by making the experience of distress concrete and legitimate.5 It was fascinating to see Reverend R’s defense mechanisms work.
Confronting patients such as Reverend R likely is not the best approach. Showing them respect and empathy is important. Creating a safe, supportive environment in which they can express themselves will encourage them to consider ongoing psychiatric care.3,6
OUTCOME: Return to nursing home
Approximately 1 week after our follow-up visit, Reverend R was discharged to the nursing home where he had resided prior to the hospitalization. Several attempts to contact him to obtain additional information and collateral history were unsuccessful, but clearly we had enough information to refute the reason we were asked to evaluate him.
Related resources
- Epstein LA, Stern TA. Factitious illness: a 3-step consultation-liaison approach. Current Psychiatry 2007;6(4):54-58.
- Birch CD, Kelln BRC, Aquino EPB. A review and case report of pseudologia fantastica. Journal of Forensic Psychiatry and Psychology 2006;17(2):299-320.
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: A tragic tale
Reverend R, a 62-year-old Methodist minister, is admitted to a general surgical service for abdominal pain secondary to a recurring bowel obstruction. While there, he learns that his pregnant 24-year-old fiancée was struck and killed by a drunk driver as she was driving to visit him. Her medical team was not able to save her child. The surgical service requests a psychiatric consultation for Reverend R to assist him with grieving.
Our team interviews Reverend R 3 days after his fiancée’s death. We did not have access to his psychiatric records before our evaluation, but his chart indicates Reverend R had been hospitalized for nearly 3 months after being transferred from another hospital. He has a history of colon cancer and cerebral palsy and has struggled with depression since college. He had 1 psychiatric hospitalization 26 years earlier and no history of suicide attempts. He has responded to pharmacotherapy and is taking sertraline, 100 mg daily.
Reverend R expresses grief, stating he has lost the love of his life. With prompting, he provides a few details about his fiancée but does not say much about the accident. He says he feels guilty and frustrated that he can’t attend his fiancée’s funeral because “I have a nasogastric tube.” He claims he has cried excessively in the last few days, repeatedly stating, “I soaked 4 towels.” He is profusely apologetic for expressing his grief, as if doing so was inappropriate.
Reverend R acknowledges feeling sad but denies pervasively depressed mood or anhedonia, excessive guilt, or feelings of hopelessness, helplessness, or worthlessness. His affect ranges from mildly dysphoric to jovial and witty. His thought form and content are logical, linear, and goal-oriented. He denies having preoccupations, obsessions, delusions, or hallucinations. Attention and concentration are intact without evidence of waxing and waning. Cognition and memory also are intact. His Folstein Mini-Mental State Exam (MMSE) score is 29/30. Insight and judgment are assessed to be good, and intellect is above average.
We end our interview by asking Reverend R for permission to contact his psychiatrist for additional information. He stops making eye contact, begins to stammer, and tells us he is acutely short of breath. We seek out his nurse to check him, and within a few minutes his shortness of breath resolves without intervention.
The authors’ observations
Reverend R’s presentation does not suggest that his fiancée died 3 days ago. Without prompting, he says little about her or the accident, but he provides a great deal of information about himself. He clearly enjoys our attention, several times enthusiastically asking, “What else would you like to know about me?” At times he focuses on irrelevant topics.
He does not appear depressed and, although Reverend R’s voice breaks at times, we do not observe tears. His intermittent jovial, witty manner is inappropriate, but he is oriented and his MMSE provides no evidence of delirium. He does not elaborate on his frustration at being unable to attend the funeral and seems satisfied with the possibility of watching a video of the service.
Reverend R does not meet DSM-IV-TR criteria for major depressive disorder. We feel his emotions and conduct are unusual in response to the stress and therefore, based on what we have learned so far, we believe he best meets criteria for an adjustment disorder.
HISTORY: A series of traumas
During our initial interview, Reverend R explains that his life has been characterized by a series of traumatic events (Table 1). He had been sexually assaulted twice: by an uncle during childhood and by a male nurse while hospitalized for depression 26 years ago. The nurse had HIV, but the Reverend tested negative.
The day before our visit was not only the Reverend’s birthday but also was to be his wedding day. The Reverend had met his fiancée, a nurse, at the nursing home where he lives. At times, she took him on outings for dinner and other activities.
We ask the Reverend precisely why he needed 24-hour care and why he had been in the nursing home for 15 years. He is not able to provide a reasonable explanation.
Table 1
Reverend R’s life story: A series of traumatic events
Period | Event |
---|---|
Childhood | Sexually assaulted by an uncle |
Young adulthood | Develops depression; 1 hospitalization in his 30s; sexually assaulted by male nurse while hospitalized |
Adulthood | Motor vehicle accident results in traumatic brain injury and leads to nursing home placement in his late 40s |
3 months ago | Hospitalized for abdominal pain secondary to recurring bowel obstruction; medical history includes colon cancer, cerebral palsy |
Presently | Loses pregnant, 24-year-old fiancée in a traffic accident |
The authors’ observations
Reverend R talks almost incessantly about the atrocities he suffered throughout his life. Times of happiness and success are the exception.
We begin to doubt the veracity of certain details of his story. We question the plausibility of a young nurse having an intimate relationship with and becoming pregnant by a 62-year-old nursing home patient who was an ordained minister. Reverend R’s claim of being the nursing home’s public relations director and performing sermons there seems unlikely. His stories are inconsistent; whenever we question him, he creates a reply that he is convinced seems believable. A collateral history is imperative for us to establish a diagnosis.
FOLLOW-UP: His story starts to fray
At a follow-up visit the next day, the Reverend states that he has been sad and at times he will “fall apart” in response to his fiancée’s death. He says that a video of the memorial service his fiancée’s father gave him had been “hard to watch.” We ask if he has the video; he says that he sent it back to the nursing home.
The authors’ observations
It seems strange that Reverend R is concerned that talking with us could compromise his return to the nursing home. His questions and behavior are paranoid; we did not observe this type of behavior during our initial interview.
We investigate Reverend R’s claims. A hospital dismissal summary from 13 years ago documents that Reverend R had been caught pulling out his NG tube. Additionally, he was observed drinking out of the sink when he was advised to take nothing by mouth.
Within days of that hospitalization, he presented to our outpatient gastrointestinal clinic for a second opinion regarding his abdominal pain. His father demanded that the Reverend be admitted. When told that hospitalization was not warranted, Reverend R and his father became angry and abruptly left the office.
Our hospital’s nursing staff is a vital source of information because they observed Reverend R often during his 3-month stay. They are suspicious of his history because they noticed discrepancies, such as Reverend R telling one nurse his fiancée died on a Thursday and another she died on a Friday. He spoke of people visiting him, but the staff never saw any visitors.
The nursing staff reports that at times he would use profanity and was quite hostile. A member of our team saw him yelling at a female chaplain. In our initial interview he told our team that the chaplain had reprimanded him for having premarital relations with his fiancée.
We find no evidence of an accident that resulted in the death of a 24-year-old pregnant female. Obviously, there was never a funeral or visits from the fictitious fiancée’s father. The sexual assault by the male nurse while hospitalized is possible but not probable, given the other falsehoods Reverend R told.
The seminary Reverend R told us he attended exists, but we are not able to determine if he was educated there. He told some staff members he had obtained a Master’s degree and others a PhD.
Reverend R refuses to sign a release of information form for the nursing home. We speak with the nurse who worked with Reverend R’s psychiatrist, who confirms that the patient’s diagnosis was depression. She tells us that the Reverend said he relocated to that area to live closer to a man with whom he had a romantic relationship. Reverend R confided to her that his father never approved of the relationship, but his mother accepted it.
DIAGNOSIS: A rarely seen symptom
Reverend R meets the DSM-IV-TR criteria for factitious disorder (Table 2).1 The presentation of a patient with this disorder may include:
- fabrication of subjective complaints
- self-inflicted conditions
- exaggeration or exacerbation of pre-existing conditions
- any combination of these.
Differential diagnosis for pseudologia fantastica includes dementia, delusional disorder, antisocial personality disorder, borderline personality disorder, factitious disorder, malingering, hypochondriasis, substance abuse/dependence, and schizophrenia/schizophreniform disorder.3
Table 2
DSM-IV-TR criteria for factitious disorder*
Intentional production or feigning of physical or psychological signs and symptoms |
Motivation for the behavior is to assume the sick role |
External incentives such as economic gain, avoiding legal responsibility, or improving physical well-being are absent |
* Specifiers include with predominantly psychological signs and symptoms, with predominantly physical signs and symptoms, or a combination of both |
Source: Reference 1 |
Characteristics of stories told by patients with pseudologia fantastica
|
|
|
|
|
Source: Reference 2 |
Because of an unstable self image, the pseudologia fantastica patient constantly battles to regulate his or her sense of self. The dramatic production of symptoms due to this constant battle is thought to be a way for the patient to stabilize the self by making the experience of distress concrete and legitimate.5 It was fascinating to see Reverend R’s defense mechanisms work.
Confronting patients such as Reverend R likely is not the best approach. Showing them respect and empathy is important. Creating a safe, supportive environment in which they can express themselves will encourage them to consider ongoing psychiatric care.3,6
OUTCOME: Return to nursing home
Approximately 1 week after our follow-up visit, Reverend R was discharged to the nursing home where he had resided prior to the hospitalization. Several attempts to contact him to obtain additional information and collateral history were unsuccessful, but clearly we had enough information to refute the reason we were asked to evaluate him.
Related resources
- Epstein LA, Stern TA. Factitious illness: a 3-step consultation-liaison approach. Current Psychiatry 2007;6(4):54-58.
- Birch CD, Kelln BRC, Aquino EPB. A review and case report of pseudologia fantastica. Journal of Forensic Psychiatry and Psychology 2006;17(2):299-320.
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
2. King BH, Ford CV. Pseudologia fantastica. Acta Psychiatr Scand 1988;77(1):1-6.
3. Newmark N, Adityanjee, Kay J. Pseudologia fantastica and factitious disorder: review of the literature and a case report. Compr Psychiatry 1999;40(2):89-95.
4. Levenson JL. Deception syndromes: factitious disorders and malingering. In: Ford CV, ed. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing; 2005:297-309.
5. Spivak H, Rodin G, Sutherland A. The psychology of factitious disorders. A reconsideration. Psychosomatics 1994;35:25-34.
6. Hoyer TV. Pseudologia fantastica: a consideration of “the lie” and a case presentation. Psychiatr Q 1959;33:203-20.
1. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
2. King BH, Ford CV. Pseudologia fantastica. Acta Psychiatr Scand 1988;77(1):1-6.
3. Newmark N, Adityanjee, Kay J. Pseudologia fantastica and factitious disorder: review of the literature and a case report. Compr Psychiatry 1999;40(2):89-95.
4. Levenson JL. Deception syndromes: factitious disorders and malingering. In: Ford CV, ed. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing; 2005:297-309.
5. Spivak H, Rodin G, Sutherland A. The psychology of factitious disorders. A reconsideration. Psychosomatics 1994;35:25-34.
6. Hoyer TV. Pseudologia fantastica: a consideration of “the lie” and a case presentation. Psychiatr Q 1959;33:203-20.
When the pain decreased, her troubles began
CASE: She’s not herself
Mrs. M, age 74, is brought to the ER by her husband after he finds her lying on their bedroom floor, incoherent and extremely drowsy. He reports that his wife, who suffers chronic arthritic back and joint pain, might have overdosed on pain medications.
According to her husband, Mrs. M has been taking combination oxycodone/acetaminophen and transdermal fentanyl at unknown dosages, but he is unsure when she started using these medications or if she is taking others. Serum toxicology screening shows twice the normal values for opioids and benzodiazepines; other laboratory results are normal.
Mrs. M is medically stable but her mental status is altered. She is oblivious to time, place and person, speaks to no one, and seems lost in her own world. The hospital’s medical service admits Mrs. M for stabilization and to determine whether the overdose was intentional.
Two days later, we evaluate Mrs. M’s mental status at the attending physician’s request. She appears confused and cannot answer our questions. Her husband tells us she was “doing fine” until approximately 4 months ago, when she started becoming increasingly forgetful and lethargic. He says she has been forgetting routine chores such as paying bills and grocery shopping. Recently, she has been getting lost during her evening walk; neighbors often help her find her way home.
The authors’ observations
Two opioid medications—oxycodone/acetaminophen combination and transdermal fentanyl—are commonly used to manage moderate or severe pain from any type of chronic arthritis.
- Oxycodone, a semisynthetic opioid analgesic indicated for moderate to moderately severe pain, is used when nondrug measures and nonnarcotic medications do not control the pain.
- Transdermal fentanyl, a potent analgesic indicated for persistent moderate to severe chronic pain, typically is prescribed to patients who tolerate oral oxycodone, 30 mg/d; morphine, 60 mg; hydromorphone, 8 mg; or an equianalgesic dosage of another opioid for ≥1 week.
Mrs. M also was taking a benzodiazepine, but which medication—and why she was taking it—were unclear. She had no psychiatric diagnosis, and her husband could not recall her medication history.
We also cannot explain Mrs. M’s negative cognitive and behavioral changes. Opioid overuse and onset of dementia-related cognitive decline are possibilities.
TRANSFER Why is she confused?
Based on information from the pharmacy department, doctors at the medical unit restart oxycodone/acetaminophen, 7.5/325 mg tid, and transdermal fentanyl, 25 mcg/hr every 3 days. After discussing how to treat Mrs. M, the psychiatric and medical services transfer her to the geriatric psychiatric inpatient unit 3 days after admission.
We visit Mrs. M hours after her transfer. She seems lethargic but not confused, although Mini-Mental State Examination (MMSE) score of 15 suggests moderate cognitive impairment. Vitamin B12 and thyroid levels, erythrocyte sedimentation rate, and syphilis test results are normal, allowing us to rule out organic causes for her dementia. Brain MRI shows no neurologic damage. On a scale of 1 to 5 with 5 being most severe, Mrs. M scores her pain as 2 (mild) and her sedation as 3 (moderate).
With Mrs. M’s permission, we call her primary care physician for collateral information. The physician tells us Mrs. M has suffered severe joint pain for 2 years. Nonnarcotic medications and treatments—including counseling, support groups, massage, yoga, exercise, biofeedback, relaxation therapy, and physical therapy—were ineffective.
Approximately 10 months ago, the physician started oxycodone/acetaminophen at 2.5/325 mg bid and titrated it over 6 weeks to 7.5/325 mg tid for Mrs. M’s persistent joint pain. Four months ago, with her pain still severe, the physician added transdermal fentanyl, 25 mcg/hr every 3 days, after which the patient reported mild improvement.
One month after starting the fentanyl patch, Mrs. M complained of sudden forgetfulness, low energy, poor concentration, and increased sleep. The physician suspected depression with possible comorbid anxiety and prescribed sertraline, 50 mg/d, and alprazolam, 0.5 mg bid. Mrs. M stopped sertraline after 3 days because it was causing diarrhea but kept taking alprazolam.
Mrs. M saw her primary care physician once after starting alprazolam and sertraline but missed her most recent appointment last month. The physician says he inadvertently approved at least 1 premature request for an alprazolam refill.
Six days after admission, Mrs. M’s sedation, cognitive impairment, and lethargy persist. She reports no mood and anxiety problems, and we have not restarted alprazolam.
The authors’ observations
The fentanyl patch most likely began to diminish Mrs. M’s alertness soon after she started using it. The doctor, however, mistook cognitive slowing for new-onset depression or anxiety. Depressive symptoms can imitate dementia, but Mrs. M’s severe sedation and denial of depressive symptoms suggest a medication side effect.
The primary care physician’s reconstruction of Mrs. M’s history explained her positive benzodiazepine reading, and her use of the short-acting benzodiazepine alprazolam could account for her sudden-onset paranoia and cognitive decline (Box). Benzodiazepines can cause behavioral side effects such as disinhibition, agitation, or paranoia, and patients age ≥65 are at increased risk for these side effects.4 In particular, benzodiazepines with half-lives ≥6 to 8 hours such as clonazepam and oxazepam can cause short-term memory impairment, confusion, and delirium.5-7
Reconstructing treatment history is critical if the patient or family members cannot recall past treatments or if the patient cannot communicate.
Get permission from the patient or family as required under the Health Insurance Portability and Accountability Act. Then contact the primary care or other prescribing physician to obtain:
- a copy of the physician’s last progress note and initial evaluation
- notes about adverse reactions to current or past medications
- trials of medications and other treatments relevant to the current complaint.
In emergent cases when the patient is unresponsive or mentally incapacitated and no family members are available, follow the above steps and initiate treatment. Carefully document that the patient was incoherent, his life was in danger, and you could not reach a family member for permission to treat.
If you cannot communicate with the patient or contact a family member but care is less emergent, consult the hospital’s ethics committee to see if a guardian has been appointed. Contact the primary care physician only after the guardian grants permission.
When prescribing benzodiazepines (especially in older patients) watch for signs of overuse or abuse, such as early requests for refills, unkempt appearance, excessive sleepiness, or agitation (Table 1).
Warning signs of opioid, benzodiazepine overuse
Frequent requests for early refills |
Patient exceeds prescribed dosage without authorization |
Patient reports lost/stolen prescription; if patient has history of substance abuse/dependence or legal problems, even 1 report should raise a red flag |
Patient increasingly unkempt or impaired |
Negative mood change |
Agitation |
Patient involved in car or other accidents |
Sedation |
Purposeful oversedation, particularly when patient has an apparent secondary gain from opioid use (such as qualifying for disability benefits or escaping from work) |
New-onset cognitive impairment |
Patient abusing alcohol or other illicit CNS depressants |
The authors’ observations
Persistent chronic pain in the elderly can diminish health and quality of life, resulting in depression, social isolation, immobility, and sleep disturbance.
Managing an older patient’s pain can be challenging (Table 2). Opioids are effective painkillers, but even at relatively low dosages they can diminish function and cognition and increase risk of delirium. Also, patients’ ability to tolerate different opioids at different dosages varies widely.
Mrs. M’s opioid regimen was intolerable and numerous other treatments did not alleviate her pain. At this point, replacing fentanyl with another opioid was our best option.8
We decided to try methadone, which is indicated for moderate to severe pain that does not respond to nonnarcotic treatments. Methadone often is used for chronic pain associated with arthritis or malignancy.
Methadone is less sedating, more tolerable, and carries a lower risk of cognitive side effects than other opioids. Methadone also is fast- and long-acting—its analgesic effects begin within 30 minutes to 1 hour of oral administration9 and last approximately 12 hours, thus reducing the risk of breakthrough pain. Methadone also:
- has no active metabolites, which decreases the risk of hepatic side effects
- offers a high volume of distribution, thus allowing clinical effect with minimal dosing.
Beware the potential for addiction when prescribing opioids to any patient.13,14 The U.S. Drug Enforcement Agency classifies both methadone and fentanyl as schedule II substances, which applies to highly addictive medications with FDA-approved indications. See patients at least biweekly, especially when switching or titrating pain medications, and watch closely for signs of overuse or addiction. Inform patients to:
- watch for symptoms such as oversedation, memory and concentration problems, and sudden changes in personality
- call you to clarify if these symptoms are methadone side effects.
Watch for other potential side effects of methadone, such as constipation, sedation, breakthrough pain, sexual dysfunction, decreased immunity, respiratory depression, or prolonged corrected QT intervals.
Patients usually tolerate an immediate switch from transdermal fentanyl to methadone, but a sudden switch from high-dose fentanyl can reduce methadone’s effectiveness. Starting methadone at a high dosage to compensate for loss of effectiveness could increase side effect risk. If the fentanyl dosage exceeds 100 mcg/hr, taper by 25 mcg weekly. Simultaneously start methadone at a low dosage and titrate by 5 to 10 mg weekly as needed.
Table 2
Chronic pain management in the elderly: Dos and don’ts
DO |
Use self rating scales, as patient can gauge his/her own pain most accurately |
Consider nonpharmacologic treatments and nonnarcotic analgesics first |
Watch closely for side effects and drug-drug/drug-disease interactions in patients receiving analgesics long-term |
Monitor patients receiving opioids long-term for oversedation, changes in cognition and function |
Consider switching to methadone or another opioid if patient cannot tolerate current opioid regimen |
DO NOT |
Prescribe propoxyphene or meperidine—which carry a higher risk of adverse effects than other opioids—to older patient |
Prescribe opioids if the medical history is unclear |
Increase opioid dosages without seeing the patient |
TREATMENT Medication change
We stop transdermal fentanyl and start oral methadone, 5 mg bid, while continuing oxycodone/acetaminophen at the previous dosage.
Two days later, Mrs. M is much more alert. Since admission 1 week ago, her sedation rating has improved from 3 (mildly sedated) to 4 (almost fully alert). She rates her pain as mild and reports no breakthrough pain or other side effects from methadone. Her MMSE score has improved to 24—suggesting close to normal cognition—and she is much more interactive with staff and family.
Eight days after we start methadone, we stop oxycodone/acetaminophen and increase methadone to 10 mg bid to further improve cognition and alertness and to see if 1 pain medication is suffcient. Two days later, we discharge Mrs. M. She is fully alert, feels little or no joint pain, and is tolerating the methadone increase.
At outpatient follow-up 4 weeks later, Mrs. M remains pain-free and her MMSE score is 29, suggesting normal cognition. Over 8 months, we continue to see her monthly and then bi-monthly, after which we refer her to her primary care physician.
Related resources
- American Association for Geriatric Psychiatry. www.aagponline.org.
- American Pain Society. www.ampainsoc.org.
- Alprazolam • Xanax
- Clonazepam • Klonopin
- Fentanyl (transdermal) • Duragesic
- Hydromorphone • Dilaudid
- Meperidine • Demerol
- Methadone • Dolophine
- Oxazepam • Serax
- Oxycodone • OxyContin, Roxicodone
- Oxycodone/acetaminophen • Percocet
- Propoxyphene • Darvon
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Edinboro LE, Poklis A, Trautman D, et al. Fatal fentanyl intoxication following excessive transdermal application. J Forenscic Sci 1997;42:741-3.
2. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 1993;77:390-1.
3. Lawlor PG, Bruera E. Side effects of opioids in chronic pain treatment. Curr Opin Anaesthesiol 1998;5:539-45.
4. Lechin F, Van der Dijs B, Benaim M. Benzodiazepines; tolerability in elderly patients. Psychother Psychosom 1996;65:171-82.
5. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacology 1981;11(suppl 1):99S-104S.
6. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993;54(suppl):49-61.
7. Paton P. Benzodiazepines and disinhibition. Psychiatr Bull 2002;26:460-2.
8. Quigley C. Opioid switching to improve pain relief and drug tolerability (review). Cochrane Database Syst Rev 2004(3);CD004847.-
9. National Highway Traffic Safety Administration. Methadone. Available at: http://www.nhtsa.dot.gov/PEOPLE/INJURY/research/job185drugs/methadone.htm. Accessed February 14, 2008.
10. Manzini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000;12:308-13.
11. Layson-Wolf C, Goode JV, Small R. Clinical use of methadone. J Pain Palliat Care 2002;16:29-59.
12. Krantz MJ, Lewkowiez L, Hays H, et al. Torsades de pointes associated with high dose methadone. Ann Intern Med 2002;139:501-4.
13. Fishbain D, Rosomoff H, Rosomoff RS. Drug abuse, dependence, and addiction in chronic patients. Clin J Pain 1992;8:77-85.
14. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict 1995;30:919-27.
CASE: She’s not herself
Mrs. M, age 74, is brought to the ER by her husband after he finds her lying on their bedroom floor, incoherent and extremely drowsy. He reports that his wife, who suffers chronic arthritic back and joint pain, might have overdosed on pain medications.
According to her husband, Mrs. M has been taking combination oxycodone/acetaminophen and transdermal fentanyl at unknown dosages, but he is unsure when she started using these medications or if she is taking others. Serum toxicology screening shows twice the normal values for opioids and benzodiazepines; other laboratory results are normal.
Mrs. M is medically stable but her mental status is altered. She is oblivious to time, place and person, speaks to no one, and seems lost in her own world. The hospital’s medical service admits Mrs. M for stabilization and to determine whether the overdose was intentional.
Two days later, we evaluate Mrs. M’s mental status at the attending physician’s request. She appears confused and cannot answer our questions. Her husband tells us she was “doing fine” until approximately 4 months ago, when she started becoming increasingly forgetful and lethargic. He says she has been forgetting routine chores such as paying bills and grocery shopping. Recently, she has been getting lost during her evening walk; neighbors often help her find her way home.
The authors’ observations
Two opioid medications—oxycodone/acetaminophen combination and transdermal fentanyl—are commonly used to manage moderate or severe pain from any type of chronic arthritis.
- Oxycodone, a semisynthetic opioid analgesic indicated for moderate to moderately severe pain, is used when nondrug measures and nonnarcotic medications do not control the pain.
- Transdermal fentanyl, a potent analgesic indicated for persistent moderate to severe chronic pain, typically is prescribed to patients who tolerate oral oxycodone, 30 mg/d; morphine, 60 mg; hydromorphone, 8 mg; or an equianalgesic dosage of another opioid for ≥1 week.
Mrs. M also was taking a benzodiazepine, but which medication—and why she was taking it—were unclear. She had no psychiatric diagnosis, and her husband could not recall her medication history.
We also cannot explain Mrs. M’s negative cognitive and behavioral changes. Opioid overuse and onset of dementia-related cognitive decline are possibilities.
TRANSFER Why is she confused?
Based on information from the pharmacy department, doctors at the medical unit restart oxycodone/acetaminophen, 7.5/325 mg tid, and transdermal fentanyl, 25 mcg/hr every 3 days. After discussing how to treat Mrs. M, the psychiatric and medical services transfer her to the geriatric psychiatric inpatient unit 3 days after admission.
We visit Mrs. M hours after her transfer. She seems lethargic but not confused, although Mini-Mental State Examination (MMSE) score of 15 suggests moderate cognitive impairment. Vitamin B12 and thyroid levels, erythrocyte sedimentation rate, and syphilis test results are normal, allowing us to rule out organic causes for her dementia. Brain MRI shows no neurologic damage. On a scale of 1 to 5 with 5 being most severe, Mrs. M scores her pain as 2 (mild) and her sedation as 3 (moderate).
With Mrs. M’s permission, we call her primary care physician for collateral information. The physician tells us Mrs. M has suffered severe joint pain for 2 years. Nonnarcotic medications and treatments—including counseling, support groups, massage, yoga, exercise, biofeedback, relaxation therapy, and physical therapy—were ineffective.
Approximately 10 months ago, the physician started oxycodone/acetaminophen at 2.5/325 mg bid and titrated it over 6 weeks to 7.5/325 mg tid for Mrs. M’s persistent joint pain. Four months ago, with her pain still severe, the physician added transdermal fentanyl, 25 mcg/hr every 3 days, after which the patient reported mild improvement.
One month after starting the fentanyl patch, Mrs. M complained of sudden forgetfulness, low energy, poor concentration, and increased sleep. The physician suspected depression with possible comorbid anxiety and prescribed sertraline, 50 mg/d, and alprazolam, 0.5 mg bid. Mrs. M stopped sertraline after 3 days because it was causing diarrhea but kept taking alprazolam.
Mrs. M saw her primary care physician once after starting alprazolam and sertraline but missed her most recent appointment last month. The physician says he inadvertently approved at least 1 premature request for an alprazolam refill.
Six days after admission, Mrs. M’s sedation, cognitive impairment, and lethargy persist. She reports no mood and anxiety problems, and we have not restarted alprazolam.
The authors’ observations
The fentanyl patch most likely began to diminish Mrs. M’s alertness soon after she started using it. The doctor, however, mistook cognitive slowing for new-onset depression or anxiety. Depressive symptoms can imitate dementia, but Mrs. M’s severe sedation and denial of depressive symptoms suggest a medication side effect.
The primary care physician’s reconstruction of Mrs. M’s history explained her positive benzodiazepine reading, and her use of the short-acting benzodiazepine alprazolam could account for her sudden-onset paranoia and cognitive decline (Box). Benzodiazepines can cause behavioral side effects such as disinhibition, agitation, or paranoia, and patients age ≥65 are at increased risk for these side effects.4 In particular, benzodiazepines with half-lives ≥6 to 8 hours such as clonazepam and oxazepam can cause short-term memory impairment, confusion, and delirium.5-7
Reconstructing treatment history is critical if the patient or family members cannot recall past treatments or if the patient cannot communicate.
Get permission from the patient or family as required under the Health Insurance Portability and Accountability Act. Then contact the primary care or other prescribing physician to obtain:
- a copy of the physician’s last progress note and initial evaluation
- notes about adverse reactions to current or past medications
- trials of medications and other treatments relevant to the current complaint.
In emergent cases when the patient is unresponsive or mentally incapacitated and no family members are available, follow the above steps and initiate treatment. Carefully document that the patient was incoherent, his life was in danger, and you could not reach a family member for permission to treat.
If you cannot communicate with the patient or contact a family member but care is less emergent, consult the hospital’s ethics committee to see if a guardian has been appointed. Contact the primary care physician only after the guardian grants permission.
When prescribing benzodiazepines (especially in older patients) watch for signs of overuse or abuse, such as early requests for refills, unkempt appearance, excessive sleepiness, or agitation (Table 1).
Warning signs of opioid, benzodiazepine overuse
Frequent requests for early refills |
Patient exceeds prescribed dosage without authorization |
Patient reports lost/stolen prescription; if patient has history of substance abuse/dependence or legal problems, even 1 report should raise a red flag |
Patient increasingly unkempt or impaired |
Negative mood change |
Agitation |
Patient involved in car or other accidents |
Sedation |
Purposeful oversedation, particularly when patient has an apparent secondary gain from opioid use (such as qualifying for disability benefits or escaping from work) |
New-onset cognitive impairment |
Patient abusing alcohol or other illicit CNS depressants |
The authors’ observations
Persistent chronic pain in the elderly can diminish health and quality of life, resulting in depression, social isolation, immobility, and sleep disturbance.
Managing an older patient’s pain can be challenging (Table 2). Opioids are effective painkillers, but even at relatively low dosages they can diminish function and cognition and increase risk of delirium. Also, patients’ ability to tolerate different opioids at different dosages varies widely.
Mrs. M’s opioid regimen was intolerable and numerous other treatments did not alleviate her pain. At this point, replacing fentanyl with another opioid was our best option.8
We decided to try methadone, which is indicated for moderate to severe pain that does not respond to nonnarcotic treatments. Methadone often is used for chronic pain associated with arthritis or malignancy.
Methadone is less sedating, more tolerable, and carries a lower risk of cognitive side effects than other opioids. Methadone also is fast- and long-acting—its analgesic effects begin within 30 minutes to 1 hour of oral administration9 and last approximately 12 hours, thus reducing the risk of breakthrough pain. Methadone also:
- has no active metabolites, which decreases the risk of hepatic side effects
- offers a high volume of distribution, thus allowing clinical effect with minimal dosing.
Beware the potential for addiction when prescribing opioids to any patient.13,14 The U.S. Drug Enforcement Agency classifies both methadone and fentanyl as schedule II substances, which applies to highly addictive medications with FDA-approved indications. See patients at least biweekly, especially when switching or titrating pain medications, and watch closely for signs of overuse or addiction. Inform patients to:
- watch for symptoms such as oversedation, memory and concentration problems, and sudden changes in personality
- call you to clarify if these symptoms are methadone side effects.
Watch for other potential side effects of methadone, such as constipation, sedation, breakthrough pain, sexual dysfunction, decreased immunity, respiratory depression, or prolonged corrected QT intervals.
Patients usually tolerate an immediate switch from transdermal fentanyl to methadone, but a sudden switch from high-dose fentanyl can reduce methadone’s effectiveness. Starting methadone at a high dosage to compensate for loss of effectiveness could increase side effect risk. If the fentanyl dosage exceeds 100 mcg/hr, taper by 25 mcg weekly. Simultaneously start methadone at a low dosage and titrate by 5 to 10 mg weekly as needed.
Table 2
Chronic pain management in the elderly: Dos and don’ts
DO |
Use self rating scales, as patient can gauge his/her own pain most accurately |
Consider nonpharmacologic treatments and nonnarcotic analgesics first |
Watch closely for side effects and drug-drug/drug-disease interactions in patients receiving analgesics long-term |
Monitor patients receiving opioids long-term for oversedation, changes in cognition and function |
Consider switching to methadone or another opioid if patient cannot tolerate current opioid regimen |
DO NOT |
Prescribe propoxyphene or meperidine—which carry a higher risk of adverse effects than other opioids—to older patient |
Prescribe opioids if the medical history is unclear |
Increase opioid dosages without seeing the patient |
TREATMENT Medication change
We stop transdermal fentanyl and start oral methadone, 5 mg bid, while continuing oxycodone/acetaminophen at the previous dosage.
Two days later, Mrs. M is much more alert. Since admission 1 week ago, her sedation rating has improved from 3 (mildly sedated) to 4 (almost fully alert). She rates her pain as mild and reports no breakthrough pain or other side effects from methadone. Her MMSE score has improved to 24—suggesting close to normal cognition—and she is much more interactive with staff and family.
Eight days after we start methadone, we stop oxycodone/acetaminophen and increase methadone to 10 mg bid to further improve cognition and alertness and to see if 1 pain medication is suffcient. Two days later, we discharge Mrs. M. She is fully alert, feels little or no joint pain, and is tolerating the methadone increase.
At outpatient follow-up 4 weeks later, Mrs. M remains pain-free and her MMSE score is 29, suggesting normal cognition. Over 8 months, we continue to see her monthly and then bi-monthly, after which we refer her to her primary care physician.
Related resources
- American Association for Geriatric Psychiatry. www.aagponline.org.
- American Pain Society. www.ampainsoc.org.
- Alprazolam • Xanax
- Clonazepam • Klonopin
- Fentanyl (transdermal) • Duragesic
- Hydromorphone • Dilaudid
- Meperidine • Demerol
- Methadone • Dolophine
- Oxazepam • Serax
- Oxycodone • OxyContin, Roxicodone
- Oxycodone/acetaminophen • Percocet
- Propoxyphene • Darvon
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: She’s not herself
Mrs. M, age 74, is brought to the ER by her husband after he finds her lying on their bedroom floor, incoherent and extremely drowsy. He reports that his wife, who suffers chronic arthritic back and joint pain, might have overdosed on pain medications.
According to her husband, Mrs. M has been taking combination oxycodone/acetaminophen and transdermal fentanyl at unknown dosages, but he is unsure when she started using these medications or if she is taking others. Serum toxicology screening shows twice the normal values for opioids and benzodiazepines; other laboratory results are normal.
Mrs. M is medically stable but her mental status is altered. She is oblivious to time, place and person, speaks to no one, and seems lost in her own world. The hospital’s medical service admits Mrs. M for stabilization and to determine whether the overdose was intentional.
Two days later, we evaluate Mrs. M’s mental status at the attending physician’s request. She appears confused and cannot answer our questions. Her husband tells us she was “doing fine” until approximately 4 months ago, when she started becoming increasingly forgetful and lethargic. He says she has been forgetting routine chores such as paying bills and grocery shopping. Recently, she has been getting lost during her evening walk; neighbors often help her find her way home.
The authors’ observations
Two opioid medications—oxycodone/acetaminophen combination and transdermal fentanyl—are commonly used to manage moderate or severe pain from any type of chronic arthritis.
- Oxycodone, a semisynthetic opioid analgesic indicated for moderate to moderately severe pain, is used when nondrug measures and nonnarcotic medications do not control the pain.
- Transdermal fentanyl, a potent analgesic indicated for persistent moderate to severe chronic pain, typically is prescribed to patients who tolerate oral oxycodone, 30 mg/d; morphine, 60 mg; hydromorphone, 8 mg; or an equianalgesic dosage of another opioid for ≥1 week.
Mrs. M also was taking a benzodiazepine, but which medication—and why she was taking it—were unclear. She had no psychiatric diagnosis, and her husband could not recall her medication history.
We also cannot explain Mrs. M’s negative cognitive and behavioral changes. Opioid overuse and onset of dementia-related cognitive decline are possibilities.
TRANSFER Why is she confused?
Based on information from the pharmacy department, doctors at the medical unit restart oxycodone/acetaminophen, 7.5/325 mg tid, and transdermal fentanyl, 25 mcg/hr every 3 days. After discussing how to treat Mrs. M, the psychiatric and medical services transfer her to the geriatric psychiatric inpatient unit 3 days after admission.
We visit Mrs. M hours after her transfer. She seems lethargic but not confused, although Mini-Mental State Examination (MMSE) score of 15 suggests moderate cognitive impairment. Vitamin B12 and thyroid levels, erythrocyte sedimentation rate, and syphilis test results are normal, allowing us to rule out organic causes for her dementia. Brain MRI shows no neurologic damage. On a scale of 1 to 5 with 5 being most severe, Mrs. M scores her pain as 2 (mild) and her sedation as 3 (moderate).
With Mrs. M’s permission, we call her primary care physician for collateral information. The physician tells us Mrs. M has suffered severe joint pain for 2 years. Nonnarcotic medications and treatments—including counseling, support groups, massage, yoga, exercise, biofeedback, relaxation therapy, and physical therapy—were ineffective.
Approximately 10 months ago, the physician started oxycodone/acetaminophen at 2.5/325 mg bid and titrated it over 6 weeks to 7.5/325 mg tid for Mrs. M’s persistent joint pain. Four months ago, with her pain still severe, the physician added transdermal fentanyl, 25 mcg/hr every 3 days, after which the patient reported mild improvement.
One month after starting the fentanyl patch, Mrs. M complained of sudden forgetfulness, low energy, poor concentration, and increased sleep. The physician suspected depression with possible comorbid anxiety and prescribed sertraline, 50 mg/d, and alprazolam, 0.5 mg bid. Mrs. M stopped sertraline after 3 days because it was causing diarrhea but kept taking alprazolam.
Mrs. M saw her primary care physician once after starting alprazolam and sertraline but missed her most recent appointment last month. The physician says he inadvertently approved at least 1 premature request for an alprazolam refill.
Six days after admission, Mrs. M’s sedation, cognitive impairment, and lethargy persist. She reports no mood and anxiety problems, and we have not restarted alprazolam.
The authors’ observations
The fentanyl patch most likely began to diminish Mrs. M’s alertness soon after she started using it. The doctor, however, mistook cognitive slowing for new-onset depression or anxiety. Depressive symptoms can imitate dementia, but Mrs. M’s severe sedation and denial of depressive symptoms suggest a medication side effect.
The primary care physician’s reconstruction of Mrs. M’s history explained her positive benzodiazepine reading, and her use of the short-acting benzodiazepine alprazolam could account for her sudden-onset paranoia and cognitive decline (Box). Benzodiazepines can cause behavioral side effects such as disinhibition, agitation, or paranoia, and patients age ≥65 are at increased risk for these side effects.4 In particular, benzodiazepines with half-lives ≥6 to 8 hours such as clonazepam and oxazepam can cause short-term memory impairment, confusion, and delirium.5-7
Reconstructing treatment history is critical if the patient or family members cannot recall past treatments or if the patient cannot communicate.
Get permission from the patient or family as required under the Health Insurance Portability and Accountability Act. Then contact the primary care or other prescribing physician to obtain:
- a copy of the physician’s last progress note and initial evaluation
- notes about adverse reactions to current or past medications
- trials of medications and other treatments relevant to the current complaint.
In emergent cases when the patient is unresponsive or mentally incapacitated and no family members are available, follow the above steps and initiate treatment. Carefully document that the patient was incoherent, his life was in danger, and you could not reach a family member for permission to treat.
If you cannot communicate with the patient or contact a family member but care is less emergent, consult the hospital’s ethics committee to see if a guardian has been appointed. Contact the primary care physician only after the guardian grants permission.
When prescribing benzodiazepines (especially in older patients) watch for signs of overuse or abuse, such as early requests for refills, unkempt appearance, excessive sleepiness, or agitation (Table 1).
Warning signs of opioid, benzodiazepine overuse
Frequent requests for early refills |
Patient exceeds prescribed dosage without authorization |
Patient reports lost/stolen prescription; if patient has history of substance abuse/dependence or legal problems, even 1 report should raise a red flag |
Patient increasingly unkempt or impaired |
Negative mood change |
Agitation |
Patient involved in car or other accidents |
Sedation |
Purposeful oversedation, particularly when patient has an apparent secondary gain from opioid use (such as qualifying for disability benefits or escaping from work) |
New-onset cognitive impairment |
Patient abusing alcohol or other illicit CNS depressants |
The authors’ observations
Persistent chronic pain in the elderly can diminish health and quality of life, resulting in depression, social isolation, immobility, and sleep disturbance.
Managing an older patient’s pain can be challenging (Table 2). Opioids are effective painkillers, but even at relatively low dosages they can diminish function and cognition and increase risk of delirium. Also, patients’ ability to tolerate different opioids at different dosages varies widely.
Mrs. M’s opioid regimen was intolerable and numerous other treatments did not alleviate her pain. At this point, replacing fentanyl with another opioid was our best option.8
We decided to try methadone, which is indicated for moderate to severe pain that does not respond to nonnarcotic treatments. Methadone often is used for chronic pain associated with arthritis or malignancy.
Methadone is less sedating, more tolerable, and carries a lower risk of cognitive side effects than other opioids. Methadone also is fast- and long-acting—its analgesic effects begin within 30 minutes to 1 hour of oral administration9 and last approximately 12 hours, thus reducing the risk of breakthrough pain. Methadone also:
- has no active metabolites, which decreases the risk of hepatic side effects
- offers a high volume of distribution, thus allowing clinical effect with minimal dosing.
Beware the potential for addiction when prescribing opioids to any patient.13,14 The U.S. Drug Enforcement Agency classifies both methadone and fentanyl as schedule II substances, which applies to highly addictive medications with FDA-approved indications. See patients at least biweekly, especially when switching or titrating pain medications, and watch closely for signs of overuse or addiction. Inform patients to:
- watch for symptoms such as oversedation, memory and concentration problems, and sudden changes in personality
- call you to clarify if these symptoms are methadone side effects.
Watch for other potential side effects of methadone, such as constipation, sedation, breakthrough pain, sexual dysfunction, decreased immunity, respiratory depression, or prolonged corrected QT intervals.
Patients usually tolerate an immediate switch from transdermal fentanyl to methadone, but a sudden switch from high-dose fentanyl can reduce methadone’s effectiveness. Starting methadone at a high dosage to compensate for loss of effectiveness could increase side effect risk. If the fentanyl dosage exceeds 100 mcg/hr, taper by 25 mcg weekly. Simultaneously start methadone at a low dosage and titrate by 5 to 10 mg weekly as needed.
Table 2
Chronic pain management in the elderly: Dos and don’ts
DO |
Use self rating scales, as patient can gauge his/her own pain most accurately |
Consider nonpharmacologic treatments and nonnarcotic analgesics first |
Watch closely for side effects and drug-drug/drug-disease interactions in patients receiving analgesics long-term |
Monitor patients receiving opioids long-term for oversedation, changes in cognition and function |
Consider switching to methadone or another opioid if patient cannot tolerate current opioid regimen |
DO NOT |
Prescribe propoxyphene or meperidine—which carry a higher risk of adverse effects than other opioids—to older patient |
Prescribe opioids if the medical history is unclear |
Increase opioid dosages without seeing the patient |
TREATMENT Medication change
We stop transdermal fentanyl and start oral methadone, 5 mg bid, while continuing oxycodone/acetaminophen at the previous dosage.
Two days later, Mrs. M is much more alert. Since admission 1 week ago, her sedation rating has improved from 3 (mildly sedated) to 4 (almost fully alert). She rates her pain as mild and reports no breakthrough pain or other side effects from methadone. Her MMSE score has improved to 24—suggesting close to normal cognition—and she is much more interactive with staff and family.
Eight days after we start methadone, we stop oxycodone/acetaminophen and increase methadone to 10 mg bid to further improve cognition and alertness and to see if 1 pain medication is suffcient. Two days later, we discharge Mrs. M. She is fully alert, feels little or no joint pain, and is tolerating the methadone increase.
At outpatient follow-up 4 weeks later, Mrs. M remains pain-free and her MMSE score is 29, suggesting normal cognition. Over 8 months, we continue to see her monthly and then bi-monthly, after which we refer her to her primary care physician.
Related resources
- American Association for Geriatric Psychiatry. www.aagponline.org.
- American Pain Society. www.ampainsoc.org.
- Alprazolam • Xanax
- Clonazepam • Klonopin
- Fentanyl (transdermal) • Duragesic
- Hydromorphone • Dilaudid
- Meperidine • Demerol
- Methadone • Dolophine
- Oxazepam • Serax
- Oxycodone • OxyContin, Roxicodone
- Oxycodone/acetaminophen • Percocet
- Propoxyphene • Darvon
- Sertraline • Zoloft
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Edinboro LE, Poklis A, Trautman D, et al. Fatal fentanyl intoxication following excessive transdermal application. J Forenscic Sci 1997;42:741-3.
2. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 1993;77:390-1.
3. Lawlor PG, Bruera E. Side effects of opioids in chronic pain treatment. Curr Opin Anaesthesiol 1998;5:539-45.
4. Lechin F, Van der Dijs B, Benaim M. Benzodiazepines; tolerability in elderly patients. Psychother Psychosom 1996;65:171-82.
5. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacology 1981;11(suppl 1):99S-104S.
6. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993;54(suppl):49-61.
7. Paton P. Benzodiazepines and disinhibition. Psychiatr Bull 2002;26:460-2.
8. Quigley C. Opioid switching to improve pain relief and drug tolerability (review). Cochrane Database Syst Rev 2004(3);CD004847.-
9. National Highway Traffic Safety Administration. Methadone. Available at: http://www.nhtsa.dot.gov/PEOPLE/INJURY/research/job185drugs/methadone.htm. Accessed February 14, 2008.
10. Manzini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000;12:308-13.
11. Layson-Wolf C, Goode JV, Small R. Clinical use of methadone. J Pain Palliat Care 2002;16:29-59.
12. Krantz MJ, Lewkowiez L, Hays H, et al. Torsades de pointes associated with high dose methadone. Ann Intern Med 2002;139:501-4.
13. Fishbain D, Rosomoff H, Rosomoff RS. Drug abuse, dependence, and addiction in chronic patients. Clin J Pain 1992;8:77-85.
14. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict 1995;30:919-27.
1. Edinboro LE, Poklis A, Trautman D, et al. Fatal fentanyl intoxication following excessive transdermal application. J Forenscic Sci 1997;42:741-3.
2. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 1993;77:390-1.
3. Lawlor PG, Bruera E. Side effects of opioids in chronic pain treatment. Curr Opin Anaesthesiol 1998;5:539-45.
4. Lechin F, Van der Dijs B, Benaim M. Benzodiazepines; tolerability in elderly patients. Psychother Psychosom 1996;65:171-82.
5. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacology 1981;11(suppl 1):99S-104S.
6. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993;54(suppl):49-61.
7. Paton P. Benzodiazepines and disinhibition. Psychiatr Bull 2002;26:460-2.
8. Quigley C. Opioid switching to improve pain relief and drug tolerability (review). Cochrane Database Syst Rev 2004(3);CD004847.-
9. National Highway Traffic Safety Administration. Methadone. Available at: http://www.nhtsa.dot.gov/PEOPLE/INJURY/research/job185drugs/methadone.htm. Accessed February 14, 2008.
10. Manzini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000;12:308-13.
11. Layson-Wolf C, Goode JV, Small R. Clinical use of methadone. J Pain Palliat Care 2002;16:29-59.
12. Krantz MJ, Lewkowiez L, Hays H, et al. Torsades de pointes associated with high dose methadone. Ann Intern Med 2002;139:501-4.
13. Fishbain D, Rosomoff H, Rosomoff RS. Drug abuse, dependence, and addiction in chronic patients. Clin J Pain 1992;8:77-85.
14. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict 1995;30:919-27.
The patient nobody liked
CASE: He bares it all
Police have arrested Mr. L, age 62, 3 times in 36 hours after spotting him walking naked in public. With the county jail jammed to capacity, police bring him each time to our hospital’s emergency room.
After his first arrest, Mr. L matter-of-factly tells us, “I want to walk naked and starve myself to death.” His self-harm exhortations amplify with each visit until—at the third presentation—he reports that he has not eaten for at least 2 days.
Mr. L had been living on the streets for nearly 1 month. Before that, he had been in jail for approximately 1 month after attacking a nursing home patient. He has been hospitalized twice in 5 months for severe depression and personality disorder and has engaged in numerous disruptive behavioral episodes and feeble suicide attempts. At this latest presentation, he appears disheveled and lacks judgment and insight into his condition.
The authors’ observations
We readmitted Mr. L with working diagnoses of:
- major depressive disorder with psychotic features, based on his suicide threats and complaints of depression
- personality disorder not otherwise specified, based on his behavioral episodes, apparent desire to be cared for (Table 1), and refusal to “get better” during 2 recent hospitalizations.
A troubled life: Mr. L’s history
Period | Mr. L’s difficulties |
---|---|
Childhood | Has no friends in school; his mother—Mr. L’s sole source of emotional support—continues to wash his laundry, buy his food and clothes into his 20s |
Adult life | Keeps ‘goofing off’ at work and has trouble staying employed; depends on wife to manage his life |
2 years ago | Shows depressive symptoms (amotivation, lack of concentration, increased fatigue, decreased appetite) after shoulder injury Develops irrational fear that household appliances will malfunction Becomes hostile toward his wife of 34 years |
5 months ago | Hospitalized after threatening to kill wife; has depressive symptoms and is disruptive during month-long hospitalization |
4 months ago | Discharged from hospital to homeless shelter because estranged wife won’t allow him back home; is readmitted after shelter staff find him banging his head on an iron gate; again behaves disruptively |
3 months ago | Discharged from second month-long hospitalization to nursing home |
2 months ago | Attacks patient at nursing home; police arrest and incarcerate him on disorderly conduct charge |
Past month | Released from jail after 1 month and spends weeks on the streets; lands in ER after police repeatedly catch him walking naked in public |
HISTORY: His best friends
As a child, Mr. L had no friends. His father was physically present but emotionally distant, so he relied on his mother for emotional support. Throughout his teens and early adulthood, his mother continued to do his laundry, buy his food and clothes, and run his life. When he married in his early 20s, his wife assumed this role.
Mr. L avoided psychiatric care for most of his life but did not socialize outside the house, lacked ambition, and seemed content to depend on his wife. He worked primarily as a janitor or housekeeper but was constantly getting fired and drifted from job to job. His wife told us that when he was supposed to be working, he spent hours staring at the walls and watching TV.
As the shoulder pain intensified, Mr. L quit his job. While out of work, he stopped attending physical therapy sessions when his depressive symptoms began to offset the shoulder pain. He suffered loss of concentration and motivation, increased fatigue with hypersomnia, and decreased appetite. He lost 10 to 12 lb in 1 year.
Mr. L also started having trouble “focusing on reality” and developed obsessive fears of malfunctions around the house, such as the furnace blowing up, the stove catching fire, or the toilet backing up. At one point, he began urinating and defecating in his pants to avoid using the toilet. He began to feel hopeless and several times tried to suffocate himself by placing a plastic bag over his head.
He also grew irritable, angry, and aggressive—mostly toward his wife, who increasingly feared him. He started blaming her for “everything wrong in my life” and began contemplating stabbing her to death or striking her head with a hammer.
Five months ago, Mr. L was involuntarily hospitalized for depressive symptoms, suicidality, and continued homicidal thoughts toward his wife. The attending psychiatrist started olanzapine, 5 mg nightly, for psychotic features, and citalopram, 10 mg/d, for depression and anxiety, and ordered one-on-one observation to prevent additional suicide attempts. Mr. L’s shoulder pain had resolved by this time.
Three days later, Mr. L began refusing to eat. The psychiatrist then increased citalopram to 20 mg/d and olanzapine to 5 mg bid and asked a hospital internist to evaluate for malnutrition and a psychologist to gauge cognitive and intellectual function.
During the psychologist’s evaluation, Mr. L showed average global intellectual functioning but delays in visual-motor speed, visual working memory, and alertness to his environment. These findings, however, did not explain the patient’s lower functioning at home or in the hospital.
We ruled out organic causes for Mr. L’s cognitive deficits after receiving normal brain MRI, urinalysis, rapid plasma reagin titer, and thyroid-stimulating hormone test results. We also ruled out malnutrition because vitamin B12 and folate levels were normal but ordered a dietary consult to help Mr. L regain weight.
Staff and family registered Mr. L for Medicare and Medicaid benefits so that he could become more independent, but his behavior soon regressed. He complained that staff and family were ignoring him and started urinating outside the bathroom, eating and smearing his feces, and bothering other patients. Staff directed Mr. L’s wife to ignore his verbal abuse over the phone and encourage him to stay motivated for treatment.
Mr. L’s disruptive behavior stopped after the psychologist tried individual therapy with behavior modification. The psychologist helped him devise a cleanliness plan and encouraged him to express his anger verbally rather than acting out. When Mr. L smeared his feces, he was to scrub the area with soap and water, take a 5-minute cold shower, put on clean clothes, and write and read an apology to hospital staff.
DISCHARGE: Nowhere to go
One month after admission, Mr. L was free of suicidal and homicidal thoughts and other symptoms. Staff prepared him for discharge, but his wife was contemplating divorce and refused to allow him back home. He also declined community outpatient treatment because he wanted his life to return to “normal” and was unaware that he was harming himself and others.
With no other disposition options, we discharged Mr. L to a homeless shelter. Later that day, shelter staff brought him back to the ER after they found him banging his head against an iron gate. We readmitted him to the psychiatric unit, at which point he endorsed suicidal thinking.
READMISSION: ‘Cold’ case
During this second hospitalization, Mr. L was again eating his feces as well as coloring himself with green markers, writing obscenities on the wall, and tearing up other patients’ papers. He repeatedly took 15-minute cold showers and told staff as they urged him out of the shower that he wanted to die by inducing hypothermia. During these episodes, he often called his estranged wife and told her what he was doing.
After the treatment team had Mr. L civilly committed, the attending psychiatrist titrated citalopram to 60 mg/d, discontinued olanzapine, and added aripiprazole to target the patient’s underlying depressive symptoms. Aripiprazole was started at 5 mg nightly and eventually titrated to 10 mg nightly. On 3 occasions during the month-long hospitalization, Mr. L refused to take his medications because he felt he did not belong in the hospital.
The attending psychiatrist diagnosed “dependent, passive-aggressive behaviors” and noted that Mr. L was “not amenable” to psychiatric hospitalization. The treatment team and outpatient community mental health department decided the patient had a personality disorder and that continued hospitalization would prevent him from attaining autonomy.
We then discharged Mr. L to a nursing home. There, he demanded a transfer back to the hospital or to jail because he feared he could not afford nursing home care and believed he could receive more attention elsewhere. His request was rejected after our ER psychiatrist found him medically and mentally fit to stay at the nursing home.
About 1 month later, Mr. L tried to smother a female patient by holding a pillow over her face but stopped when she began to struggle. After he told the nurses what he had done, staff immediately called police, who arrested Mr. L and transferred him to the county jail.
Because police and nursing home staff viewed the incident as a cry for help rather than a cold-blooded attack, police charged Mr. L with disorderly conduct. One month later, police dropped the charge and released him to the streets.
The authors’ observations
Mr. L triggered hateful reactions among several treatment team members, many of whom felt vindicated by his arrest. Clinicians might react this way if they feel a patient is wasting their time, manipulating them, not recognizing their narcissistic need for the patient to change, or ignoring their treatment plans.1
Acknowledging the staff’s—and your own—reaction to a difficult patient is critical. Not doing so can lead to treatment decisions based on emotions rather than evidence. In a busy clinical setting, it’s easy to lose sight of this.
The following strategies can help you manage hateful countertransference, cope with a patient’s offensive behaviors, and make appropriate decisions:
- Allow staff members to discuss their feelings. Encourage them to acknowledge and discuss their feelings during team meetings or daily treatment discussions. This helped members of our team recognize that their identification with Mr. L’s self-rejection fueled their desire to “reject” him by discharging him to police or the homeless shelter.
- Joke about the patient’s behavior when appropriate. Humor is a mature and potentially healing defense mechanism. When not treating Mr. L, for example, we joked among ourselves about publishing a case report titled, “The case of the poop-eater.” Never joke about the patient in the therapeutic milieu, where it can be disruptive.
- See the behavior as a defense mechanism. Viewing patients’ reactions as defense mechanisms—rather than effects of a psychiatric disorder—can help you better understand the patient’s underlying pathophysiology.
READMISSION: More bad behavior
After his 3 arrests for public nudity, we readmit Mr. L, restart citalopram at 20 mg/d, and titrate it back to 60 mg/d to target his depression. We also switch back to olanzapine, 10 mg nightly, because the patient has seen little clinical benefit from aripiprazole and feels that olanzapine had improved his sleep.
In the psychiatric ward, Mr. L is once again disturbing patients, smearing and eating feces, and making half-hearted suicide attempts. Upset that staff is “ignoring” him, he enters other patients’ rooms without invitation and urinates in places other than the bathroom.
The authors’ observations
After 3 hospital admissions, Mr. L’s diagnosis remained unclear (Table 2). At his first admission, his symptoms suggested major depression with psychotic features. With his subsequent behaviors in the inpatient psychiatric unit—including primitive suicide attempts and smearing and eating feces—Mr. L showed a strong desire to be cared for. This and his past dependence on his wife and mother suggested a severe dependent personality disorder.
At his first discharge, Mr. L was diagnosed with a personality disorder with significant passive-aggressive traits. His lifelong dysphoria and lack of ambition also suggested dysthymia.
With discharge from this latest hospitalization pending, we searched for options. We considered Mr. L’s ongoing suicidality, persistent acting out, and aggression. Treatment team members discussed his use of “primitive defenses”2 stemming from his limited coping skills in the face of severe depression.
Table 2
Mr. L’s differential diagnosis
Possible diagnosis | Mr. L’s symptoms |
---|---|
Major depression |
|
Personality disorder |
|
Depression with psychotic features |
|
TREATMENT: A different course
One week after admission, Mr. L’s inpatient psychiatrist recommends electroconvulsive therapy (ECT) to target the patient’s presumed severe depressive episodes and disruptive behaviors. The psychiatrist is experienced in performing ECT, which in clinical trials3 has shown efficacy in treatment-refractory major depression.
After giving informed consent, Mr. L receives 8 bilateral ECT treatments in 3 weeks. Also, the hospital psychologist performs behavioral modification similar to the previous cleanliness plan and again encourages Mr. L to express his anger and anxiety verbally.
By the second week of ECT, Mr. L’s disruptive behaviors have ceased. By the end of week 3, his mood and motivation have improved to the point where he shows interest in becoming independent. He says he wants to show his estranged wife he can care for himself and eventually reunite with her.
As Mr. L continues to improve, we discharge him to outpatient community mental health services and continue citalopram, 60 mg/d, and olanzapine, 5 mg nightly.
Nearly 2 years later, Mr. L is living independently. He has been regularly seeing his psychiatrist at the community mental health center and is maintained on citalopram and olanzapine. He continues trying to make amends with his wife but is still out of work and receives Social Security disability benefits.
The authors’ observations
Mr. L was fortunate that his inpatient psychiatrist could re-evaluate the diagnosis after identifying the staff’s significantly hateful countertransference. This allowed staff to offer ECT, which—despite its documented efficacy for major depression—is not widely available in the United States.
If no ECT providers were available, we would have considered medication change and long-term treatment in a state mental hospital until Mr. L showed he could care for himself.
Related resources
- Nagera H. Countertransference (PowerPoint presentation). Tampa, FL: The Carter Jenkins Center; 2003. www.thecjc.org/ppoint/ppoint/ct.ppt.
- MayoClinic.com video: Electroconvulsive therapy (ECT): One woman’s journey. Click on “Video” at top, then scroll to title.
- Aripiprazole • Abilify
- Olanzapine • Zyprexa
- Citalopram • Celexa
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Green LB. The value of hate in the countertransference. Clin Soc Work J 2006;34:188-99.
2. Vaillant GE. Ego mechanisms of defense and personality psychopathology. J Abnorm Psychol 1994;103:44-50.
3. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20:13-20.
CASE: He bares it all
Police have arrested Mr. L, age 62, 3 times in 36 hours after spotting him walking naked in public. With the county jail jammed to capacity, police bring him each time to our hospital’s emergency room.
After his first arrest, Mr. L matter-of-factly tells us, “I want to walk naked and starve myself to death.” His self-harm exhortations amplify with each visit until—at the third presentation—he reports that he has not eaten for at least 2 days.
Mr. L had been living on the streets for nearly 1 month. Before that, he had been in jail for approximately 1 month after attacking a nursing home patient. He has been hospitalized twice in 5 months for severe depression and personality disorder and has engaged in numerous disruptive behavioral episodes and feeble suicide attempts. At this latest presentation, he appears disheveled and lacks judgment and insight into his condition.
The authors’ observations
We readmitted Mr. L with working diagnoses of:
- major depressive disorder with psychotic features, based on his suicide threats and complaints of depression
- personality disorder not otherwise specified, based on his behavioral episodes, apparent desire to be cared for (Table 1), and refusal to “get better” during 2 recent hospitalizations.
A troubled life: Mr. L’s history
Period | Mr. L’s difficulties |
---|---|
Childhood | Has no friends in school; his mother—Mr. L’s sole source of emotional support—continues to wash his laundry, buy his food and clothes into his 20s |
Adult life | Keeps ‘goofing off’ at work and has trouble staying employed; depends on wife to manage his life |
2 years ago | Shows depressive symptoms (amotivation, lack of concentration, increased fatigue, decreased appetite) after shoulder injury Develops irrational fear that household appliances will malfunction Becomes hostile toward his wife of 34 years |
5 months ago | Hospitalized after threatening to kill wife; has depressive symptoms and is disruptive during month-long hospitalization |
4 months ago | Discharged from hospital to homeless shelter because estranged wife won’t allow him back home; is readmitted after shelter staff find him banging his head on an iron gate; again behaves disruptively |
3 months ago | Discharged from second month-long hospitalization to nursing home |
2 months ago | Attacks patient at nursing home; police arrest and incarcerate him on disorderly conduct charge |
Past month | Released from jail after 1 month and spends weeks on the streets; lands in ER after police repeatedly catch him walking naked in public |
HISTORY: His best friends
As a child, Mr. L had no friends. His father was physically present but emotionally distant, so he relied on his mother for emotional support. Throughout his teens and early adulthood, his mother continued to do his laundry, buy his food and clothes, and run his life. When he married in his early 20s, his wife assumed this role.
Mr. L avoided psychiatric care for most of his life but did not socialize outside the house, lacked ambition, and seemed content to depend on his wife. He worked primarily as a janitor or housekeeper but was constantly getting fired and drifted from job to job. His wife told us that when he was supposed to be working, he spent hours staring at the walls and watching TV.
As the shoulder pain intensified, Mr. L quit his job. While out of work, he stopped attending physical therapy sessions when his depressive symptoms began to offset the shoulder pain. He suffered loss of concentration and motivation, increased fatigue with hypersomnia, and decreased appetite. He lost 10 to 12 lb in 1 year.
Mr. L also started having trouble “focusing on reality” and developed obsessive fears of malfunctions around the house, such as the furnace blowing up, the stove catching fire, or the toilet backing up. At one point, he began urinating and defecating in his pants to avoid using the toilet. He began to feel hopeless and several times tried to suffocate himself by placing a plastic bag over his head.
He also grew irritable, angry, and aggressive—mostly toward his wife, who increasingly feared him. He started blaming her for “everything wrong in my life” and began contemplating stabbing her to death or striking her head with a hammer.
Five months ago, Mr. L was involuntarily hospitalized for depressive symptoms, suicidality, and continued homicidal thoughts toward his wife. The attending psychiatrist started olanzapine, 5 mg nightly, for psychotic features, and citalopram, 10 mg/d, for depression and anxiety, and ordered one-on-one observation to prevent additional suicide attempts. Mr. L’s shoulder pain had resolved by this time.
Three days later, Mr. L began refusing to eat. The psychiatrist then increased citalopram to 20 mg/d and olanzapine to 5 mg bid and asked a hospital internist to evaluate for malnutrition and a psychologist to gauge cognitive and intellectual function.
During the psychologist’s evaluation, Mr. L showed average global intellectual functioning but delays in visual-motor speed, visual working memory, and alertness to his environment. These findings, however, did not explain the patient’s lower functioning at home or in the hospital.
We ruled out organic causes for Mr. L’s cognitive deficits after receiving normal brain MRI, urinalysis, rapid plasma reagin titer, and thyroid-stimulating hormone test results. We also ruled out malnutrition because vitamin B12 and folate levels were normal but ordered a dietary consult to help Mr. L regain weight.
Staff and family registered Mr. L for Medicare and Medicaid benefits so that he could become more independent, but his behavior soon regressed. He complained that staff and family were ignoring him and started urinating outside the bathroom, eating and smearing his feces, and bothering other patients. Staff directed Mr. L’s wife to ignore his verbal abuse over the phone and encourage him to stay motivated for treatment.
Mr. L’s disruptive behavior stopped after the psychologist tried individual therapy with behavior modification. The psychologist helped him devise a cleanliness plan and encouraged him to express his anger verbally rather than acting out. When Mr. L smeared his feces, he was to scrub the area with soap and water, take a 5-minute cold shower, put on clean clothes, and write and read an apology to hospital staff.
DISCHARGE: Nowhere to go
One month after admission, Mr. L was free of suicidal and homicidal thoughts and other symptoms. Staff prepared him for discharge, but his wife was contemplating divorce and refused to allow him back home. He also declined community outpatient treatment because he wanted his life to return to “normal” and was unaware that he was harming himself and others.
With no other disposition options, we discharged Mr. L to a homeless shelter. Later that day, shelter staff brought him back to the ER after they found him banging his head against an iron gate. We readmitted him to the psychiatric unit, at which point he endorsed suicidal thinking.
READMISSION: ‘Cold’ case
During this second hospitalization, Mr. L was again eating his feces as well as coloring himself with green markers, writing obscenities on the wall, and tearing up other patients’ papers. He repeatedly took 15-minute cold showers and told staff as they urged him out of the shower that he wanted to die by inducing hypothermia. During these episodes, he often called his estranged wife and told her what he was doing.
After the treatment team had Mr. L civilly committed, the attending psychiatrist titrated citalopram to 60 mg/d, discontinued olanzapine, and added aripiprazole to target the patient’s underlying depressive symptoms. Aripiprazole was started at 5 mg nightly and eventually titrated to 10 mg nightly. On 3 occasions during the month-long hospitalization, Mr. L refused to take his medications because he felt he did not belong in the hospital.
The attending psychiatrist diagnosed “dependent, passive-aggressive behaviors” and noted that Mr. L was “not amenable” to psychiatric hospitalization. The treatment team and outpatient community mental health department decided the patient had a personality disorder and that continued hospitalization would prevent him from attaining autonomy.
We then discharged Mr. L to a nursing home. There, he demanded a transfer back to the hospital or to jail because he feared he could not afford nursing home care and believed he could receive more attention elsewhere. His request was rejected after our ER psychiatrist found him medically and mentally fit to stay at the nursing home.
About 1 month later, Mr. L tried to smother a female patient by holding a pillow over her face but stopped when she began to struggle. After he told the nurses what he had done, staff immediately called police, who arrested Mr. L and transferred him to the county jail.
Because police and nursing home staff viewed the incident as a cry for help rather than a cold-blooded attack, police charged Mr. L with disorderly conduct. One month later, police dropped the charge and released him to the streets.
The authors’ observations
Mr. L triggered hateful reactions among several treatment team members, many of whom felt vindicated by his arrest. Clinicians might react this way if they feel a patient is wasting their time, manipulating them, not recognizing their narcissistic need for the patient to change, or ignoring their treatment plans.1
Acknowledging the staff’s—and your own—reaction to a difficult patient is critical. Not doing so can lead to treatment decisions based on emotions rather than evidence. In a busy clinical setting, it’s easy to lose sight of this.
The following strategies can help you manage hateful countertransference, cope with a patient’s offensive behaviors, and make appropriate decisions:
- Allow staff members to discuss their feelings. Encourage them to acknowledge and discuss their feelings during team meetings or daily treatment discussions. This helped members of our team recognize that their identification with Mr. L’s self-rejection fueled their desire to “reject” him by discharging him to police or the homeless shelter.
- Joke about the patient’s behavior when appropriate. Humor is a mature and potentially healing defense mechanism. When not treating Mr. L, for example, we joked among ourselves about publishing a case report titled, “The case of the poop-eater.” Never joke about the patient in the therapeutic milieu, where it can be disruptive.
- See the behavior as a defense mechanism. Viewing patients’ reactions as defense mechanisms—rather than effects of a psychiatric disorder—can help you better understand the patient’s underlying pathophysiology.
READMISSION: More bad behavior
After his 3 arrests for public nudity, we readmit Mr. L, restart citalopram at 20 mg/d, and titrate it back to 60 mg/d to target his depression. We also switch back to olanzapine, 10 mg nightly, because the patient has seen little clinical benefit from aripiprazole and feels that olanzapine had improved his sleep.
In the psychiatric ward, Mr. L is once again disturbing patients, smearing and eating feces, and making half-hearted suicide attempts. Upset that staff is “ignoring” him, he enters other patients’ rooms without invitation and urinates in places other than the bathroom.
The authors’ observations
After 3 hospital admissions, Mr. L’s diagnosis remained unclear (Table 2). At his first admission, his symptoms suggested major depression with psychotic features. With his subsequent behaviors in the inpatient psychiatric unit—including primitive suicide attempts and smearing and eating feces—Mr. L showed a strong desire to be cared for. This and his past dependence on his wife and mother suggested a severe dependent personality disorder.
At his first discharge, Mr. L was diagnosed with a personality disorder with significant passive-aggressive traits. His lifelong dysphoria and lack of ambition also suggested dysthymia.
With discharge from this latest hospitalization pending, we searched for options. We considered Mr. L’s ongoing suicidality, persistent acting out, and aggression. Treatment team members discussed his use of “primitive defenses”2 stemming from his limited coping skills in the face of severe depression.
Table 2
Mr. L’s differential diagnosis
Possible diagnosis | Mr. L’s symptoms |
---|---|
Major depression |
|
Personality disorder |
|
Depression with psychotic features |
|
TREATMENT: A different course
One week after admission, Mr. L’s inpatient psychiatrist recommends electroconvulsive therapy (ECT) to target the patient’s presumed severe depressive episodes and disruptive behaviors. The psychiatrist is experienced in performing ECT, which in clinical trials3 has shown efficacy in treatment-refractory major depression.
After giving informed consent, Mr. L receives 8 bilateral ECT treatments in 3 weeks. Also, the hospital psychologist performs behavioral modification similar to the previous cleanliness plan and again encourages Mr. L to express his anger and anxiety verbally.
By the second week of ECT, Mr. L’s disruptive behaviors have ceased. By the end of week 3, his mood and motivation have improved to the point where he shows interest in becoming independent. He says he wants to show his estranged wife he can care for himself and eventually reunite with her.
As Mr. L continues to improve, we discharge him to outpatient community mental health services and continue citalopram, 60 mg/d, and olanzapine, 5 mg nightly.
Nearly 2 years later, Mr. L is living independently. He has been regularly seeing his psychiatrist at the community mental health center and is maintained on citalopram and olanzapine. He continues trying to make amends with his wife but is still out of work and receives Social Security disability benefits.
The authors’ observations
Mr. L was fortunate that his inpatient psychiatrist could re-evaluate the diagnosis after identifying the staff’s significantly hateful countertransference. This allowed staff to offer ECT, which—despite its documented efficacy for major depression—is not widely available in the United States.
If no ECT providers were available, we would have considered medication change and long-term treatment in a state mental hospital until Mr. L showed he could care for himself.
Related resources
- Nagera H. Countertransference (PowerPoint presentation). Tampa, FL: The Carter Jenkins Center; 2003. www.thecjc.org/ppoint/ppoint/ct.ppt.
- MayoClinic.com video: Electroconvulsive therapy (ECT): One woman’s journey. Click on “Video” at top, then scroll to title.
- Aripiprazole • Abilify
- Olanzapine • Zyprexa
- Citalopram • Celexa
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: He bares it all
Police have arrested Mr. L, age 62, 3 times in 36 hours after spotting him walking naked in public. With the county jail jammed to capacity, police bring him each time to our hospital’s emergency room.
After his first arrest, Mr. L matter-of-factly tells us, “I want to walk naked and starve myself to death.” His self-harm exhortations amplify with each visit until—at the third presentation—he reports that he has not eaten for at least 2 days.
Mr. L had been living on the streets for nearly 1 month. Before that, he had been in jail for approximately 1 month after attacking a nursing home patient. He has been hospitalized twice in 5 months for severe depression and personality disorder and has engaged in numerous disruptive behavioral episodes and feeble suicide attempts. At this latest presentation, he appears disheveled and lacks judgment and insight into his condition.
The authors’ observations
We readmitted Mr. L with working diagnoses of:
- major depressive disorder with psychotic features, based on his suicide threats and complaints of depression
- personality disorder not otherwise specified, based on his behavioral episodes, apparent desire to be cared for (Table 1), and refusal to “get better” during 2 recent hospitalizations.
A troubled life: Mr. L’s history
Period | Mr. L’s difficulties |
---|---|
Childhood | Has no friends in school; his mother—Mr. L’s sole source of emotional support—continues to wash his laundry, buy his food and clothes into his 20s |
Adult life | Keeps ‘goofing off’ at work and has trouble staying employed; depends on wife to manage his life |
2 years ago | Shows depressive symptoms (amotivation, lack of concentration, increased fatigue, decreased appetite) after shoulder injury Develops irrational fear that household appliances will malfunction Becomes hostile toward his wife of 34 years |
5 months ago | Hospitalized after threatening to kill wife; has depressive symptoms and is disruptive during month-long hospitalization |
4 months ago | Discharged from hospital to homeless shelter because estranged wife won’t allow him back home; is readmitted after shelter staff find him banging his head on an iron gate; again behaves disruptively |
3 months ago | Discharged from second month-long hospitalization to nursing home |
2 months ago | Attacks patient at nursing home; police arrest and incarcerate him on disorderly conduct charge |
Past month | Released from jail after 1 month and spends weeks on the streets; lands in ER after police repeatedly catch him walking naked in public |
HISTORY: His best friends
As a child, Mr. L had no friends. His father was physically present but emotionally distant, so he relied on his mother for emotional support. Throughout his teens and early adulthood, his mother continued to do his laundry, buy his food and clothes, and run his life. When he married in his early 20s, his wife assumed this role.
Mr. L avoided psychiatric care for most of his life but did not socialize outside the house, lacked ambition, and seemed content to depend on his wife. He worked primarily as a janitor or housekeeper but was constantly getting fired and drifted from job to job. His wife told us that when he was supposed to be working, he spent hours staring at the walls and watching TV.
As the shoulder pain intensified, Mr. L quit his job. While out of work, he stopped attending physical therapy sessions when his depressive symptoms began to offset the shoulder pain. He suffered loss of concentration and motivation, increased fatigue with hypersomnia, and decreased appetite. He lost 10 to 12 lb in 1 year.
Mr. L also started having trouble “focusing on reality” and developed obsessive fears of malfunctions around the house, such as the furnace blowing up, the stove catching fire, or the toilet backing up. At one point, he began urinating and defecating in his pants to avoid using the toilet. He began to feel hopeless and several times tried to suffocate himself by placing a plastic bag over his head.
He also grew irritable, angry, and aggressive—mostly toward his wife, who increasingly feared him. He started blaming her for “everything wrong in my life” and began contemplating stabbing her to death or striking her head with a hammer.
Five months ago, Mr. L was involuntarily hospitalized for depressive symptoms, suicidality, and continued homicidal thoughts toward his wife. The attending psychiatrist started olanzapine, 5 mg nightly, for psychotic features, and citalopram, 10 mg/d, for depression and anxiety, and ordered one-on-one observation to prevent additional suicide attempts. Mr. L’s shoulder pain had resolved by this time.
Three days later, Mr. L began refusing to eat. The psychiatrist then increased citalopram to 20 mg/d and olanzapine to 5 mg bid and asked a hospital internist to evaluate for malnutrition and a psychologist to gauge cognitive and intellectual function.
During the psychologist’s evaluation, Mr. L showed average global intellectual functioning but delays in visual-motor speed, visual working memory, and alertness to his environment. These findings, however, did not explain the patient’s lower functioning at home or in the hospital.
We ruled out organic causes for Mr. L’s cognitive deficits after receiving normal brain MRI, urinalysis, rapid plasma reagin titer, and thyroid-stimulating hormone test results. We also ruled out malnutrition because vitamin B12 and folate levels were normal but ordered a dietary consult to help Mr. L regain weight.
Staff and family registered Mr. L for Medicare and Medicaid benefits so that he could become more independent, but his behavior soon regressed. He complained that staff and family were ignoring him and started urinating outside the bathroom, eating and smearing his feces, and bothering other patients. Staff directed Mr. L’s wife to ignore his verbal abuse over the phone and encourage him to stay motivated for treatment.
Mr. L’s disruptive behavior stopped after the psychologist tried individual therapy with behavior modification. The psychologist helped him devise a cleanliness plan and encouraged him to express his anger verbally rather than acting out. When Mr. L smeared his feces, he was to scrub the area with soap and water, take a 5-minute cold shower, put on clean clothes, and write and read an apology to hospital staff.
DISCHARGE: Nowhere to go
One month after admission, Mr. L was free of suicidal and homicidal thoughts and other symptoms. Staff prepared him for discharge, but his wife was contemplating divorce and refused to allow him back home. He also declined community outpatient treatment because he wanted his life to return to “normal” and was unaware that he was harming himself and others.
With no other disposition options, we discharged Mr. L to a homeless shelter. Later that day, shelter staff brought him back to the ER after they found him banging his head against an iron gate. We readmitted him to the psychiatric unit, at which point he endorsed suicidal thinking.
READMISSION: ‘Cold’ case
During this second hospitalization, Mr. L was again eating his feces as well as coloring himself with green markers, writing obscenities on the wall, and tearing up other patients’ papers. He repeatedly took 15-minute cold showers and told staff as they urged him out of the shower that he wanted to die by inducing hypothermia. During these episodes, he often called his estranged wife and told her what he was doing.
After the treatment team had Mr. L civilly committed, the attending psychiatrist titrated citalopram to 60 mg/d, discontinued olanzapine, and added aripiprazole to target the patient’s underlying depressive symptoms. Aripiprazole was started at 5 mg nightly and eventually titrated to 10 mg nightly. On 3 occasions during the month-long hospitalization, Mr. L refused to take his medications because he felt he did not belong in the hospital.
The attending psychiatrist diagnosed “dependent, passive-aggressive behaviors” and noted that Mr. L was “not amenable” to psychiatric hospitalization. The treatment team and outpatient community mental health department decided the patient had a personality disorder and that continued hospitalization would prevent him from attaining autonomy.
We then discharged Mr. L to a nursing home. There, he demanded a transfer back to the hospital or to jail because he feared he could not afford nursing home care and believed he could receive more attention elsewhere. His request was rejected after our ER psychiatrist found him medically and mentally fit to stay at the nursing home.
About 1 month later, Mr. L tried to smother a female patient by holding a pillow over her face but stopped when she began to struggle. After he told the nurses what he had done, staff immediately called police, who arrested Mr. L and transferred him to the county jail.
Because police and nursing home staff viewed the incident as a cry for help rather than a cold-blooded attack, police charged Mr. L with disorderly conduct. One month later, police dropped the charge and released him to the streets.
The authors’ observations
Mr. L triggered hateful reactions among several treatment team members, many of whom felt vindicated by his arrest. Clinicians might react this way if they feel a patient is wasting their time, manipulating them, not recognizing their narcissistic need for the patient to change, or ignoring their treatment plans.1
Acknowledging the staff’s—and your own—reaction to a difficult patient is critical. Not doing so can lead to treatment decisions based on emotions rather than evidence. In a busy clinical setting, it’s easy to lose sight of this.
The following strategies can help you manage hateful countertransference, cope with a patient’s offensive behaviors, and make appropriate decisions:
- Allow staff members to discuss their feelings. Encourage them to acknowledge and discuss their feelings during team meetings or daily treatment discussions. This helped members of our team recognize that their identification with Mr. L’s self-rejection fueled their desire to “reject” him by discharging him to police or the homeless shelter.
- Joke about the patient’s behavior when appropriate. Humor is a mature and potentially healing defense mechanism. When not treating Mr. L, for example, we joked among ourselves about publishing a case report titled, “The case of the poop-eater.” Never joke about the patient in the therapeutic milieu, where it can be disruptive.
- See the behavior as a defense mechanism. Viewing patients’ reactions as defense mechanisms—rather than effects of a psychiatric disorder—can help you better understand the patient’s underlying pathophysiology.
READMISSION: More bad behavior
After his 3 arrests for public nudity, we readmit Mr. L, restart citalopram at 20 mg/d, and titrate it back to 60 mg/d to target his depression. We also switch back to olanzapine, 10 mg nightly, because the patient has seen little clinical benefit from aripiprazole and feels that olanzapine had improved his sleep.
In the psychiatric ward, Mr. L is once again disturbing patients, smearing and eating feces, and making half-hearted suicide attempts. Upset that staff is “ignoring” him, he enters other patients’ rooms without invitation and urinates in places other than the bathroom.
The authors’ observations
After 3 hospital admissions, Mr. L’s diagnosis remained unclear (Table 2). At his first admission, his symptoms suggested major depression with psychotic features. With his subsequent behaviors in the inpatient psychiatric unit—including primitive suicide attempts and smearing and eating feces—Mr. L showed a strong desire to be cared for. This and his past dependence on his wife and mother suggested a severe dependent personality disorder.
At his first discharge, Mr. L was diagnosed with a personality disorder with significant passive-aggressive traits. His lifelong dysphoria and lack of ambition also suggested dysthymia.
With discharge from this latest hospitalization pending, we searched for options. We considered Mr. L’s ongoing suicidality, persistent acting out, and aggression. Treatment team members discussed his use of “primitive defenses”2 stemming from his limited coping skills in the face of severe depression.
Table 2
Mr. L’s differential diagnosis
Possible diagnosis | Mr. L’s symptoms |
---|---|
Major depression |
|
Personality disorder |
|
Depression with psychotic features |
|
TREATMENT: A different course
One week after admission, Mr. L’s inpatient psychiatrist recommends electroconvulsive therapy (ECT) to target the patient’s presumed severe depressive episodes and disruptive behaviors. The psychiatrist is experienced in performing ECT, which in clinical trials3 has shown efficacy in treatment-refractory major depression.
After giving informed consent, Mr. L receives 8 bilateral ECT treatments in 3 weeks. Also, the hospital psychologist performs behavioral modification similar to the previous cleanliness plan and again encourages Mr. L to express his anger and anxiety verbally.
By the second week of ECT, Mr. L’s disruptive behaviors have ceased. By the end of week 3, his mood and motivation have improved to the point where he shows interest in becoming independent. He says he wants to show his estranged wife he can care for himself and eventually reunite with her.
As Mr. L continues to improve, we discharge him to outpatient community mental health services and continue citalopram, 60 mg/d, and olanzapine, 5 mg nightly.
Nearly 2 years later, Mr. L is living independently. He has been regularly seeing his psychiatrist at the community mental health center and is maintained on citalopram and olanzapine. He continues trying to make amends with his wife but is still out of work and receives Social Security disability benefits.
The authors’ observations
Mr. L was fortunate that his inpatient psychiatrist could re-evaluate the diagnosis after identifying the staff’s significantly hateful countertransference. This allowed staff to offer ECT, which—despite its documented efficacy for major depression—is not widely available in the United States.
If no ECT providers were available, we would have considered medication change and long-term treatment in a state mental hospital until Mr. L showed he could care for himself.
Related resources
- Nagera H. Countertransference (PowerPoint presentation). Tampa, FL: The Carter Jenkins Center; 2003. www.thecjc.org/ppoint/ppoint/ct.ppt.
- MayoClinic.com video: Electroconvulsive therapy (ECT): One woman’s journey. Click on “Video” at top, then scroll to title.
- Aripiprazole • Abilify
- Olanzapine • Zyprexa
- Citalopram • Celexa
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Green LB. The value of hate in the countertransference. Clin Soc Work J 2006;34:188-99.
2. Vaillant GE. Ego mechanisms of defense and personality psychopathology. J Abnorm Psychol 1994;103:44-50.
3. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20:13-20.
1. Green LB. The value of hate in the countertransference. Clin Soc Work J 2006;34:188-99.
2. Vaillant GE. Ego mechanisms of defense and personality psychopathology. J Abnorm Psychol 1994;103:44-50.
3. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20:13-20.
One patient’s ‘shot’ at redemption
CASE: A ‘purification’
Mr. B, age 61, is in the ICU after shooting himself in the abdomen. The trauma team asks our psychiatry consultation/liaison service to determine if he needs special observation to prevent further self-harm.
Two days ago, Mr. B stood in the parking lot of a nearby hospital, aimed his rifle toward the left upper part of his abdomen, and fired. Bleeding profusely, he dragged himself to the hospital’s emergency room. ER staff stabilized him hemodynamically, then transferred him to our hospital’s regional trauma center, where surgeons performed an emergency laparotomy and found 2 sigmoid colon perforations, with feces floating outside the bowel.
After a partial colectomy and colostomy, Mr. B received broad-spectrum antibiotics, narcotic pain medication, and bowel rest in the ICU. When the trauma team called us, the patient’s condition was stable and he had awakened enough to communicate, although he still needed frequent monitoring.
We visit Mr. B in the ICU and ask him why he shot himself. He denies he was attempting suicide but adds that for months he has been feeling depressed, stressed, and guilty about “all the bad things I’ve done in my life.” Shooting himself helped him forget these negative thoughts.
A devout Roman Catholic, Mr. B has been researching flagellation and other forms of physical penance and considers the shooting a purification. He says he shot himself in the abdomen 2 previous times and felt better for months or years after each shooting.
Four years ago, Mr. B donated his left kidney to an unknown recipient. He does not equate the kidney donation with the shootings but says he felt happy while recuperating. He was later disappointed, however, because the procedure did not help him attract the “attention” he had hoped for.
Mr. B says he had been considering the latest shooting for at least 8 months and had carefully planned it. After studying anatomy textbooks, he figured he could fire into the left upper portion of his abdomen without striking a vital organ.
For several evenings, Mr. B aimed his rifle toward his abdomen but could not bring himself to pull the trigger. On the night of the shooting, he said, he “accidentally” fired at a more damaging angle than he had planned.
Cognitive examination results are mostly normal, although Mr. B has trouble interpreting similarities and proverbs. He appears pale but well-nourished, well-groomed, and serene. He speaks softly, often closing his eyes or staring into the distance. He says he feels “relieved” and “happy” after the shooting but did not anticipate such a severe injury. He denies suicidal thoughts and—because of his current euphoric mood—he hopes he never “needs” to shoot himself again.
The authors’ observations
We first considered delusional disorder and major depressive disorder with psychotic features. Mr. B’s belief that shooting himself would solve his problems seemed delusional, although he did not appear psychotic otherwise. Confusingly, Mr. B’s pre-admission symptoms seemed to suggest major depressive disorder, but he was happy in the ICU.
We explored other diagnoses, such as an odd form of OCD and a personality disorder (especially cluster A, given his strange beliefs), though at this point we had too little information for either diagnosis.
The authors’ observations
Mr. B was recovering from major abdominal surgery, was taking nothing orally, and claimed to feel fine psychologically. Because he was not grossly psychotic and did not endorse anxiety or depression, we decided against medication but recommended a chaplain consult and planned to visit Mr. B daily to gather more history.
We considered Mr. B a low suicide risk—especially while hospitalized—after he said his “need” to shoot himself had dissipated. He also endorsed no suicidal thoughts or other depressive symptoms, and the nursing staff viewed him as pleasant and compliant. We noted this evidence in the chart and continued to reassess him daily.
HISTORY: Dreams, nightmares
Over the next week, Mr. B shares his life story. He says his parents divorced when he was age 5, and around that time he spent approximately 2 weeks in the hospital after being hit by a truck. He considers those 2 weeks a bright spot in an otherwise turbulent childhood because his parents did not fight and he was showered with gifts and attention.
Soon after, Mr. B lived with his mother. When he was 9, he heard his divorced parents arguing during a family gathering and prayed for his own death.
Throughout his childhood, Mr. B dreamed of becoming a priest and a war hero. In his early teens, he attended a church youth program where he and other youths were taught that masturbation is a mortal sin. Through high school, Mr. B’s inability to stop masturbating shook his faith and discouraged him from pursuing the priesthood.
In high school, Mr. B did not use alcohol or drugs and excelled academically but had few friends. After graduating, he enlisted in the U.S. Army and hoped to serve in Vietnam, but basic training became too stressful. The relentless harangues from drill instructors reminded him of his parents’ frequent shouting matches during his childhood.
Approximately 2 weeks into basic training, Mr. B shot himself in the abdomen and injured his liver. He underwent laparotomy and cholecystectomy and was discharged from the military. His anxiety dissipated as he recovered, though he later regretted not serving in Vietnam.
Mr. B married at age 44 and was divorced 13 years later. Throughout the marriage, he says, he verbally abused his wife and was emotionally unsupportive. After the divorce, he felt remorse over having mistreated her. His guilt disappeared after he donated his left kidney to an unknown recipient, but the guilt soon returned and drove him to shoot himself a second time in 2005.
Mr. B worked as a special education teacher for 20 years before retiring 4 years ago and has since been pursuing a similar position because he misses going to work. His inability to find a permanent job has led to anxiety, insomnia, increased guilt, and decreased appetite. He says these feelings fueled his desire to shoot himself a third time.
Since his divorce, Mr. B has lived alone and has no family or friends nearby. He feels isolated and is hurt that his family has not acknowledged the cards and notes he sent to them but adds that he did not include his return address on the mailings.
FOLLOW-UP: No relief
Eleven days after admission, Mr. B says shooting himself has not relieved his negative feelings, and his impending discharge makes him feel anxious with some suicidal thoughts. The surgical team delays discharge after Mr. B develops ileus with nausea and vomiting. The trauma team’s attending physician prescribes an antiemetic, and ileus resolves after 4 days. Mr. B then is discharged in stable condition after he denies intention to harm himself.
- Nonbizarre delusions (involving situations that occur in real life) lasting ≥1 month.
- Criterion A for schizophrenia has never been met. (Note: Tactile and olfactory hallucinations may be present in delusional disorder if they are related to the delusional disorder.)
- Apart from the impact or ramifications of the delusion(s), functioning is not markedly impaired and behavior is not obviously odd or bizarre.
- If mood episodes have occurred concurrently with delusions, their total duration has been brief relative to the duration of the delusional periods.
- The disturbance is not due to the direct physiologic effects of a substance or a general medical condition.
Source:Reference 6. Reprinted with permission
The authors’ observations
Some of Mr. B’s symptoms suggested OCD, including thought-related anxiety that is relieved after performing an action—in his case shooting himself. Whereas obsessions and/or compulsions occur daily in OCD, Mr. B would perform the action and then feel fine for months to years before his anxiety resurfaced. Also, he did not consider his thoughts wrong or obtrusive.
- Intentional production or feigning of physical or psychological signs or symptoms.
- The motivation for the behavior is to assume the sick role.
- External incentives for the behavior are absent.
Source:Reference 6. Reprinted with permission
- cluster A (odd ideas, solitary lifestyle)
- cluster B (self-harm, narcissistic tendencies)
- and cluster C (avoiding his relatives, dependence on others to meet his needs).
Mr. B’s intentional production of physical symptoms strongly suggested malingering, but we instead diagnosed factitious disorder because he was clearly motivated to play the sick role despite lack of a secondary gain (Box 2). The patient admitted causing the gunshot wound and clearly connected his subsequent emotional relief with both his positive childhood experience in the hospital and his satisfaction after donating a kidney.
Researchers have tried to distinguish between factitious disorder and other types of self-harm. Claes and Vandereycken4 would consider Mr. B’s behavior “self-mutilation” rather than factitious. Turner calls DSM-IV-TR criteria for factitious disorder nebulous and says that lying about symptoms or their origin should be a necessary criterion.5 If so, then Mr. B’s condition might fit no DSM diagnosis.6
The authors’ observations
Although Mr. B’s diagnosis remained elusive, he needed a treatment plan before discharge to prevent another shooting and save his life.
Although we did not diagnose a major depressive or anxiety-spectrum disorder, we felt an SSRI such as citalopram could help. According to some investigators, SSRIs might benefit patients with over-valued ideas that are not as persistent as delusions.7,8
Additionally, we felt supportive therapy could help Mr. B establish a therapeutic relationship with a provider to whom he could turn during future crises. Should Mr. B contemplate self-harm, the therapist could suggest medications, hospitalization, or other interventions. We also recommended pastoral counseling to increase his support within his faith.
OUTCOME Another shot?
Before discharge, we start citalopram, 10 mg/d, and schedule a follow-up appointment within 2 weeks. We also suggest that Mr. B:
- move into an apartment near his outpatient doctors
- get involved with the local Catholic community to build his support network.
Mr. B calls his recent hospitalization upsetting because “I did not get the attention I wanted.” He endorses no immediate plan to shoot himself but voices concern that when his physical problems resolve, he might shoot Himself in the liver—as he had done 40 years ago—to bring himself full circle. “There’s still something attractive about this,” he says.
The authors’ observations
Patients with factitious illness commonly refuse mental health treatment.9
We feel Mr. B needs frequent ongoing appointments in a medical clinic where doctors can provide sufficient attention to counter his persistent self-harm urges. Regular appointments with a primary care physician—regardless of whether Mr. B is medically ill—could help him feel supported.
Related resources
- Feldman MD, Eisendrath SJ, eds. The spectrum of factitious disorders. Washington, DC: American Psychiatric Press; 1996.
- Sutton J, Martinson D. Self-injury Web site: What self-injury is.www.palace.net/~llama/psych/fwhat.html.
- Citalopram • Celexa
- Omeprazole • Prilosec
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. The mysteries of Opus Dei. US News and World Report; December 14, 2003 (health section). Available at: http://www.usnews.com/usnews/culture/articles/031222/22jesus.b.htm. Accessed December 10, 2007.
2. Toke LA. transcribed by Potter DJ Flagellants. In: Catholic encyclopedia, vol. 6. New York: Robert Appleton Co.; 1909. Available at: http://www.newadvent.org/cathen/06089c.htm. Accessed December 10, 2007.
3. Glucklich A. Sacred pain: hurting the body for the sake of the soul. New York: Oxford University Press; 2001.
4. Claes L, Vandereycken W. Self-injurious behavior: differential diagnosis and functional differentiation. Compr Psychiatry 2007;48:137-44.
5. Turner MA. Factitious disorders: reformulating the DSM-IV criteria. Psychosomatics 2006;47:23-32.
6. Diagnostic and statistical manual of mental disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.
7. Veale D. Over-valued ideas: a conceptual analysis. Behav Res Ther 2002;40:383-400.
8. Jones E, Watson JP. Delusion, the overvalued idea and religious beliefs: a comparative analysis of their characteristics. Br J Psychiatry 1997;170:381-6.
9. Sutherland AJ, Rodin GM. Factitious disorders in a general hospital setting: clinical features and a review of the literature. Psychosomatics 1990;31:392-9.
CASE: A ‘purification’
Mr. B, age 61, is in the ICU after shooting himself in the abdomen. The trauma team asks our psychiatry consultation/liaison service to determine if he needs special observation to prevent further self-harm.
Two days ago, Mr. B stood in the parking lot of a nearby hospital, aimed his rifle toward the left upper part of his abdomen, and fired. Bleeding profusely, he dragged himself to the hospital’s emergency room. ER staff stabilized him hemodynamically, then transferred him to our hospital’s regional trauma center, where surgeons performed an emergency laparotomy and found 2 sigmoid colon perforations, with feces floating outside the bowel.
After a partial colectomy and colostomy, Mr. B received broad-spectrum antibiotics, narcotic pain medication, and bowel rest in the ICU. When the trauma team called us, the patient’s condition was stable and he had awakened enough to communicate, although he still needed frequent monitoring.
We visit Mr. B in the ICU and ask him why he shot himself. He denies he was attempting suicide but adds that for months he has been feeling depressed, stressed, and guilty about “all the bad things I’ve done in my life.” Shooting himself helped him forget these negative thoughts.
A devout Roman Catholic, Mr. B has been researching flagellation and other forms of physical penance and considers the shooting a purification. He says he shot himself in the abdomen 2 previous times and felt better for months or years after each shooting.
Four years ago, Mr. B donated his left kidney to an unknown recipient. He does not equate the kidney donation with the shootings but says he felt happy while recuperating. He was later disappointed, however, because the procedure did not help him attract the “attention” he had hoped for.
Mr. B says he had been considering the latest shooting for at least 8 months and had carefully planned it. After studying anatomy textbooks, he figured he could fire into the left upper portion of his abdomen without striking a vital organ.
For several evenings, Mr. B aimed his rifle toward his abdomen but could not bring himself to pull the trigger. On the night of the shooting, he said, he “accidentally” fired at a more damaging angle than he had planned.
Cognitive examination results are mostly normal, although Mr. B has trouble interpreting similarities and proverbs. He appears pale but well-nourished, well-groomed, and serene. He speaks softly, often closing his eyes or staring into the distance. He says he feels “relieved” and “happy” after the shooting but did not anticipate such a severe injury. He denies suicidal thoughts and—because of his current euphoric mood—he hopes he never “needs” to shoot himself again.
The authors’ observations
We first considered delusional disorder and major depressive disorder with psychotic features. Mr. B’s belief that shooting himself would solve his problems seemed delusional, although he did not appear psychotic otherwise. Confusingly, Mr. B’s pre-admission symptoms seemed to suggest major depressive disorder, but he was happy in the ICU.
We explored other diagnoses, such as an odd form of OCD and a personality disorder (especially cluster A, given his strange beliefs), though at this point we had too little information for either diagnosis.
The authors’ observations
Mr. B was recovering from major abdominal surgery, was taking nothing orally, and claimed to feel fine psychologically. Because he was not grossly psychotic and did not endorse anxiety or depression, we decided against medication but recommended a chaplain consult and planned to visit Mr. B daily to gather more history.
We considered Mr. B a low suicide risk—especially while hospitalized—after he said his “need” to shoot himself had dissipated. He also endorsed no suicidal thoughts or other depressive symptoms, and the nursing staff viewed him as pleasant and compliant. We noted this evidence in the chart and continued to reassess him daily.
HISTORY: Dreams, nightmares
Over the next week, Mr. B shares his life story. He says his parents divorced when he was age 5, and around that time he spent approximately 2 weeks in the hospital after being hit by a truck. He considers those 2 weeks a bright spot in an otherwise turbulent childhood because his parents did not fight and he was showered with gifts and attention.
Soon after, Mr. B lived with his mother. When he was 9, he heard his divorced parents arguing during a family gathering and prayed for his own death.
Throughout his childhood, Mr. B dreamed of becoming a priest and a war hero. In his early teens, he attended a church youth program where he and other youths were taught that masturbation is a mortal sin. Through high school, Mr. B’s inability to stop masturbating shook his faith and discouraged him from pursuing the priesthood.
In high school, Mr. B did not use alcohol or drugs and excelled academically but had few friends. After graduating, he enlisted in the U.S. Army and hoped to serve in Vietnam, but basic training became too stressful. The relentless harangues from drill instructors reminded him of his parents’ frequent shouting matches during his childhood.
Approximately 2 weeks into basic training, Mr. B shot himself in the abdomen and injured his liver. He underwent laparotomy and cholecystectomy and was discharged from the military. His anxiety dissipated as he recovered, though he later regretted not serving in Vietnam.
Mr. B married at age 44 and was divorced 13 years later. Throughout the marriage, he says, he verbally abused his wife and was emotionally unsupportive. After the divorce, he felt remorse over having mistreated her. His guilt disappeared after he donated his left kidney to an unknown recipient, but the guilt soon returned and drove him to shoot himself a second time in 2005.
Mr. B worked as a special education teacher for 20 years before retiring 4 years ago and has since been pursuing a similar position because he misses going to work. His inability to find a permanent job has led to anxiety, insomnia, increased guilt, and decreased appetite. He says these feelings fueled his desire to shoot himself a third time.
Since his divorce, Mr. B has lived alone and has no family or friends nearby. He feels isolated and is hurt that his family has not acknowledged the cards and notes he sent to them but adds that he did not include his return address on the mailings.
FOLLOW-UP: No relief
Eleven days after admission, Mr. B says shooting himself has not relieved his negative feelings, and his impending discharge makes him feel anxious with some suicidal thoughts. The surgical team delays discharge after Mr. B develops ileus with nausea and vomiting. The trauma team’s attending physician prescribes an antiemetic, and ileus resolves after 4 days. Mr. B then is discharged in stable condition after he denies intention to harm himself.
- Nonbizarre delusions (involving situations that occur in real life) lasting ≥1 month.
- Criterion A for schizophrenia has never been met. (Note: Tactile and olfactory hallucinations may be present in delusional disorder if they are related to the delusional disorder.)
- Apart from the impact or ramifications of the delusion(s), functioning is not markedly impaired and behavior is not obviously odd or bizarre.
- If mood episodes have occurred concurrently with delusions, their total duration has been brief relative to the duration of the delusional periods.
- The disturbance is not due to the direct physiologic effects of a substance or a general medical condition.
Source:Reference 6. Reprinted with permission
The authors’ observations
Some of Mr. B’s symptoms suggested OCD, including thought-related anxiety that is relieved after performing an action—in his case shooting himself. Whereas obsessions and/or compulsions occur daily in OCD, Mr. B would perform the action and then feel fine for months to years before his anxiety resurfaced. Also, he did not consider his thoughts wrong or obtrusive.
- Intentional production or feigning of physical or psychological signs or symptoms.
- The motivation for the behavior is to assume the sick role.
- External incentives for the behavior are absent.
Source:Reference 6. Reprinted with permission
- cluster A (odd ideas, solitary lifestyle)
- cluster B (self-harm, narcissistic tendencies)
- and cluster C (avoiding his relatives, dependence on others to meet his needs).
Mr. B’s intentional production of physical symptoms strongly suggested malingering, but we instead diagnosed factitious disorder because he was clearly motivated to play the sick role despite lack of a secondary gain (Box 2). The patient admitted causing the gunshot wound and clearly connected his subsequent emotional relief with both his positive childhood experience in the hospital and his satisfaction after donating a kidney.
Researchers have tried to distinguish between factitious disorder and other types of self-harm. Claes and Vandereycken4 would consider Mr. B’s behavior “self-mutilation” rather than factitious. Turner calls DSM-IV-TR criteria for factitious disorder nebulous and says that lying about symptoms or their origin should be a necessary criterion.5 If so, then Mr. B’s condition might fit no DSM diagnosis.6
The authors’ observations
Although Mr. B’s diagnosis remained elusive, he needed a treatment plan before discharge to prevent another shooting and save his life.
Although we did not diagnose a major depressive or anxiety-spectrum disorder, we felt an SSRI such as citalopram could help. According to some investigators, SSRIs might benefit patients with over-valued ideas that are not as persistent as delusions.7,8
Additionally, we felt supportive therapy could help Mr. B establish a therapeutic relationship with a provider to whom he could turn during future crises. Should Mr. B contemplate self-harm, the therapist could suggest medications, hospitalization, or other interventions. We also recommended pastoral counseling to increase his support within his faith.
OUTCOME Another shot?
Before discharge, we start citalopram, 10 mg/d, and schedule a follow-up appointment within 2 weeks. We also suggest that Mr. B:
- move into an apartment near his outpatient doctors
- get involved with the local Catholic community to build his support network.
Mr. B calls his recent hospitalization upsetting because “I did not get the attention I wanted.” He endorses no immediate plan to shoot himself but voices concern that when his physical problems resolve, he might shoot Himself in the liver—as he had done 40 years ago—to bring himself full circle. “There’s still something attractive about this,” he says.
The authors’ observations
Patients with factitious illness commonly refuse mental health treatment.9
We feel Mr. B needs frequent ongoing appointments in a medical clinic where doctors can provide sufficient attention to counter his persistent self-harm urges. Regular appointments with a primary care physician—regardless of whether Mr. B is medically ill—could help him feel supported.
Related resources
- Feldman MD, Eisendrath SJ, eds. The spectrum of factitious disorders. Washington, DC: American Psychiatric Press; 1996.
- Sutton J, Martinson D. Self-injury Web site: What self-injury is.www.palace.net/~llama/psych/fwhat.html.
- Citalopram • Celexa
- Omeprazole • Prilosec
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: A ‘purification’
Mr. B, age 61, is in the ICU after shooting himself in the abdomen. The trauma team asks our psychiatry consultation/liaison service to determine if he needs special observation to prevent further self-harm.
Two days ago, Mr. B stood in the parking lot of a nearby hospital, aimed his rifle toward the left upper part of his abdomen, and fired. Bleeding profusely, he dragged himself to the hospital’s emergency room. ER staff stabilized him hemodynamically, then transferred him to our hospital’s regional trauma center, where surgeons performed an emergency laparotomy and found 2 sigmoid colon perforations, with feces floating outside the bowel.
After a partial colectomy and colostomy, Mr. B received broad-spectrum antibiotics, narcotic pain medication, and bowel rest in the ICU. When the trauma team called us, the patient’s condition was stable and he had awakened enough to communicate, although he still needed frequent monitoring.
We visit Mr. B in the ICU and ask him why he shot himself. He denies he was attempting suicide but adds that for months he has been feeling depressed, stressed, and guilty about “all the bad things I’ve done in my life.” Shooting himself helped him forget these negative thoughts.
A devout Roman Catholic, Mr. B has been researching flagellation and other forms of physical penance and considers the shooting a purification. He says he shot himself in the abdomen 2 previous times and felt better for months or years after each shooting.
Four years ago, Mr. B donated his left kidney to an unknown recipient. He does not equate the kidney donation with the shootings but says he felt happy while recuperating. He was later disappointed, however, because the procedure did not help him attract the “attention” he had hoped for.
Mr. B says he had been considering the latest shooting for at least 8 months and had carefully planned it. After studying anatomy textbooks, he figured he could fire into the left upper portion of his abdomen without striking a vital organ.
For several evenings, Mr. B aimed his rifle toward his abdomen but could not bring himself to pull the trigger. On the night of the shooting, he said, he “accidentally” fired at a more damaging angle than he had planned.
Cognitive examination results are mostly normal, although Mr. B has trouble interpreting similarities and proverbs. He appears pale but well-nourished, well-groomed, and serene. He speaks softly, often closing his eyes or staring into the distance. He says he feels “relieved” and “happy” after the shooting but did not anticipate such a severe injury. He denies suicidal thoughts and—because of his current euphoric mood—he hopes he never “needs” to shoot himself again.
The authors’ observations
We first considered delusional disorder and major depressive disorder with psychotic features. Mr. B’s belief that shooting himself would solve his problems seemed delusional, although he did not appear psychotic otherwise. Confusingly, Mr. B’s pre-admission symptoms seemed to suggest major depressive disorder, but he was happy in the ICU.
We explored other diagnoses, such as an odd form of OCD and a personality disorder (especially cluster A, given his strange beliefs), though at this point we had too little information for either diagnosis.
The authors’ observations
Mr. B was recovering from major abdominal surgery, was taking nothing orally, and claimed to feel fine psychologically. Because he was not grossly psychotic and did not endorse anxiety or depression, we decided against medication but recommended a chaplain consult and planned to visit Mr. B daily to gather more history.
We considered Mr. B a low suicide risk—especially while hospitalized—after he said his “need” to shoot himself had dissipated. He also endorsed no suicidal thoughts or other depressive symptoms, and the nursing staff viewed him as pleasant and compliant. We noted this evidence in the chart and continued to reassess him daily.
HISTORY: Dreams, nightmares
Over the next week, Mr. B shares his life story. He says his parents divorced when he was age 5, and around that time he spent approximately 2 weeks in the hospital after being hit by a truck. He considers those 2 weeks a bright spot in an otherwise turbulent childhood because his parents did not fight and he was showered with gifts and attention.
Soon after, Mr. B lived with his mother. When he was 9, he heard his divorced parents arguing during a family gathering and prayed for his own death.
Throughout his childhood, Mr. B dreamed of becoming a priest and a war hero. In his early teens, he attended a church youth program where he and other youths were taught that masturbation is a mortal sin. Through high school, Mr. B’s inability to stop masturbating shook his faith and discouraged him from pursuing the priesthood.
In high school, Mr. B did not use alcohol or drugs and excelled academically but had few friends. After graduating, he enlisted in the U.S. Army and hoped to serve in Vietnam, but basic training became too stressful. The relentless harangues from drill instructors reminded him of his parents’ frequent shouting matches during his childhood.
Approximately 2 weeks into basic training, Mr. B shot himself in the abdomen and injured his liver. He underwent laparotomy and cholecystectomy and was discharged from the military. His anxiety dissipated as he recovered, though he later regretted not serving in Vietnam.
Mr. B married at age 44 and was divorced 13 years later. Throughout the marriage, he says, he verbally abused his wife and was emotionally unsupportive. After the divorce, he felt remorse over having mistreated her. His guilt disappeared after he donated his left kidney to an unknown recipient, but the guilt soon returned and drove him to shoot himself a second time in 2005.
Mr. B worked as a special education teacher for 20 years before retiring 4 years ago and has since been pursuing a similar position because he misses going to work. His inability to find a permanent job has led to anxiety, insomnia, increased guilt, and decreased appetite. He says these feelings fueled his desire to shoot himself a third time.
Since his divorce, Mr. B has lived alone and has no family or friends nearby. He feels isolated and is hurt that his family has not acknowledged the cards and notes he sent to them but adds that he did not include his return address on the mailings.
FOLLOW-UP: No relief
Eleven days after admission, Mr. B says shooting himself has not relieved his negative feelings, and his impending discharge makes him feel anxious with some suicidal thoughts. The surgical team delays discharge after Mr. B develops ileus with nausea and vomiting. The trauma team’s attending physician prescribes an antiemetic, and ileus resolves after 4 days. Mr. B then is discharged in stable condition after he denies intention to harm himself.
- Nonbizarre delusions (involving situations that occur in real life) lasting ≥1 month.
- Criterion A for schizophrenia has never been met. (Note: Tactile and olfactory hallucinations may be present in delusional disorder if they are related to the delusional disorder.)
- Apart from the impact or ramifications of the delusion(s), functioning is not markedly impaired and behavior is not obviously odd or bizarre.
- If mood episodes have occurred concurrently with delusions, their total duration has been brief relative to the duration of the delusional periods.
- The disturbance is not due to the direct physiologic effects of a substance or a general medical condition.
Source:Reference 6. Reprinted with permission
The authors’ observations
Some of Mr. B’s symptoms suggested OCD, including thought-related anxiety that is relieved after performing an action—in his case shooting himself. Whereas obsessions and/or compulsions occur daily in OCD, Mr. B would perform the action and then feel fine for months to years before his anxiety resurfaced. Also, he did not consider his thoughts wrong or obtrusive.
- Intentional production or feigning of physical or psychological signs or symptoms.
- The motivation for the behavior is to assume the sick role.
- External incentives for the behavior are absent.
Source:Reference 6. Reprinted with permission
- cluster A (odd ideas, solitary lifestyle)
- cluster B (self-harm, narcissistic tendencies)
- and cluster C (avoiding his relatives, dependence on others to meet his needs).
Mr. B’s intentional production of physical symptoms strongly suggested malingering, but we instead diagnosed factitious disorder because he was clearly motivated to play the sick role despite lack of a secondary gain (Box 2). The patient admitted causing the gunshot wound and clearly connected his subsequent emotional relief with both his positive childhood experience in the hospital and his satisfaction after donating a kidney.
Researchers have tried to distinguish between factitious disorder and other types of self-harm. Claes and Vandereycken4 would consider Mr. B’s behavior “self-mutilation” rather than factitious. Turner calls DSM-IV-TR criteria for factitious disorder nebulous and says that lying about symptoms or their origin should be a necessary criterion.5 If so, then Mr. B’s condition might fit no DSM diagnosis.6
The authors’ observations
Although Mr. B’s diagnosis remained elusive, he needed a treatment plan before discharge to prevent another shooting and save his life.
Although we did not diagnose a major depressive or anxiety-spectrum disorder, we felt an SSRI such as citalopram could help. According to some investigators, SSRIs might benefit patients with over-valued ideas that are not as persistent as delusions.7,8
Additionally, we felt supportive therapy could help Mr. B establish a therapeutic relationship with a provider to whom he could turn during future crises. Should Mr. B contemplate self-harm, the therapist could suggest medications, hospitalization, or other interventions. We also recommended pastoral counseling to increase his support within his faith.
OUTCOME Another shot?
Before discharge, we start citalopram, 10 mg/d, and schedule a follow-up appointment within 2 weeks. We also suggest that Mr. B:
- move into an apartment near his outpatient doctors
- get involved with the local Catholic community to build his support network.
Mr. B calls his recent hospitalization upsetting because “I did not get the attention I wanted.” He endorses no immediate plan to shoot himself but voices concern that when his physical problems resolve, he might shoot Himself in the liver—as he had done 40 years ago—to bring himself full circle. “There’s still something attractive about this,” he says.
The authors’ observations
Patients with factitious illness commonly refuse mental health treatment.9
We feel Mr. B needs frequent ongoing appointments in a medical clinic where doctors can provide sufficient attention to counter his persistent self-harm urges. Regular appointments with a primary care physician—regardless of whether Mr. B is medically ill—could help him feel supported.
Related resources
- Feldman MD, Eisendrath SJ, eds. The spectrum of factitious disorders. Washington, DC: American Psychiatric Press; 1996.
- Sutton J, Martinson D. Self-injury Web site: What self-injury is.www.palace.net/~llama/psych/fwhat.html.
- Citalopram • Celexa
- Omeprazole • Prilosec
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. The mysteries of Opus Dei. US News and World Report; December 14, 2003 (health section). Available at: http://www.usnews.com/usnews/culture/articles/031222/22jesus.b.htm. Accessed December 10, 2007.
2. Toke LA. transcribed by Potter DJ Flagellants. In: Catholic encyclopedia, vol. 6. New York: Robert Appleton Co.; 1909. Available at: http://www.newadvent.org/cathen/06089c.htm. Accessed December 10, 2007.
3. Glucklich A. Sacred pain: hurting the body for the sake of the soul. New York: Oxford University Press; 2001.
4. Claes L, Vandereycken W. Self-injurious behavior: differential diagnosis and functional differentiation. Compr Psychiatry 2007;48:137-44.
5. Turner MA. Factitious disorders: reformulating the DSM-IV criteria. Psychosomatics 2006;47:23-32.
6. Diagnostic and statistical manual of mental disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.
7. Veale D. Over-valued ideas: a conceptual analysis. Behav Res Ther 2002;40:383-400.
8. Jones E, Watson JP. Delusion, the overvalued idea and religious beliefs: a comparative analysis of their characteristics. Br J Psychiatry 1997;170:381-6.
9. Sutherland AJ, Rodin GM. Factitious disorders in a general hospital setting: clinical features and a review of the literature. Psychosomatics 1990;31:392-9.
1. The mysteries of Opus Dei. US News and World Report; December 14, 2003 (health section). Available at: http://www.usnews.com/usnews/culture/articles/031222/22jesus.b.htm. Accessed December 10, 2007.
2. Toke LA. transcribed by Potter DJ Flagellants. In: Catholic encyclopedia, vol. 6. New York: Robert Appleton Co.; 1909. Available at: http://www.newadvent.org/cathen/06089c.htm. Accessed December 10, 2007.
3. Glucklich A. Sacred pain: hurting the body for the sake of the soul. New York: Oxford University Press; 2001.
4. Claes L, Vandereycken W. Self-injurious behavior: differential diagnosis and functional differentiation. Compr Psychiatry 2007;48:137-44.
5. Turner MA. Factitious disorders: reformulating the DSM-IV criteria. Psychosomatics 2006;47:23-32.
6. Diagnostic and statistical manual of mental disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.
7. Veale D. Over-valued ideas: a conceptual analysis. Behav Res Ther 2002;40:383-400.
8. Jones E, Watson JP. Delusion, the overvalued idea and religious beliefs: a comparative analysis of their characteristics. Br J Psychiatry 1997;170:381-6.
9. Sutherland AJ, Rodin GM. Factitious disorders in a general hospital setting: clinical features and a review of the literature. Psychosomatics 1990;31:392-9.
A young man’s ‘trips’ to heaven and hell
CASE: The man from Betelgeuse
Mr. F, age 33, has been hospitalized repeatedly for psychotic episodes after abuse of dextromethorphan in cold medications.
Approximately 1 week before presenting to us, Mr. F stormed out of his house after his father, with whom he lived, confronted him about spending his allowance on cold medications. He spent the week living on the streets, abusing dextromethorphan whenever he could get it.
One night, Mr. F approached a police officer at an accident scene and exclaimed, “Dude, I’m from the planet Betelgeuse.” He appeared disorganized as police questioned him, and officers transported him to the county hospital’s psychiatric emergency service.
At presentation, Mr. F is at times silly, irritable, and sleepy, and chants incantations during the intake interview. Alternately, he hears Jesus Christ and aliens from Betelgeuse telling him “everything is going to be cool” and voices of aliens threatening to abduct him.
We admit Mr. F to the inpatient psychiatric unit, start risperidone at 2 mg nightly, and titrate it to 6 mg nightly over 3 days, after which he is significantly more organized with reduced auditory hallucinations. At discharge 6 days later, he still occasionally hears Jesus but has partial insight into his obsession with aliens and no paranoid delusions. We continue risperidone, 6 mg nightly, and refer him to an outpatient mental health program. He visits the clinic once but avoids the attending psychiatrist.
Five days later, Mr. F begins hallucinating at home and his father brings him back to the emergency psychiatry unit. At presentation, the patient claims to be an agent of Satan and waves his arms wildly while performing “black magic.” He believes he is damned and that previous messages he thought came from Jesus and extraterrestrials were instead from the devil.
Mr. F’s father reports that over the weekend his son ingested 6 boxes of cold medicine—each with 16 tablets containing 30 mg of dextromethorphan. Peeling skin on the lower part of Mr. F’s forehead, the bridge of his nose, and under his eyes suggests chronic cold tablet abuse. We re-admit the patient after extended urine drug screen shows traces of chlorpheniramine.
The authors’ observations
Routine urine drug screens based on radio-immunoassay detect many substances, but an extended or comprehensive urine drug screen based on gas chromatography-mass spectrometry is needed to detect dextromethorphan.1 Tertiary hospitals and reference laboratories usually offer these tests.
An extended urine screen will not detect dextromethorphan 24 hours after use because the agent has a 3- to 11-hour half-life. The test can, however, detect other active cold preparation compounds with longer half-lives, such as chlorpheniramine.
If extended urine screening is not available, clinical findings discussed later in this article can confirm recent cold medication abuse. Blood testing can reveal dextromethorphan levels, but a 3- to 6-mL sample may be needed.
HISTORY: ‘Sick’ at 16
Mr. F began abusing dextromethorphan at age 16, when friends would “turn him on” to 8-ounce bottles of cough syrup every other week. He later tried marijuana, cocaine, phencyclidine, methamphetamine, morphine, and LSD. Soon after graduating from high school, he stopped using substances and remained clean for several years.
Mr. F worked as a restaurant manager for about 4 months but found the job stressful and constantly argued with staff. He resumed abusing cough syrup to relieve his stress but soon became hooked on its dissociative and hallucinogenic effects. One night he ingested enough cough syrup to remain “high” until the next morning. He was hallucinating when he reported to work that day and was fired.
Since then, Mr. F’s cold medication abuse has escalated from biweekly to almost daily at presentation. He switched to tablets because the syrup induced cold symptoms and he finds the “buzz” from the tablets easier to control.
He typically dresses in black (in keeping with his satanic obsessions) and wears a long black overcoat with several pockets, that allows him to carry boxes of cold capsules, books, and other items.
Mr. F’s father has repeatedly tried to stop his son’s cold tablet abuse by cutting off his allowance. Dextromethorphan-containing cold medications are inexpensive, however—a box of 16 30-mg tablets costs as little as $1.50. Also, Mr. F often would get money for cold capsules by going to malls and participating in market research surveys.
In the past year, Mr. F was hospitalized 6 times after dextromethorphan-induced psychotic decompensations. He has been unemployed for more than 5 years, has not been in a serious romantic relationship since college, and depends on his father for financial support. He is not abusing other substances.
The authors’ observations
As many as 80% of patients with schizophrenia also have a substance abuse disorder.2 Access to psychoactive substances, kindling associated with schizophrenia, and attempts to stop hallucinations with alcohol or illicit drugs may explain this high prevalence.2 Also, genetic or phenotypic vulnerability in schizophrenia might alter the mesolimbic dopamine system that moderates reward.
Compared with patients with schizophrenia who are substance-free, comorbid substance abuse in schizophrenia increases:
- severity of psychotic symptoms
- likelihood of emergency service use
- risk of suicide, illness, injury, hospitalization, or incarceration.3
How does dextromethorphan cause hallucinations and/or psychosis, and at what doses can these effects occur?
Dextromethorphan, a synthetic dextroisomer of codeine, exerts antitussigenic effects via the sigma opioid receptor but lacks other opioid activity.
In patients age ≥12, dextromethorphan in cold medications is well tolerated at 60 to 120 mg/d in divided doses, with mostly benign adverse reactions such as drowsiness, dizziness, upset stomach, nervousness, and restlessness.7
Hallucinogenic effects surface at 160 to ≥300 mg and psychosis often occurs at >600 mg.8 Nonsuicidal use of 3,600 mg has been described.9
Hallucinogenic effects are caused by dextrorphan, a metabolite of dextromethorphan resulting from degradation by the cytochrome P-450 2D6 isoenzyme. Dextrorphan is serotonergic and blocks N-methyl-D-aspartate glutamate receptors.10
Patients who are extensive metabolizers of CYP-450 2D6 substrates show higher blood dextrorphan and increased potential to abuse dextromethorphan for its dissociative and hallucinogenic effects.10,11
Mr. F responded well to risperidone when he wasn’t abusing cold tablets. After his last hospitalization, we referred him to a comprehensive outpatient program that could have addressed his cold medicine abuse and reintegrated him into the workplace. He avoided seeing the clinic psychiatrist, however, after promising his case manager that he would stop abusing dextromethorphan.
TREATMENT: Back to Betelgeuse
Upon re-admission, we restart risperidone, 6 mg nightly. Mr. F shows extreme somnolence caused by massive cold capsule use and is minimally cooperative with the psychiatrist’s follow-up interview. Over 36 hours, he awakens only for meals and medication and to use the bathroom. Once the somnolence passes, he cannot fall asleep at night.
Six days after admission, Mr. F is organized and hears voices mostly from Jesus with some demonic delusions. Extended urine drug screen taken 3 days after admission shows traces of chlorpheniramine but no dextromethorphan.
By day 7, Mr. F is nearly free of delusions and is discharged the next day. We continue risperidone, 6 mg nightly, to prevent the “voices,” and add diphenhydramine, 50 mg nightly, to regulate his sleep. We arrange follow-up care at an outpatient clinic, but Mr. F again avoids the clinic psychiatrist.
The authors’ observations
Mr. F’s “robo” binge triggered a profound and prolonged psychotic decompensation.
Dextrorphan—a pharmacologically active metabolite of dextromethorphan— might have disrupted cortical and sub-cortical glutamatergic neurotransmission,6 leading to florid psychosis and delayed recovery. Induction of the cytochrome P-450 2D6 isoenzyme, which metabolizes dextromethorphan, also could have prolonged Mr. F’s psychosis (Box 1).7-11
RELAPSE: Return visits
Three weeks after discharge, Mr. F fights with police officers after they find him hallucinating in the streets. Police charge him with disorderly conduct and resisting arrest and bring him back to the psychiatric ER. We again resolve his auditory hallucinations with risperidone, 6 mg nightly. After 8 days we discharge him to police, who then transport him to jail and later release him on bail.
Six months later, Mr. F is hospitalized twice in 2 months after dextromethorphan-induced decompensations. He recovers quickly both times but lacks insight into his mental illness and his “robo” problem.
The authors’ observations
Dextromethorphan, known by many street names (Box 2), is contained in more than 100 OTC preparations, and is sold on the Internet in powder form.
13 Numerous factors explain this increase:
- Most people do not know that dextromethorphan-laced medications are dangerous if misused.
- These preparations can be purchased at many stores or snatched from the medicine chest.
- Several Web sites describe how to “safely” abuse dextromethorphan.13
medical consequences
Many dextromethorphan-laced preparations contain other active compounds—such as pseudoephedrine, acetaminophen, chlorpheniramine, guaifenesin, or bromide—that can cause serious adverse effects at above-normal doses. Abuse of medications containing both chlorpheniramine and dextromethorphan leads to hallucinogenic euphoria and dissociation, followed by hours of intense somnolence.
Dextromethorphan can cause serotonin syndrome when taken with serotonergic drugs such as amphetamines, cocaine, monoamine oxidase inhibitors, or selective serotonin reuptake inhibitors. Symptoms include tachycardia, hypertension, diaphoresis, mydriasis, myoclonus, agitation, and seizures.
Street names
CCC, triple C, DM, DXM, skittles, tuss, robo, poor man’s PCP
Dosing forms
Liquid, capsules, liquid gelatin capsules, lozenge tablets, powder
Most commonly abused OTC preparations
Coricidin, Robitussin
The authors’ observations
Physical and psychiatric symptoms, patient history, and collateral information together can confirm dextromethorphan abuse in patients who present with mainly visual and tactile hallucinations. The signs are easy to miss in patients with schizophrenia because schizophrenia is believed to be causing the psychosis.
Psychiatric/physical symptoms. Psychiatric symptoms of “robo” intoxication include euphoria, altered time perception, disorientation, and tactile, visual and auditory hallucinations.7 Physical symptoms include excitation, nystagmus, tachycardia, hypertension, hyperthermia, vomiting, urinary retention, drowsiness, and rash. Extreme dextromethorphan withdrawal can cause dysphoria, insomnia, vomiting, diaphoresis, abdominal pain, and diarrhea.7
Also watch for dermatitis on the forehead, nose, or cheeks, which can result from chronic abuse of preparations containing dextromethorphan plus bromide or chlorpheniramine.
Patient history. Has the patient abused dextromethorphan before? If so, how often? When was he last treated for decompensation after cold medication abuse?
Also check for abuse of other substances, and ask teenage patients if their friends use cold preparations recreationally.
Collateral information. Ask family members to search the patient’s room for supplies of cold medicine and for empty boxes and capsule cards, check the medicine chest regularly to see if cold medications are missing, and check the patient’s jacket or coat pockets for cold tablets or cough syrup.
Treating ‘robo’ abuse
Convincing the patient and family that dextromethorphan abuse can cause severe harm is critical to promoting a positive outcome. Referral to a substance abuse rehabilitation program or 12-step group can help.
Related resources
- U.S. Department of Justice, National Drug Intelligence Center. Intelligence bulletin: DXM (dextromethorphan). www.usdoj.gov/ndic/pubs11/11563/index.htm.
- Partnership for a Drug-Free America. Resource for parents. www.drugfree.org/Parent. Click on “Cough Medicine Abuse” under “Special Drug Reports.”
- U.S. Food and Drug Administraton. FDA warns against abuse of dextromethorphan (DXM). www.fda.gov, enter “dextromethorphan” in search field.
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Cherkes JK, Friedman JH. Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. Neurology 2006;66:1952-3.
2. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 2006;15:345-55.
3. Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006;8:37-43.
4. Orrell MW, Campbell PG. Dependence on dextromethorphan hydrobromyde. Br Med J 1986;293:1242-3.
5. Iaboni RP, Aronowitz JS. Dextromethorphan abuse in a dually diagnosed patient. J Nerv Ment Dis 1995;183:341-2.
6. Krystal JH, D’Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169:215-33.
7. Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995;13:174-6.
8. Cranston JW, Yoast R. Abuse of dextromethorphan. Arch Fam Med 1999;8:99-100.
9. Schadel M, Sellers EM. Psychosis with Vicks Formula 44-D abuse. CMAJ 1992;147:843-4.
10. Miller SC. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 2005;10:325-7.
11. Zawertailo LA, Kaplan HL, Busto UE, et al. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 1998;18:332-7.
12. Ball JK, Albright V. Emergency department visits involving dextromethorphan. Drug Abuse Warning Network Report 2006;32:1-4.
13. Bryner JK, Wang UK, Hui JW, et al. Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med 2006;160:1217-22.
14. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225-34.
15. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of Dserine. Neuropsychopharmacology 2004;29:1080-90.
CASE: The man from Betelgeuse
Mr. F, age 33, has been hospitalized repeatedly for psychotic episodes after abuse of dextromethorphan in cold medications.
Approximately 1 week before presenting to us, Mr. F stormed out of his house after his father, with whom he lived, confronted him about spending his allowance on cold medications. He spent the week living on the streets, abusing dextromethorphan whenever he could get it.
One night, Mr. F approached a police officer at an accident scene and exclaimed, “Dude, I’m from the planet Betelgeuse.” He appeared disorganized as police questioned him, and officers transported him to the county hospital’s psychiatric emergency service.
At presentation, Mr. F is at times silly, irritable, and sleepy, and chants incantations during the intake interview. Alternately, he hears Jesus Christ and aliens from Betelgeuse telling him “everything is going to be cool” and voices of aliens threatening to abduct him.
We admit Mr. F to the inpatient psychiatric unit, start risperidone at 2 mg nightly, and titrate it to 6 mg nightly over 3 days, after which he is significantly more organized with reduced auditory hallucinations. At discharge 6 days later, he still occasionally hears Jesus but has partial insight into his obsession with aliens and no paranoid delusions. We continue risperidone, 6 mg nightly, and refer him to an outpatient mental health program. He visits the clinic once but avoids the attending psychiatrist.
Five days later, Mr. F begins hallucinating at home and his father brings him back to the emergency psychiatry unit. At presentation, the patient claims to be an agent of Satan and waves his arms wildly while performing “black magic.” He believes he is damned and that previous messages he thought came from Jesus and extraterrestrials were instead from the devil.
Mr. F’s father reports that over the weekend his son ingested 6 boxes of cold medicine—each with 16 tablets containing 30 mg of dextromethorphan. Peeling skin on the lower part of Mr. F’s forehead, the bridge of his nose, and under his eyes suggests chronic cold tablet abuse. We re-admit the patient after extended urine drug screen shows traces of chlorpheniramine.
The authors’ observations
Routine urine drug screens based on radio-immunoassay detect many substances, but an extended or comprehensive urine drug screen based on gas chromatography-mass spectrometry is needed to detect dextromethorphan.1 Tertiary hospitals and reference laboratories usually offer these tests.
An extended urine screen will not detect dextromethorphan 24 hours after use because the agent has a 3- to 11-hour half-life. The test can, however, detect other active cold preparation compounds with longer half-lives, such as chlorpheniramine.
If extended urine screening is not available, clinical findings discussed later in this article can confirm recent cold medication abuse. Blood testing can reveal dextromethorphan levels, but a 3- to 6-mL sample may be needed.
HISTORY: ‘Sick’ at 16
Mr. F began abusing dextromethorphan at age 16, when friends would “turn him on” to 8-ounce bottles of cough syrup every other week. He later tried marijuana, cocaine, phencyclidine, methamphetamine, morphine, and LSD. Soon after graduating from high school, he stopped using substances and remained clean for several years.
Mr. F worked as a restaurant manager for about 4 months but found the job stressful and constantly argued with staff. He resumed abusing cough syrup to relieve his stress but soon became hooked on its dissociative and hallucinogenic effects. One night he ingested enough cough syrup to remain “high” until the next morning. He was hallucinating when he reported to work that day and was fired.
Since then, Mr. F’s cold medication abuse has escalated from biweekly to almost daily at presentation. He switched to tablets because the syrup induced cold symptoms and he finds the “buzz” from the tablets easier to control.
He typically dresses in black (in keeping with his satanic obsessions) and wears a long black overcoat with several pockets, that allows him to carry boxes of cold capsules, books, and other items.
Mr. F’s father has repeatedly tried to stop his son’s cold tablet abuse by cutting off his allowance. Dextromethorphan-containing cold medications are inexpensive, however—a box of 16 30-mg tablets costs as little as $1.50. Also, Mr. F often would get money for cold capsules by going to malls and participating in market research surveys.
In the past year, Mr. F was hospitalized 6 times after dextromethorphan-induced psychotic decompensations. He has been unemployed for more than 5 years, has not been in a serious romantic relationship since college, and depends on his father for financial support. He is not abusing other substances.
The authors’ observations
As many as 80% of patients with schizophrenia also have a substance abuse disorder.2 Access to psychoactive substances, kindling associated with schizophrenia, and attempts to stop hallucinations with alcohol or illicit drugs may explain this high prevalence.2 Also, genetic or phenotypic vulnerability in schizophrenia might alter the mesolimbic dopamine system that moderates reward.
Compared with patients with schizophrenia who are substance-free, comorbid substance abuse in schizophrenia increases:
- severity of psychotic symptoms
- likelihood of emergency service use
- risk of suicide, illness, injury, hospitalization, or incarceration.3
How does dextromethorphan cause hallucinations and/or psychosis, and at what doses can these effects occur?
Dextromethorphan, a synthetic dextroisomer of codeine, exerts antitussigenic effects via the sigma opioid receptor but lacks other opioid activity.
In patients age ≥12, dextromethorphan in cold medications is well tolerated at 60 to 120 mg/d in divided doses, with mostly benign adverse reactions such as drowsiness, dizziness, upset stomach, nervousness, and restlessness.7
Hallucinogenic effects surface at 160 to ≥300 mg and psychosis often occurs at >600 mg.8 Nonsuicidal use of 3,600 mg has been described.9
Hallucinogenic effects are caused by dextrorphan, a metabolite of dextromethorphan resulting from degradation by the cytochrome P-450 2D6 isoenzyme. Dextrorphan is serotonergic and blocks N-methyl-D-aspartate glutamate receptors.10
Patients who are extensive metabolizers of CYP-450 2D6 substrates show higher blood dextrorphan and increased potential to abuse dextromethorphan for its dissociative and hallucinogenic effects.10,11
Mr. F responded well to risperidone when he wasn’t abusing cold tablets. After his last hospitalization, we referred him to a comprehensive outpatient program that could have addressed his cold medicine abuse and reintegrated him into the workplace. He avoided seeing the clinic psychiatrist, however, after promising his case manager that he would stop abusing dextromethorphan.
TREATMENT: Back to Betelgeuse
Upon re-admission, we restart risperidone, 6 mg nightly. Mr. F shows extreme somnolence caused by massive cold capsule use and is minimally cooperative with the psychiatrist’s follow-up interview. Over 36 hours, he awakens only for meals and medication and to use the bathroom. Once the somnolence passes, he cannot fall asleep at night.
Six days after admission, Mr. F is organized and hears voices mostly from Jesus with some demonic delusions. Extended urine drug screen taken 3 days after admission shows traces of chlorpheniramine but no dextromethorphan.
By day 7, Mr. F is nearly free of delusions and is discharged the next day. We continue risperidone, 6 mg nightly, to prevent the “voices,” and add diphenhydramine, 50 mg nightly, to regulate his sleep. We arrange follow-up care at an outpatient clinic, but Mr. F again avoids the clinic psychiatrist.
The authors’ observations
Mr. F’s “robo” binge triggered a profound and prolonged psychotic decompensation.
Dextrorphan—a pharmacologically active metabolite of dextromethorphan— might have disrupted cortical and sub-cortical glutamatergic neurotransmission,6 leading to florid psychosis and delayed recovery. Induction of the cytochrome P-450 2D6 isoenzyme, which metabolizes dextromethorphan, also could have prolonged Mr. F’s psychosis (Box 1).7-11
RELAPSE: Return visits
Three weeks after discharge, Mr. F fights with police officers after they find him hallucinating in the streets. Police charge him with disorderly conduct and resisting arrest and bring him back to the psychiatric ER. We again resolve his auditory hallucinations with risperidone, 6 mg nightly. After 8 days we discharge him to police, who then transport him to jail and later release him on bail.
Six months later, Mr. F is hospitalized twice in 2 months after dextromethorphan-induced decompensations. He recovers quickly both times but lacks insight into his mental illness and his “robo” problem.
The authors’ observations
Dextromethorphan, known by many street names (Box 2), is contained in more than 100 OTC preparations, and is sold on the Internet in powder form.
13 Numerous factors explain this increase:
- Most people do not know that dextromethorphan-laced medications are dangerous if misused.
- These preparations can be purchased at many stores or snatched from the medicine chest.
- Several Web sites describe how to “safely” abuse dextromethorphan.13
medical consequences
Many dextromethorphan-laced preparations contain other active compounds—such as pseudoephedrine, acetaminophen, chlorpheniramine, guaifenesin, or bromide—that can cause serious adverse effects at above-normal doses. Abuse of medications containing both chlorpheniramine and dextromethorphan leads to hallucinogenic euphoria and dissociation, followed by hours of intense somnolence.
Dextromethorphan can cause serotonin syndrome when taken with serotonergic drugs such as amphetamines, cocaine, monoamine oxidase inhibitors, or selective serotonin reuptake inhibitors. Symptoms include tachycardia, hypertension, diaphoresis, mydriasis, myoclonus, agitation, and seizures.
Street names
CCC, triple C, DM, DXM, skittles, tuss, robo, poor man’s PCP
Dosing forms
Liquid, capsules, liquid gelatin capsules, lozenge tablets, powder
Most commonly abused OTC preparations
Coricidin, Robitussin
The authors’ observations
Physical and psychiatric symptoms, patient history, and collateral information together can confirm dextromethorphan abuse in patients who present with mainly visual and tactile hallucinations. The signs are easy to miss in patients with schizophrenia because schizophrenia is believed to be causing the psychosis.
Psychiatric/physical symptoms. Psychiatric symptoms of “robo” intoxication include euphoria, altered time perception, disorientation, and tactile, visual and auditory hallucinations.7 Physical symptoms include excitation, nystagmus, tachycardia, hypertension, hyperthermia, vomiting, urinary retention, drowsiness, and rash. Extreme dextromethorphan withdrawal can cause dysphoria, insomnia, vomiting, diaphoresis, abdominal pain, and diarrhea.7
Also watch for dermatitis on the forehead, nose, or cheeks, which can result from chronic abuse of preparations containing dextromethorphan plus bromide or chlorpheniramine.
Patient history. Has the patient abused dextromethorphan before? If so, how often? When was he last treated for decompensation after cold medication abuse?
Also check for abuse of other substances, and ask teenage patients if their friends use cold preparations recreationally.
Collateral information. Ask family members to search the patient’s room for supplies of cold medicine and for empty boxes and capsule cards, check the medicine chest regularly to see if cold medications are missing, and check the patient’s jacket or coat pockets for cold tablets or cough syrup.
Treating ‘robo’ abuse
Convincing the patient and family that dextromethorphan abuse can cause severe harm is critical to promoting a positive outcome. Referral to a substance abuse rehabilitation program or 12-step group can help.
Related resources
- U.S. Department of Justice, National Drug Intelligence Center. Intelligence bulletin: DXM (dextromethorphan). www.usdoj.gov/ndic/pubs11/11563/index.htm.
- Partnership for a Drug-Free America. Resource for parents. www.drugfree.org/Parent. Click on “Cough Medicine Abuse” under “Special Drug Reports.”
- U.S. Food and Drug Administraton. FDA warns against abuse of dextromethorphan (DXM). www.fda.gov, enter “dextromethorphan” in search field.
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
CASE: The man from Betelgeuse
Mr. F, age 33, has been hospitalized repeatedly for psychotic episodes after abuse of dextromethorphan in cold medications.
Approximately 1 week before presenting to us, Mr. F stormed out of his house after his father, with whom he lived, confronted him about spending his allowance on cold medications. He spent the week living on the streets, abusing dextromethorphan whenever he could get it.
One night, Mr. F approached a police officer at an accident scene and exclaimed, “Dude, I’m from the planet Betelgeuse.” He appeared disorganized as police questioned him, and officers transported him to the county hospital’s psychiatric emergency service.
At presentation, Mr. F is at times silly, irritable, and sleepy, and chants incantations during the intake interview. Alternately, he hears Jesus Christ and aliens from Betelgeuse telling him “everything is going to be cool” and voices of aliens threatening to abduct him.
We admit Mr. F to the inpatient psychiatric unit, start risperidone at 2 mg nightly, and titrate it to 6 mg nightly over 3 days, after which he is significantly more organized with reduced auditory hallucinations. At discharge 6 days later, he still occasionally hears Jesus but has partial insight into his obsession with aliens and no paranoid delusions. We continue risperidone, 6 mg nightly, and refer him to an outpatient mental health program. He visits the clinic once but avoids the attending psychiatrist.
Five days later, Mr. F begins hallucinating at home and his father brings him back to the emergency psychiatry unit. At presentation, the patient claims to be an agent of Satan and waves his arms wildly while performing “black magic.” He believes he is damned and that previous messages he thought came from Jesus and extraterrestrials were instead from the devil.
Mr. F’s father reports that over the weekend his son ingested 6 boxes of cold medicine—each with 16 tablets containing 30 mg of dextromethorphan. Peeling skin on the lower part of Mr. F’s forehead, the bridge of his nose, and under his eyes suggests chronic cold tablet abuse. We re-admit the patient after extended urine drug screen shows traces of chlorpheniramine.
The authors’ observations
Routine urine drug screens based on radio-immunoassay detect many substances, but an extended or comprehensive urine drug screen based on gas chromatography-mass spectrometry is needed to detect dextromethorphan.1 Tertiary hospitals and reference laboratories usually offer these tests.
An extended urine screen will not detect dextromethorphan 24 hours after use because the agent has a 3- to 11-hour half-life. The test can, however, detect other active cold preparation compounds with longer half-lives, such as chlorpheniramine.
If extended urine screening is not available, clinical findings discussed later in this article can confirm recent cold medication abuse. Blood testing can reveal dextromethorphan levels, but a 3- to 6-mL sample may be needed.
HISTORY: ‘Sick’ at 16
Mr. F began abusing dextromethorphan at age 16, when friends would “turn him on” to 8-ounce bottles of cough syrup every other week. He later tried marijuana, cocaine, phencyclidine, methamphetamine, morphine, and LSD. Soon after graduating from high school, he stopped using substances and remained clean for several years.
Mr. F worked as a restaurant manager for about 4 months but found the job stressful and constantly argued with staff. He resumed abusing cough syrup to relieve his stress but soon became hooked on its dissociative and hallucinogenic effects. One night he ingested enough cough syrup to remain “high” until the next morning. He was hallucinating when he reported to work that day and was fired.
Since then, Mr. F’s cold medication abuse has escalated from biweekly to almost daily at presentation. He switched to tablets because the syrup induced cold symptoms and he finds the “buzz” from the tablets easier to control.
He typically dresses in black (in keeping with his satanic obsessions) and wears a long black overcoat with several pockets, that allows him to carry boxes of cold capsules, books, and other items.
Mr. F’s father has repeatedly tried to stop his son’s cold tablet abuse by cutting off his allowance. Dextromethorphan-containing cold medications are inexpensive, however—a box of 16 30-mg tablets costs as little as $1.50. Also, Mr. F often would get money for cold capsules by going to malls and participating in market research surveys.
In the past year, Mr. F was hospitalized 6 times after dextromethorphan-induced psychotic decompensations. He has been unemployed for more than 5 years, has not been in a serious romantic relationship since college, and depends on his father for financial support. He is not abusing other substances.
The authors’ observations
As many as 80% of patients with schizophrenia also have a substance abuse disorder.2 Access to psychoactive substances, kindling associated with schizophrenia, and attempts to stop hallucinations with alcohol or illicit drugs may explain this high prevalence.2 Also, genetic or phenotypic vulnerability in schizophrenia might alter the mesolimbic dopamine system that moderates reward.
Compared with patients with schizophrenia who are substance-free, comorbid substance abuse in schizophrenia increases:
- severity of psychotic symptoms
- likelihood of emergency service use
- risk of suicide, illness, injury, hospitalization, or incarceration.3
How does dextromethorphan cause hallucinations and/or psychosis, and at what doses can these effects occur?
Dextromethorphan, a synthetic dextroisomer of codeine, exerts antitussigenic effects via the sigma opioid receptor but lacks other opioid activity.
In patients age ≥12, dextromethorphan in cold medications is well tolerated at 60 to 120 mg/d in divided doses, with mostly benign adverse reactions such as drowsiness, dizziness, upset stomach, nervousness, and restlessness.7
Hallucinogenic effects surface at 160 to ≥300 mg and psychosis often occurs at >600 mg.8 Nonsuicidal use of 3,600 mg has been described.9
Hallucinogenic effects are caused by dextrorphan, a metabolite of dextromethorphan resulting from degradation by the cytochrome P-450 2D6 isoenzyme. Dextrorphan is serotonergic and blocks N-methyl-D-aspartate glutamate receptors.10
Patients who are extensive metabolizers of CYP-450 2D6 substrates show higher blood dextrorphan and increased potential to abuse dextromethorphan for its dissociative and hallucinogenic effects.10,11
Mr. F responded well to risperidone when he wasn’t abusing cold tablets. After his last hospitalization, we referred him to a comprehensive outpatient program that could have addressed his cold medicine abuse and reintegrated him into the workplace. He avoided seeing the clinic psychiatrist, however, after promising his case manager that he would stop abusing dextromethorphan.
TREATMENT: Back to Betelgeuse
Upon re-admission, we restart risperidone, 6 mg nightly. Mr. F shows extreme somnolence caused by massive cold capsule use and is minimally cooperative with the psychiatrist’s follow-up interview. Over 36 hours, he awakens only for meals and medication and to use the bathroom. Once the somnolence passes, he cannot fall asleep at night.
Six days after admission, Mr. F is organized and hears voices mostly from Jesus with some demonic delusions. Extended urine drug screen taken 3 days after admission shows traces of chlorpheniramine but no dextromethorphan.
By day 7, Mr. F is nearly free of delusions and is discharged the next day. We continue risperidone, 6 mg nightly, to prevent the “voices,” and add diphenhydramine, 50 mg nightly, to regulate his sleep. We arrange follow-up care at an outpatient clinic, but Mr. F again avoids the clinic psychiatrist.
The authors’ observations
Mr. F’s “robo” binge triggered a profound and prolonged psychotic decompensation.
Dextrorphan—a pharmacologically active metabolite of dextromethorphan— might have disrupted cortical and sub-cortical glutamatergic neurotransmission,6 leading to florid psychosis and delayed recovery. Induction of the cytochrome P-450 2D6 isoenzyme, which metabolizes dextromethorphan, also could have prolonged Mr. F’s psychosis (Box 1).7-11
RELAPSE: Return visits
Three weeks after discharge, Mr. F fights with police officers after they find him hallucinating in the streets. Police charge him with disorderly conduct and resisting arrest and bring him back to the psychiatric ER. We again resolve his auditory hallucinations with risperidone, 6 mg nightly. After 8 days we discharge him to police, who then transport him to jail and later release him on bail.
Six months later, Mr. F is hospitalized twice in 2 months after dextromethorphan-induced decompensations. He recovers quickly both times but lacks insight into his mental illness and his “robo” problem.
The authors’ observations
Dextromethorphan, known by many street names (Box 2), is contained in more than 100 OTC preparations, and is sold on the Internet in powder form.
13 Numerous factors explain this increase:
- Most people do not know that dextromethorphan-laced medications are dangerous if misused.
- These preparations can be purchased at many stores or snatched from the medicine chest.
- Several Web sites describe how to “safely” abuse dextromethorphan.13
medical consequences
Many dextromethorphan-laced preparations contain other active compounds—such as pseudoephedrine, acetaminophen, chlorpheniramine, guaifenesin, or bromide—that can cause serious adverse effects at above-normal doses. Abuse of medications containing both chlorpheniramine and dextromethorphan leads to hallucinogenic euphoria and dissociation, followed by hours of intense somnolence.
Dextromethorphan can cause serotonin syndrome when taken with serotonergic drugs such as amphetamines, cocaine, monoamine oxidase inhibitors, or selective serotonin reuptake inhibitors. Symptoms include tachycardia, hypertension, diaphoresis, mydriasis, myoclonus, agitation, and seizures.
Street names
CCC, triple C, DM, DXM, skittles, tuss, robo, poor man’s PCP
Dosing forms
Liquid, capsules, liquid gelatin capsules, lozenge tablets, powder
Most commonly abused OTC preparations
Coricidin, Robitussin
The authors’ observations
Physical and psychiatric symptoms, patient history, and collateral information together can confirm dextromethorphan abuse in patients who present with mainly visual and tactile hallucinations. The signs are easy to miss in patients with schizophrenia because schizophrenia is believed to be causing the psychosis.
Psychiatric/physical symptoms. Psychiatric symptoms of “robo” intoxication include euphoria, altered time perception, disorientation, and tactile, visual and auditory hallucinations.7 Physical symptoms include excitation, nystagmus, tachycardia, hypertension, hyperthermia, vomiting, urinary retention, drowsiness, and rash. Extreme dextromethorphan withdrawal can cause dysphoria, insomnia, vomiting, diaphoresis, abdominal pain, and diarrhea.7
Also watch for dermatitis on the forehead, nose, or cheeks, which can result from chronic abuse of preparations containing dextromethorphan plus bromide or chlorpheniramine.
Patient history. Has the patient abused dextromethorphan before? If so, how often? When was he last treated for decompensation after cold medication abuse?
Also check for abuse of other substances, and ask teenage patients if their friends use cold preparations recreationally.
Collateral information. Ask family members to search the patient’s room for supplies of cold medicine and for empty boxes and capsule cards, check the medicine chest regularly to see if cold medications are missing, and check the patient’s jacket or coat pockets for cold tablets or cough syrup.
Treating ‘robo’ abuse
Convincing the patient and family that dextromethorphan abuse can cause severe harm is critical to promoting a positive outcome. Referral to a substance abuse rehabilitation program or 12-step group can help.
Related resources
- U.S. Department of Justice, National Drug Intelligence Center. Intelligence bulletin: DXM (dextromethorphan). www.usdoj.gov/ndic/pubs11/11563/index.htm.
- Partnership for a Drug-Free America. Resource for parents. www.drugfree.org/Parent. Click on “Cough Medicine Abuse” under “Special Drug Reports.”
- U.S. Food and Drug Administraton. FDA warns against abuse of dextromethorphan (DXM). www.fda.gov, enter “dextromethorphan” in search field.
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Cherkes JK, Friedman JH. Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. Neurology 2006;66:1952-3.
2. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 2006;15:345-55.
3. Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006;8:37-43.
4. Orrell MW, Campbell PG. Dependence on dextromethorphan hydrobromyde. Br Med J 1986;293:1242-3.
5. Iaboni RP, Aronowitz JS. Dextromethorphan abuse in a dually diagnosed patient. J Nerv Ment Dis 1995;183:341-2.
6. Krystal JH, D’Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169:215-33.
7. Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995;13:174-6.
8. Cranston JW, Yoast R. Abuse of dextromethorphan. Arch Fam Med 1999;8:99-100.
9. Schadel M, Sellers EM. Psychosis with Vicks Formula 44-D abuse. CMAJ 1992;147:843-4.
10. Miller SC. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 2005;10:325-7.
11. Zawertailo LA, Kaplan HL, Busto UE, et al. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 1998;18:332-7.
12. Ball JK, Albright V. Emergency department visits involving dextromethorphan. Drug Abuse Warning Network Report 2006;32:1-4.
13. Bryner JK, Wang UK, Hui JW, et al. Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med 2006;160:1217-22.
14. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225-34.
15. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of Dserine. Neuropsychopharmacology 2004;29:1080-90.
1. Cherkes JK, Friedman JH. Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. Neurology 2006;66:1952-3.
2. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 2006;15:345-55.
3. Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006;8:37-43.
4. Orrell MW, Campbell PG. Dependence on dextromethorphan hydrobromyde. Br Med J 1986;293:1242-3.
5. Iaboni RP, Aronowitz JS. Dextromethorphan abuse in a dually diagnosed patient. J Nerv Ment Dis 1995;183:341-2.
6. Krystal JH, D’Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169:215-33.
7. Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995;13:174-6.
8. Cranston JW, Yoast R. Abuse of dextromethorphan. Arch Fam Med 1999;8:99-100.
9. Schadel M, Sellers EM. Psychosis with Vicks Formula 44-D abuse. CMAJ 1992;147:843-4.
10. Miller SC. Dextromethorphan psychosis, dependence and physical withdrawal. Addict Biol 2005;10:325-7.
11. Zawertailo LA, Kaplan HL, Busto UE, et al. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 1998;18:332-7.
12. Ball JK, Albright V. Emergency department visits involving dextromethorphan. Drug Abuse Warning Network Report 2006;32:1-4.
13. Bryner JK, Wang UK, Hui JW, et al. Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med 2006;160:1217-22.
14. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225-34.
15. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of Dserine. Neuropsychopharmacology 2004;29:1080-90.
Is she being abused or ‘acting out’?
HISTORY: ‘Unusual behavior’
Ms. L, age 44, has severe cerebral palsy and has used a wheelchair since childhood. Her mother, who had been her primary caretaker, died 12 years ago, and her stepsister has been caring for her since.
Ms. L’s primary care physician reports that the patient has been “acting out” lately and asks us to evaluate her “unusual behavior.” Six months ago, the physician prescribed escitalopram, 30 mg/d, to treat depressive symptoms stemming from her chronic neurologic disorder.
We interview Ms. L and her stepsister together. The patient says she has been depressed, irritable, and moody, and her stepsister confirms this. The patient shows no signs of distress during the interview, and her answers appear short and guarded.
The stepsister says she typically spends her day turning Ms. L to prevent bedsores, feeding and bathing her, replacing her urinary catheter and emptying her urinary bag, and helping her to the bathroom. At day’s end, the stepsister has little time to spend with her husband or for other activities. She says at times she resents tending to Ms. L’s constant needs and feels “stressed out.”
We diagnose Ms. L with a mood disorder caused by a general medical condition. We continue escitalopram, 30 mg/d, and add oxcarbazepine, 150 mg bid, to treat her irritability and lability.
FOLLOW-UP: ‘She’s abusing me’
At Ms. L’s follow-up visit 2 weeks later, we ask her stepsister to leave the examination room and interview the patient alone to gauge her emotional condition and insight.
Seconds later, Ms. L starts crying hysterically, then reports that for 12 years her stepsister has been beating her, usually after she requests something. Yesterday, she says, her stepsister started punching her after she asked to be taken to the park.
Ms. L says the abuse is escalating and now occurs daily. She says she is covered with bruises from the last beating, although no bruises are visible at first glance. Afraid to go home with her stepsister, she pleads for help.
- call the primary care physician for collateral information
- examine Ms. L for bruises
- get the stepsister’s side of the story
- contact state protective services
- all of the above
The authors’ observations
Is Ms. L being physically abused, or is a psychiatric condition driving her to fabricate these allegations?
We saw nothing suspicious during the first interview with the stepsister, although she acknowledged difficulty coping with Ms. L’s constant requests (Box 1).1 Caring for a severely disabled person day in and day out can be trying for both the caregiver and her family, and the stepsister could be taking her frustrations out on Ms. L.
Until proven otherwise, we must assume Ms. L is being harmed and seek more information. We also must watch for signs of a delusional or factitious disorder or malingering—any of which would suggest the allegations are false.
Is often a family member
Experiences stress brought on by the strain of caregiving coupled with marital problems, lack of money, overcrowded living conditions, or lack of needed health or social services
Often abuses alcohol and/or drugs
Might have emotional problems:
- Caregiver often resents patient’s dependency
- If patient is caregiver’s parent, caregiver might be retaliating for past mistreatment
Depends on vulnerable adult for basic needs such as money or housing
Might come from a family where abusive behavior is normal
Source: Reference 1
HISTORY: A second opinion
We ask Ms. L if we can discuss the allegations with her and her stepsister, but she fears retaliation and insists that we not speak to the caretaker.
We then call Ms. L’s primary care physician, who has been managing her care for several years. He says the patient has begged him numerous times for protection from her stepsister, but adds he has found no evidence of abuse. He notes that he has witnessed tension between the 2 women during office visits and cannot dismiss the possibility of abuse.
The attending psychiatrist performs a brief physical exam with the resident looking on but finds no bruises, excoriations, or unusual scarring on her arms and legs. Because our outpatient clinic lacks an examination room, we do not perform a whole-body exam.
We then notify state protective services. There, an agent tells us that in the past year, Ms. L has made 4 allegations of caretaker abuse, none of which were substantiated after extensive investigation. The agent says her office will assign a case worker but considers the case a low priority.
When we inform Ms. L of our findings, she frantically insists that her caretaker is beating her once a week and that the abuse has gone undetected. We become skeptical, recalling that Ms. L earlier said the beatings were daily.
Ms. L says she is afraid to go home and wonders where she can stay. Having no friends or other family members nearby, she requests hospitalization.
At this point, I would:
- discharge Ms. L to a safe house with close follow-up
- hospitalize her for safety and diagnostic clarification
- discharge her to her stepsister with close follow-up
The authors’ observations
Ms. L’s allegations pose a medical, ethical, and legal challenge. Physical examination and input from a protective services officer suggest Ms. L is fabricating the allegations. On the other hand, if the accusations are true, sending Ms. L home with her stepsister would endanger her.
We could hospitalize the patient and substantiate the allegations later, but we cannot justify taxing limited hospital resources when the need is questionable. We cannot send her to a safe house because of her severe physical disability, nor can we discuss the allegations with her stepsister because Ms. L instructed us not to.
- Caregiver.com (online magazine)
www.caregiver.com - Caring Today
www.caringtoday.com - National Alliance for Caregiving
www.caregiving.org - National Alliance on Mental Illness
www.nami.org (Click on “Find Support,” then “Education, Training, and Peer Support Programs”)
DISPOSITION: Going home
After meeting with hospital officials and clinic staff, we decide that Ms. L does not meet admission criteria. We discharge her to her stepsister and see the patient again the next day.
The authors’ observations
Legal duty. Our legal duty to protect a suspected abuse victim depends on the jurisdiction in which treatment is delivered.
Many states do not require physicians to report suspected abuse, but this complicates the decision process. If the suspicion is correct, not reporting it might constitute malpractice or negligence and could provoke future lawsuits or complaints to the state medical board. Worse, the abuse may escalate and cause irreparable harm to the patient. Conversely, reporting unfounded suspicions of abuse can destroy the doctor-patient relationship, prompt the caregiver to retaliate against the patient, or inspire patients or caregivers to sue the physician.
If you suspect patient abuse and your state mandates reporting, contact the state protective services agency at once (seeRelated Resources,). Base your report on a thorough history and physical, psychiatric evaluation, and—when available—collateral information.
If your state does not mandate reporting, obtain the patient’s consent to file a complaint with state protective services. By providing informed consent, the patient gives permission to disclose protected health information, and confidentiality is not breached.
Be careful when obtaining informed consent, especially when the patient is ambivalent about reporting because of:
- fear of retaliation from the abuser
- fear of the social stigma associated with abuse
- or the patient’s false belief that she deserves the abuse.
Ethical responsibility. Even if our legal responsibility is minimal, we should go further to do what is best for the patient.
Texas, for example, does not require physicians to hospitalize or find a safe environment for a suspected abuse victim.2 But if you see evidence of abuse, notify authorities and offer the patient information about local safe houses, support groups, and social services—even if not mandated by law. If resources are available, consider hospitalizing the patient and work with his or her social worker, therapist, or clergy to orchestrate outpatient services.
Whether or not abuse has occurred, empathizing with the caretaker about the difficulty of caring for the patient could diminish the caretaker’s stress and reduce the risk of abuse.
FOLLOW-UP: Truth or delusion?
At her appointment the next day, Ms. L says things are fine at home and does not bring up the abuse allegations. We then see her every 3 days for 2 weeks, weekly for 4 weeks, and every 3 weeks thereafter as the apparent risk of abuse diminishes. At each visit, she says her caretaker is not beating her but occasionally complains that she is verbally abusive.
Three weeks after her first follow-up, Ms. L enters the examination room agitated and frightened; she says another patient in the waiting room has just tried to strangle her for no apparent reason. Upon questioning, office staff say they saw no attack and note that the accused patient is a feeble woman with no history of violence; we doubt she assaulted Ms. L.
Ms. L suffers from:
- repeated physical abuse
- delusional disorder
- factitious disorder
- malingering
The authors’ observations
Although Ms. L clearly was not assaulted in the waiting room, this complaint is key to understanding her case. Although whether she is being abused at home remains unclear, evidence increasingly suggests that she suffers from delusions.
Delusions are beliefs that are fixed, false, and not ordinarily accepted by others in a patient’s culture or subculture.3 Delusional disorder is characterized by nonbizarre delusions lasting >1 month (>3 months according to ICD-10 criteria)4 with relatively preserved functioning and without prominent hallucinations. DSM-IV-TR defines bizarre delusions as “clearly implausible, not understandable, and not derived from ordinary life experience.”4,5
Ms. L most likely has a paranoid or persecutory type delusional disorder in which she is convinced she is being harmed. Her delusional thoughts might yield mood symptoms such as anger and irritability, and she might become assaultive. Often, such patients are extraordinarily determined to succeed against “the conspirators” and frequently appeal to the legal system or law enforcement.3
Differentiating between a patient’s delusions and reality can be difficult, leading clinicians to seek collateral information from family, past medical records, or providers to establish a diagnosis. The delusions might become less circumscribed over time, or additional information might clear the clinical picture.
Ms. L’s psychological makeup might help us rule out other diagnoses. Her request for hospitalization, for example, could suggest factitious illness, but she is disabled enough to play the sick role without manufacturing symptoms. Also, she seeks hospitalization because she has no family or friends to turn to. We rule out malingering because Ms. L has nothing to gain by accusing a stranger of choking her in the waiting room.
Treating delusional disorder
Pharmacotherapy and psychotherapy typically are used together to treat delusional disorder.
Pharmacotherapy. Antipsychotics such as olanzapine, 5 to 10 mg nightly, or risperidone, 1 to 2 mg nightly, can decrease the delusional thoughts’ intensity and frequency, allowing patients to function more appropriately.3 If 2 or more antipsychotic trials do not control delusional thoughts, consider starting clozapine at 300 mg/d and titrating to 900 mg/d.
Add an antidepressant if delusional thinking causes depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, 10 to 20 mg/d, or fluoxetine, 20 to 40 mg/d, are a good starting point. Consider other antidepressant types if SSRIs do not work.
Adjunctive benzodiazepines such as clonazepam, 1 to 2 mg/d, or lorazepam, 1 to 2 mg bid as needed, can help manage acute anxiety or agitation stemming from delusions.
Once rapport is established, consider challenging delusional beliefs by having the patient list evidence supporting or refuting the delusions. Be careful not to confront delusional thinking too quickly or aggressively, as this approach often does not change the patient’s beliefs and weakens the therapeutic alliance.3
TREATMENT: Fewer complaints
We still see Ms. L every 3 weeks for supportive psychotherapy and medication management. We continue oxcarbazepine, 150 mg bid, and escitalopram, 30 mg/d, and add risperidone, 1 mg at bedtime, to target her delusional thinking, lability, and irritability.
Over 6 months, Ms. L’s complaints of abuse become less emphatic. She endorses the abuse less frequently—every 3 to 4 visits—and only if the clinician specifically asks about it. Most often, she denies abuse is occurring but says it happened previously. At each visit, we document her statements and explain in her chart why we have not notified adult protective services or police.
- National Adult Protective Services Association. Links to adult protection agencies nationwide. www.apsnetwork.org.
- National Center on Elder Abuse. www.elderabusecenter.org.
Drug brand names
- Clonazepam • Klonopin
- Clozapine • Clozaril
- Escitalopram • Lexapro
- Fluoxetine • Prozac
- Lorazepam • Ativan
- Olanzapine • Zyprexa
- Oxcarbazepine • Trileptal
- Paroxetine • Paxil
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Fairfax County, VA (June 15, 2006). Adult Protection Services. Available at: http://www.fairfaxcounty.gov/aaa/ombud/abuse.htm. Accessed October 26, 2007.
2. Texas medical jurisprudence manual, 15th ed. Austin, TX: Texas Medical Association; 2004;454–6.
3. Fennig S, Fochtman L, Bromet E. Chapter 12.16c Delusional disorder and shared psychotic disorder. In: Sadock B, Sadock V, eds. Kaplan & Sadock’s comprehensive textbook of psychiatry, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005;1525–32.
4. International Classification of Diseases, 10th rev. Geneva, Switzerland: World Health Organization; 1992.
5. Diagnostic and statistical of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
HISTORY: ‘Unusual behavior’
Ms. L, age 44, has severe cerebral palsy and has used a wheelchair since childhood. Her mother, who had been her primary caretaker, died 12 years ago, and her stepsister has been caring for her since.
Ms. L’s primary care physician reports that the patient has been “acting out” lately and asks us to evaluate her “unusual behavior.” Six months ago, the physician prescribed escitalopram, 30 mg/d, to treat depressive symptoms stemming from her chronic neurologic disorder.
We interview Ms. L and her stepsister together. The patient says she has been depressed, irritable, and moody, and her stepsister confirms this. The patient shows no signs of distress during the interview, and her answers appear short and guarded.
The stepsister says she typically spends her day turning Ms. L to prevent bedsores, feeding and bathing her, replacing her urinary catheter and emptying her urinary bag, and helping her to the bathroom. At day’s end, the stepsister has little time to spend with her husband or for other activities. She says at times she resents tending to Ms. L’s constant needs and feels “stressed out.”
We diagnose Ms. L with a mood disorder caused by a general medical condition. We continue escitalopram, 30 mg/d, and add oxcarbazepine, 150 mg bid, to treat her irritability and lability.
FOLLOW-UP: ‘She’s abusing me’
At Ms. L’s follow-up visit 2 weeks later, we ask her stepsister to leave the examination room and interview the patient alone to gauge her emotional condition and insight.
Seconds later, Ms. L starts crying hysterically, then reports that for 12 years her stepsister has been beating her, usually after she requests something. Yesterday, she says, her stepsister started punching her after she asked to be taken to the park.
Ms. L says the abuse is escalating and now occurs daily. She says she is covered with bruises from the last beating, although no bruises are visible at first glance. Afraid to go home with her stepsister, she pleads for help.
- call the primary care physician for collateral information
- examine Ms. L for bruises
- get the stepsister’s side of the story
- contact state protective services
- all of the above
The authors’ observations
Is Ms. L being physically abused, or is a psychiatric condition driving her to fabricate these allegations?
We saw nothing suspicious during the first interview with the stepsister, although she acknowledged difficulty coping with Ms. L’s constant requests (Box 1).1 Caring for a severely disabled person day in and day out can be trying for both the caregiver and her family, and the stepsister could be taking her frustrations out on Ms. L.
Until proven otherwise, we must assume Ms. L is being harmed and seek more information. We also must watch for signs of a delusional or factitious disorder or malingering—any of which would suggest the allegations are false.
Is often a family member
Experiences stress brought on by the strain of caregiving coupled with marital problems, lack of money, overcrowded living conditions, or lack of needed health or social services
Often abuses alcohol and/or drugs
Might have emotional problems:
- Caregiver often resents patient’s dependency
- If patient is caregiver’s parent, caregiver might be retaliating for past mistreatment
Depends on vulnerable adult for basic needs such as money or housing
Might come from a family where abusive behavior is normal
Source: Reference 1
HISTORY: A second opinion
We ask Ms. L if we can discuss the allegations with her and her stepsister, but she fears retaliation and insists that we not speak to the caretaker.
We then call Ms. L’s primary care physician, who has been managing her care for several years. He says the patient has begged him numerous times for protection from her stepsister, but adds he has found no evidence of abuse. He notes that he has witnessed tension between the 2 women during office visits and cannot dismiss the possibility of abuse.
The attending psychiatrist performs a brief physical exam with the resident looking on but finds no bruises, excoriations, or unusual scarring on her arms and legs. Because our outpatient clinic lacks an examination room, we do not perform a whole-body exam.
We then notify state protective services. There, an agent tells us that in the past year, Ms. L has made 4 allegations of caretaker abuse, none of which were substantiated after extensive investigation. The agent says her office will assign a case worker but considers the case a low priority.
When we inform Ms. L of our findings, she frantically insists that her caretaker is beating her once a week and that the abuse has gone undetected. We become skeptical, recalling that Ms. L earlier said the beatings were daily.
Ms. L says she is afraid to go home and wonders where she can stay. Having no friends or other family members nearby, she requests hospitalization.
At this point, I would:
- discharge Ms. L to a safe house with close follow-up
- hospitalize her for safety and diagnostic clarification
- discharge her to her stepsister with close follow-up
The authors’ observations
Ms. L’s allegations pose a medical, ethical, and legal challenge. Physical examination and input from a protective services officer suggest Ms. L is fabricating the allegations. On the other hand, if the accusations are true, sending Ms. L home with her stepsister would endanger her.
We could hospitalize the patient and substantiate the allegations later, but we cannot justify taxing limited hospital resources when the need is questionable. We cannot send her to a safe house because of her severe physical disability, nor can we discuss the allegations with her stepsister because Ms. L instructed us not to.
- Caregiver.com (online magazine)
www.caregiver.com - Caring Today
www.caringtoday.com - National Alliance for Caregiving
www.caregiving.org - National Alliance on Mental Illness
www.nami.org (Click on “Find Support,” then “Education, Training, and Peer Support Programs”)
DISPOSITION: Going home
After meeting with hospital officials and clinic staff, we decide that Ms. L does not meet admission criteria. We discharge her to her stepsister and see the patient again the next day.
The authors’ observations
Legal duty. Our legal duty to protect a suspected abuse victim depends on the jurisdiction in which treatment is delivered.
Many states do not require physicians to report suspected abuse, but this complicates the decision process. If the suspicion is correct, not reporting it might constitute malpractice or negligence and could provoke future lawsuits or complaints to the state medical board. Worse, the abuse may escalate and cause irreparable harm to the patient. Conversely, reporting unfounded suspicions of abuse can destroy the doctor-patient relationship, prompt the caregiver to retaliate against the patient, or inspire patients or caregivers to sue the physician.
If you suspect patient abuse and your state mandates reporting, contact the state protective services agency at once (seeRelated Resources,). Base your report on a thorough history and physical, psychiatric evaluation, and—when available—collateral information.
If your state does not mandate reporting, obtain the patient’s consent to file a complaint with state protective services. By providing informed consent, the patient gives permission to disclose protected health information, and confidentiality is not breached.
Be careful when obtaining informed consent, especially when the patient is ambivalent about reporting because of:
- fear of retaliation from the abuser
- fear of the social stigma associated with abuse
- or the patient’s false belief that she deserves the abuse.
Ethical responsibility. Even if our legal responsibility is minimal, we should go further to do what is best for the patient.
Texas, for example, does not require physicians to hospitalize or find a safe environment for a suspected abuse victim.2 But if you see evidence of abuse, notify authorities and offer the patient information about local safe houses, support groups, and social services—even if not mandated by law. If resources are available, consider hospitalizing the patient and work with his or her social worker, therapist, or clergy to orchestrate outpatient services.
Whether or not abuse has occurred, empathizing with the caretaker about the difficulty of caring for the patient could diminish the caretaker’s stress and reduce the risk of abuse.
FOLLOW-UP: Truth or delusion?
At her appointment the next day, Ms. L says things are fine at home and does not bring up the abuse allegations. We then see her every 3 days for 2 weeks, weekly for 4 weeks, and every 3 weeks thereafter as the apparent risk of abuse diminishes. At each visit, she says her caretaker is not beating her but occasionally complains that she is verbally abusive.
Three weeks after her first follow-up, Ms. L enters the examination room agitated and frightened; she says another patient in the waiting room has just tried to strangle her for no apparent reason. Upon questioning, office staff say they saw no attack and note that the accused patient is a feeble woman with no history of violence; we doubt she assaulted Ms. L.
Ms. L suffers from:
- repeated physical abuse
- delusional disorder
- factitious disorder
- malingering
The authors’ observations
Although Ms. L clearly was not assaulted in the waiting room, this complaint is key to understanding her case. Although whether she is being abused at home remains unclear, evidence increasingly suggests that she suffers from delusions.
Delusions are beliefs that are fixed, false, and not ordinarily accepted by others in a patient’s culture or subculture.3 Delusional disorder is characterized by nonbizarre delusions lasting >1 month (>3 months according to ICD-10 criteria)4 with relatively preserved functioning and without prominent hallucinations. DSM-IV-TR defines bizarre delusions as “clearly implausible, not understandable, and not derived from ordinary life experience.”4,5
Ms. L most likely has a paranoid or persecutory type delusional disorder in which she is convinced she is being harmed. Her delusional thoughts might yield mood symptoms such as anger and irritability, and she might become assaultive. Often, such patients are extraordinarily determined to succeed against “the conspirators” and frequently appeal to the legal system or law enforcement.3
Differentiating between a patient’s delusions and reality can be difficult, leading clinicians to seek collateral information from family, past medical records, or providers to establish a diagnosis. The delusions might become less circumscribed over time, or additional information might clear the clinical picture.
Ms. L’s psychological makeup might help us rule out other diagnoses. Her request for hospitalization, for example, could suggest factitious illness, but she is disabled enough to play the sick role without manufacturing symptoms. Also, she seeks hospitalization because she has no family or friends to turn to. We rule out malingering because Ms. L has nothing to gain by accusing a stranger of choking her in the waiting room.
Treating delusional disorder
Pharmacotherapy and psychotherapy typically are used together to treat delusional disorder.
Pharmacotherapy. Antipsychotics such as olanzapine, 5 to 10 mg nightly, or risperidone, 1 to 2 mg nightly, can decrease the delusional thoughts’ intensity and frequency, allowing patients to function more appropriately.3 If 2 or more antipsychotic trials do not control delusional thoughts, consider starting clozapine at 300 mg/d and titrating to 900 mg/d.
Add an antidepressant if delusional thinking causes depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, 10 to 20 mg/d, or fluoxetine, 20 to 40 mg/d, are a good starting point. Consider other antidepressant types if SSRIs do not work.
Adjunctive benzodiazepines such as clonazepam, 1 to 2 mg/d, or lorazepam, 1 to 2 mg bid as needed, can help manage acute anxiety or agitation stemming from delusions.
Once rapport is established, consider challenging delusional beliefs by having the patient list evidence supporting or refuting the delusions. Be careful not to confront delusional thinking too quickly or aggressively, as this approach often does not change the patient’s beliefs and weakens the therapeutic alliance.3
TREATMENT: Fewer complaints
We still see Ms. L every 3 weeks for supportive psychotherapy and medication management. We continue oxcarbazepine, 150 mg bid, and escitalopram, 30 mg/d, and add risperidone, 1 mg at bedtime, to target her delusional thinking, lability, and irritability.
Over 6 months, Ms. L’s complaints of abuse become less emphatic. She endorses the abuse less frequently—every 3 to 4 visits—and only if the clinician specifically asks about it. Most often, she denies abuse is occurring but says it happened previously. At each visit, we document her statements and explain in her chart why we have not notified adult protective services or police.
- National Adult Protective Services Association. Links to adult protection agencies nationwide. www.apsnetwork.org.
- National Center on Elder Abuse. www.elderabusecenter.org.
Drug brand names
- Clonazepam • Klonopin
- Clozapine • Clozaril
- Escitalopram • Lexapro
- Fluoxetine • Prozac
- Lorazepam • Ativan
- Olanzapine • Zyprexa
- Oxcarbazepine • Trileptal
- Paroxetine • Paxil
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
HISTORY: ‘Unusual behavior’
Ms. L, age 44, has severe cerebral palsy and has used a wheelchair since childhood. Her mother, who had been her primary caretaker, died 12 years ago, and her stepsister has been caring for her since.
Ms. L’s primary care physician reports that the patient has been “acting out” lately and asks us to evaluate her “unusual behavior.” Six months ago, the physician prescribed escitalopram, 30 mg/d, to treat depressive symptoms stemming from her chronic neurologic disorder.
We interview Ms. L and her stepsister together. The patient says she has been depressed, irritable, and moody, and her stepsister confirms this. The patient shows no signs of distress during the interview, and her answers appear short and guarded.
The stepsister says she typically spends her day turning Ms. L to prevent bedsores, feeding and bathing her, replacing her urinary catheter and emptying her urinary bag, and helping her to the bathroom. At day’s end, the stepsister has little time to spend with her husband or for other activities. She says at times she resents tending to Ms. L’s constant needs and feels “stressed out.”
We diagnose Ms. L with a mood disorder caused by a general medical condition. We continue escitalopram, 30 mg/d, and add oxcarbazepine, 150 mg bid, to treat her irritability and lability.
FOLLOW-UP: ‘She’s abusing me’
At Ms. L’s follow-up visit 2 weeks later, we ask her stepsister to leave the examination room and interview the patient alone to gauge her emotional condition and insight.
Seconds later, Ms. L starts crying hysterically, then reports that for 12 years her stepsister has been beating her, usually after she requests something. Yesterday, she says, her stepsister started punching her after she asked to be taken to the park.
Ms. L says the abuse is escalating and now occurs daily. She says she is covered with bruises from the last beating, although no bruises are visible at first glance. Afraid to go home with her stepsister, she pleads for help.
- call the primary care physician for collateral information
- examine Ms. L for bruises
- get the stepsister’s side of the story
- contact state protective services
- all of the above
The authors’ observations
Is Ms. L being physically abused, or is a psychiatric condition driving her to fabricate these allegations?
We saw nothing suspicious during the first interview with the stepsister, although she acknowledged difficulty coping with Ms. L’s constant requests (Box 1).1 Caring for a severely disabled person day in and day out can be trying for both the caregiver and her family, and the stepsister could be taking her frustrations out on Ms. L.
Until proven otherwise, we must assume Ms. L is being harmed and seek more information. We also must watch for signs of a delusional or factitious disorder or malingering—any of which would suggest the allegations are false.
Is often a family member
Experiences stress brought on by the strain of caregiving coupled with marital problems, lack of money, overcrowded living conditions, or lack of needed health or social services
Often abuses alcohol and/or drugs
Might have emotional problems:
- Caregiver often resents patient’s dependency
- If patient is caregiver’s parent, caregiver might be retaliating for past mistreatment
Depends on vulnerable adult for basic needs such as money or housing
Might come from a family where abusive behavior is normal
Source: Reference 1
HISTORY: A second opinion
We ask Ms. L if we can discuss the allegations with her and her stepsister, but she fears retaliation and insists that we not speak to the caretaker.
We then call Ms. L’s primary care physician, who has been managing her care for several years. He says the patient has begged him numerous times for protection from her stepsister, but adds he has found no evidence of abuse. He notes that he has witnessed tension between the 2 women during office visits and cannot dismiss the possibility of abuse.
The attending psychiatrist performs a brief physical exam with the resident looking on but finds no bruises, excoriations, or unusual scarring on her arms and legs. Because our outpatient clinic lacks an examination room, we do not perform a whole-body exam.
We then notify state protective services. There, an agent tells us that in the past year, Ms. L has made 4 allegations of caretaker abuse, none of which were substantiated after extensive investigation. The agent says her office will assign a case worker but considers the case a low priority.
When we inform Ms. L of our findings, she frantically insists that her caretaker is beating her once a week and that the abuse has gone undetected. We become skeptical, recalling that Ms. L earlier said the beatings were daily.
Ms. L says she is afraid to go home and wonders where she can stay. Having no friends or other family members nearby, she requests hospitalization.
At this point, I would:
- discharge Ms. L to a safe house with close follow-up
- hospitalize her for safety and diagnostic clarification
- discharge her to her stepsister with close follow-up
The authors’ observations
Ms. L’s allegations pose a medical, ethical, and legal challenge. Physical examination and input from a protective services officer suggest Ms. L is fabricating the allegations. On the other hand, if the accusations are true, sending Ms. L home with her stepsister would endanger her.
We could hospitalize the patient and substantiate the allegations later, but we cannot justify taxing limited hospital resources when the need is questionable. We cannot send her to a safe house because of her severe physical disability, nor can we discuss the allegations with her stepsister because Ms. L instructed us not to.
- Caregiver.com (online magazine)
www.caregiver.com - Caring Today
www.caringtoday.com - National Alliance for Caregiving
www.caregiving.org - National Alliance on Mental Illness
www.nami.org (Click on “Find Support,” then “Education, Training, and Peer Support Programs”)
DISPOSITION: Going home
After meeting with hospital officials and clinic staff, we decide that Ms. L does not meet admission criteria. We discharge her to her stepsister and see the patient again the next day.
The authors’ observations
Legal duty. Our legal duty to protect a suspected abuse victim depends on the jurisdiction in which treatment is delivered.
Many states do not require physicians to report suspected abuse, but this complicates the decision process. If the suspicion is correct, not reporting it might constitute malpractice or negligence and could provoke future lawsuits or complaints to the state medical board. Worse, the abuse may escalate and cause irreparable harm to the patient. Conversely, reporting unfounded suspicions of abuse can destroy the doctor-patient relationship, prompt the caregiver to retaliate against the patient, or inspire patients or caregivers to sue the physician.
If you suspect patient abuse and your state mandates reporting, contact the state protective services agency at once (seeRelated Resources,). Base your report on a thorough history and physical, psychiatric evaluation, and—when available—collateral information.
If your state does not mandate reporting, obtain the patient’s consent to file a complaint with state protective services. By providing informed consent, the patient gives permission to disclose protected health information, and confidentiality is not breached.
Be careful when obtaining informed consent, especially when the patient is ambivalent about reporting because of:
- fear of retaliation from the abuser
- fear of the social stigma associated with abuse
- or the patient’s false belief that she deserves the abuse.
Ethical responsibility. Even if our legal responsibility is minimal, we should go further to do what is best for the patient.
Texas, for example, does not require physicians to hospitalize or find a safe environment for a suspected abuse victim.2 But if you see evidence of abuse, notify authorities and offer the patient information about local safe houses, support groups, and social services—even if not mandated by law. If resources are available, consider hospitalizing the patient and work with his or her social worker, therapist, or clergy to orchestrate outpatient services.
Whether or not abuse has occurred, empathizing with the caretaker about the difficulty of caring for the patient could diminish the caretaker’s stress and reduce the risk of abuse.
FOLLOW-UP: Truth or delusion?
At her appointment the next day, Ms. L says things are fine at home and does not bring up the abuse allegations. We then see her every 3 days for 2 weeks, weekly for 4 weeks, and every 3 weeks thereafter as the apparent risk of abuse diminishes. At each visit, she says her caretaker is not beating her but occasionally complains that she is verbally abusive.
Three weeks after her first follow-up, Ms. L enters the examination room agitated and frightened; she says another patient in the waiting room has just tried to strangle her for no apparent reason. Upon questioning, office staff say they saw no attack and note that the accused patient is a feeble woman with no history of violence; we doubt she assaulted Ms. L.
Ms. L suffers from:
- repeated physical abuse
- delusional disorder
- factitious disorder
- malingering
The authors’ observations
Although Ms. L clearly was not assaulted in the waiting room, this complaint is key to understanding her case. Although whether she is being abused at home remains unclear, evidence increasingly suggests that she suffers from delusions.
Delusions are beliefs that are fixed, false, and not ordinarily accepted by others in a patient’s culture or subculture.3 Delusional disorder is characterized by nonbizarre delusions lasting >1 month (>3 months according to ICD-10 criteria)4 with relatively preserved functioning and without prominent hallucinations. DSM-IV-TR defines bizarre delusions as “clearly implausible, not understandable, and not derived from ordinary life experience.”4,5
Ms. L most likely has a paranoid or persecutory type delusional disorder in which she is convinced she is being harmed. Her delusional thoughts might yield mood symptoms such as anger and irritability, and she might become assaultive. Often, such patients are extraordinarily determined to succeed against “the conspirators” and frequently appeal to the legal system or law enforcement.3
Differentiating between a patient’s delusions and reality can be difficult, leading clinicians to seek collateral information from family, past medical records, or providers to establish a diagnosis. The delusions might become less circumscribed over time, or additional information might clear the clinical picture.
Ms. L’s psychological makeup might help us rule out other diagnoses. Her request for hospitalization, for example, could suggest factitious illness, but she is disabled enough to play the sick role without manufacturing symptoms. Also, she seeks hospitalization because she has no family or friends to turn to. We rule out malingering because Ms. L has nothing to gain by accusing a stranger of choking her in the waiting room.
Treating delusional disorder
Pharmacotherapy and psychotherapy typically are used together to treat delusional disorder.
Pharmacotherapy. Antipsychotics such as olanzapine, 5 to 10 mg nightly, or risperidone, 1 to 2 mg nightly, can decrease the delusional thoughts’ intensity and frequency, allowing patients to function more appropriately.3 If 2 or more antipsychotic trials do not control delusional thoughts, consider starting clozapine at 300 mg/d and titrating to 900 mg/d.
Add an antidepressant if delusional thinking causes depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, 10 to 20 mg/d, or fluoxetine, 20 to 40 mg/d, are a good starting point. Consider other antidepressant types if SSRIs do not work.
Adjunctive benzodiazepines such as clonazepam, 1 to 2 mg/d, or lorazepam, 1 to 2 mg bid as needed, can help manage acute anxiety or agitation stemming from delusions.
Once rapport is established, consider challenging delusional beliefs by having the patient list evidence supporting or refuting the delusions. Be careful not to confront delusional thinking too quickly or aggressively, as this approach often does not change the patient’s beliefs and weakens the therapeutic alliance.3
TREATMENT: Fewer complaints
We still see Ms. L every 3 weeks for supportive psychotherapy and medication management. We continue oxcarbazepine, 150 mg bid, and escitalopram, 30 mg/d, and add risperidone, 1 mg at bedtime, to target her delusional thinking, lability, and irritability.
Over 6 months, Ms. L’s complaints of abuse become less emphatic. She endorses the abuse less frequently—every 3 to 4 visits—and only if the clinician specifically asks about it. Most often, she denies abuse is occurring but says it happened previously. At each visit, we document her statements and explain in her chart why we have not notified adult protective services or police.
- National Adult Protective Services Association. Links to adult protection agencies nationwide. www.apsnetwork.org.
- National Center on Elder Abuse. www.elderabusecenter.org.
Drug brand names
- Clonazepam • Klonopin
- Clozapine • Clozaril
- Escitalopram • Lexapro
- Fluoxetine • Prozac
- Lorazepam • Ativan
- Olanzapine • Zyprexa
- Oxcarbazepine • Trileptal
- Paroxetine • Paxil
- Risperidone • Risperdal
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Fairfax County, VA (June 15, 2006). Adult Protection Services. Available at: http://www.fairfaxcounty.gov/aaa/ombud/abuse.htm. Accessed October 26, 2007.
2. Texas medical jurisprudence manual, 15th ed. Austin, TX: Texas Medical Association; 2004;454–6.
3. Fennig S, Fochtman L, Bromet E. Chapter 12.16c Delusional disorder and shared psychotic disorder. In: Sadock B, Sadock V, eds. Kaplan & Sadock’s comprehensive textbook of psychiatry, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005;1525–32.
4. International Classification of Diseases, 10th rev. Geneva, Switzerland: World Health Organization; 1992.
5. Diagnostic and statistical of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
1. Fairfax County, VA (June 15, 2006). Adult Protection Services. Available at: http://www.fairfaxcounty.gov/aaa/ombud/abuse.htm. Accessed October 26, 2007.
2. Texas medical jurisprudence manual, 15th ed. Austin, TX: Texas Medical Association; 2004;454–6.
3. Fennig S, Fochtman L, Bromet E. Chapter 12.16c Delusional disorder and shared psychotic disorder. In: Sadock B, Sadock V, eds. Kaplan & Sadock’s comprehensive textbook of psychiatry, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005;1525–32.
4. International Classification of Diseases, 10th rev. Geneva, Switzerland: World Health Organization; 1992.
5. Diagnostic and statistical of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
After the ‘pink clouds,’ he sees red
HISTORY: Depressed and sick
Mr. T, age 53, was diagnosed last year with hepatitis C and for 20 years has battled recurrent major depression with euthymia between episodes. His hepatologist asks us to evaluate his recent depressed mood and erratic behavior.
Less than 2 months ago, the hepatologist prescribed ribavirin, 1,000 mg bid, and peginterferon alfa-2B, 10 million IU/1.0 mL weekly, for hepatitis C. Soon afterward, Mr. T became irritable, especially toward his wife. He now refuses to leave his house most days because of overwhelming sadness and hopelessness. Once an avid motorcycle enthusiast, Mr. T has stopped riding and complains of fatigue, “fuzzy” thinking, and diminished concentration, but he denies suicidal thoughts or intent. He weighs 232 lb but has lost 15 lb in the last 6 weeks.
Five weeks ago, the hepatologist added bupropion XL, 150 mg/d, for Mr. T’s depressive symptoms, but the patient complained that the antidepressant “amped me up” and “made my mind race.” After 3 weeks, the hepatologist switched to escitalopram, 10 mg/d, but Mr. T’s agitation continued.
Several days after starting escitalopram, Mr. T experienced what he calls a “pink cloud” period—intensely pleasurable episodes that he says began in late childhood, usually last about 4 days, and occur 6 times annually. During these episodes, his thoughts race, his speech is mildly pressured, and he sleeps 5 hours or less nightly. While euphoric, he drives his motorcycle at 100 mph, starts several projects at once, and is distractible.
Once the “pink clouds” clear, Mr. T feels fatigued and “let down” as he does now. He says he has never reported these euphoric periods because he usually enjoys them.
Mr. T also has longstanding anxiety. Most days he is “on edge” and restless, feels muscle tension in his neck, and has trouble falling and staying sleep. After changing jobs last year, he began having panic attacks triggered by excessive worry. He denies anticipatory fear or avoidance, so we rule out panic disorder.
Additionally, Mr. T has been engaging in weekly binge-eating episodes during which he consumes nearly 50 large-sized cookies and 2 to 3 2-ounce bags of potato chips in 2 hours. He is wracked with guilt after bingeing and often feels embarrassed about being overweight (body mass index, 31 kg/m2). He does not purge but moderately restricts his diet between binges. He says he started bingeing at age 20, and at one point was bingeing 3 times a week.
Mr. T also complains that ribavirin and peginterferon are causing headaches, fatigue, and myalgias. He also takes hydrochlorothiazide, 25 mg/d, for hypertension, and is allergic to sulfonamides. He denies using alcohol and drugs but smokes 2 packs of cigarettes per day.
We diagnose bipolar II disorder based on Mr. T’s extreme mood shifts, history of major depressive episodes, recent hypomania, lack of manic or mixed episodes, and significant distress. His hypomania episodes last <1 week; episodes that last ≥1 week or require hospitalization would signal bipolar I disorder.
We rule out interferon-induced depression and hypomania1 because Mr. T showed signs of mood dysfunction long before he contracted hepatitis C. We also diagnose generalized anxiety disorder and eating disorder, not otherwise specified.
The authors’ observations
Diagnosing and managing bipolar disorder is challenging, especially when hypomania is not readily apparent.2
After we discuss treatment options with Mr. T, he chooses lamotrigine because it causes relatively few side effects and is less likely than valproic acid and other mood-stabilizing anticonvulsants to cause hepatotoxicity or pancreatitis.3 Lamotrigine also might reduce Mr. T’s anxiety.4
We do not try lithium because Mr. T is taking a diuretic (hydrochlorothiazide), which can cause lithium toxicity when used concomitantly. Also, lithium requires close laboratory monitoring, interacts with many medications, and can cause drowsiness, dry mouth, blurry vision, and fatigue.5 These
factors contraindicate lithium for Mr. T, who is taking several medications and suffers side effects from ribavirin and interferon.
Olanzapine might control Mr. T’s mood swings, but the neuroleptic can cause weight gain and metabolic syndrome6 and might complicate his eating disorder.
TREATMENT: A ‘rash’ reaction
We add lamotrigine, 25 mg/d, for 2 weeks and then increase to 50 mg/d.
Two days after the lamotrigine increase, Mr. T reports a rash on the left side of his trunk and left hip, buttock, and elbow (Figure). He also complains of mild chills and night sweats, although these symptoms emerged several weeks ago. He denies blistering, fevers, dysuria, nausea, or vomiting. We see no signs of lymphadenopathy, and mucosae are unaffected. Since he started lamotrigine, he says, he has not tried unfamiliar brands of shampoos, laundry detergents, or shower gels that might irritate his skin.
Figure: Did lamotrigine cause Mr. T’s rash?
Folliculocentric pustules around patient’s left elbow and throughout his left side.We have Mr. T come in that day for an emergency physical examination. At presentation, the rash appears infectious with isolated pustules throughout. We refer him to a dermatologist for same-day evaluation.
The authors’ observations
A rash is an immunologic reaction to an offending agent. If lamotrigine were causing the rash, lowering the dosage would not mitigate it.
We continued lamotrigine because the dermatologist could examine the rash within 24 hours of Mr. T’s complaint. Also, the agent was decreasing the patient’s mood, irritability, and anger. If we believed lamotrigine was causing the rash and could not obtain an immediate dermatology consult, we would have stopped the medication.
FOLLOW-UP: ‘Hot’ findings
During the patient history interview, the dermatologist discovers that Mr. T recently installed a whirlpool bath, and that the eruption occurred 3 to 5 days after the patient first used it. Physical examination shows groups of discrete folliculocentric pustules with surrounding erythema mainly on his extensor surfaces and left buttock. These findings and Mr. T’s history suggest a skin infection.
The dermatologist diagnoses hot tub folliculitis, an infection caused by exposure to contaminated whirlpools, hot tubs, or water slides. Cultures obtained that day grow Pseudomonas aeruginosa, confirming the diagnosis. The dermatologist tells Mr. T to stop using his whirlpool bath and prescribes topical gentamicin and ciprofloxacin, 500 mg bid for 10 days. We continue lamotrigine based on the dermatologist’s recommendation.
Two weeks later, Mr. T’s eruption resolves, and we increase lamotrigine to 100 mg/d, which improves his mood and achieves steady-state effectiveness.7 We continue escitalopram, 10 mg/d, then increase to 20 mg/d to treat his generalized anxiety. Mr. T begins experiencing anorgasmia 1 week after the escitalopram increase, so we switch to buspirone, 15 mg bid. After another 4 weeks, his anger, irritability, panic attacks, anxiety, and depression have diminished.
After 3 months, Mr. T’s hepatologist stops ribavirin and peginterferon because they are not helping his hepatitis C infection. Days later, Mr. T’s chills, sweats, and fatigue remit.
The hepatologist considers an experimental hepatitis C
medication.
We see Mr. T once monthly for supportive psychotherapy and medication management. Despite divorce proceedings and persistent mild depression he is optimistic, enjoys work, and rides his motorcycle safely twice a week.
The authors’ observations
Although Mr. T’s presentation and patient history clearly suggested an independent skin infection, distinguishing between an infection and anticonvulsant-induced rash can be difficult.
Lamotrigine and other antiepileptics (Table 1)8 have been associated with morbilliform eruptions, anticonvulsant hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), a severe form of SJS with a 20% to 30% mortality rate.9,10
Table 1
Estimated risk of severe rash among first-time antiepileptic users*
Drug | Total new users† | Total SJS/TEN cases | Risk per 10,000 new users |
---|---|---|---|
Carbamazepine | 286,360 | 39 | 1.4 |
Lamotrigine | 55,154 | 14 | 2.5 |
Phenobarbital | 8,659 | 7 | 8.1 |
Phenytoin | 36,171 | 30 | 8.3 |
Valproic acid | 103,150 | 4 | 0.4 |
* Researchers reviewed records of patients hospitalized between 1998 and 2001 with SJS or TEN after using an anticonvulsant. | |||
† Estimates based on number of dispensed prescriptions, average prescribed dosages, and duration of anticonvulsant use as recorded in Germany’s Mediplus database. | |||
SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis | |||
Source: Adapted from reference 8 |
Although most lamotrigine-induced cutaneous eruptions are mild or self-limited, some are severe and potentially fatal. In clinical trials, approximately 10% of patients receiving lamotrigine for epilepsy developed cutaneous reactions.11 Among 3,348 patients with epilepsy who received lamotrigine, 11 (0.3%) required hospitalization for SJS or TEN.11
Anticonvulsant hypersensitivity syndrome, estimated to occur once per 1,000 to 10,000 exposures to anticonvulsants,12 can lead to fever, lymphadenopathy, hepatomegaly, and arthralgias. Although hypersensitivity to aromatic anticonvulsants such as phenytoin, carbamazepine, or phenobarbital is most common, hypersensitivity to lamotrigine also has been reported.13,14
Roughly 90% of patients with anticonvulsant hypersensitivity syndrome develop leukocytosis with eosinophilia, and some develop leukocytosis with agranulocytosis.15-17 Fulminant hepatitis can occur, which leads to most deaths associated with this syndrome.
4 steps to gauging rash
Taking a thorough history, examining the eruption, ordering liver function tests (LFTs) and a complete blood count (CBC), and referring the patient to a dermatologist are key to determining the seriousness of an eruption and planning treatment in patients taking anticonvulsants (Table 2). See the patient within 12 hours after he reports the rash, as SJS and TEN often progress rapidly.
Table 2
4 steps to determining rash severity and cause
Take a thorough history | Find out when eruption occurred and when patient started the anticonvulsant |
Ask about past rashes, other medicines, and family history of reactions to medications | |
Find out if patient has had fever/chills, malaise, lymphadenopathy, or mucosal symptoms such as photophobia or dysuria | |
Examine the eruption | Examine for mucosal involvement, facial edema, and blistering; describe the symmetry and extent of involvement |
Look for systemic findings such as fever, chills, lymphadenopathy, and organomegaly | |
Photograph the eruption for the dermatologist if possible | |
Order laboratory tests | Order liver function tests and complete blood count with differentials; assess for eosinophilia |
Closely monitor patient | Stop anticonvulsant if history, physical findings suggest a drug-induced eruption |
Refer patient to a dermatologist |
STEP 1: Take a thorough history
Ask the patient:
What medications are you taking? Because more than 100 medications could cause SJS or TEN, a detailed drug history is critical to determining whether a medication has induced the eruption.
When did you start taking the potentially offending medication? True lamotrigine-induced eruptions usually occur 5 days to 8 weeks after the first dose.10 SJS and TEN generally take 1 to 2 weeks to develop.
What is your current dosage? Has it increased or decreased recently? Rapid lamotrigine dosage escalations or use of lamotrigine with valproic acid can cause severe rash.9,10,18 Valproic acid increases serum lamotrigine by inhibiting its hepatic metabolism, thereby raising side-effect risk. In clinical trials, 30% of patients who received both anticonvulsants developed a rash.10
Have any family members had rashes after taking an anticonvulsant? Compared with the general population, siblings and first-degree relatives of patients with anticonvulsant-related eruptions are at higher risk for this complication.19 Decreased epoxide hydrolase activity might negate these patients’ ability to detoxify the arene oxide metabolite, which can cause adverse effects if it accumulates.
Do you have other medical problems? Hepatitis C, for example, can theoretically increase lamotrigine’s half-life, thereby elevating side-effect risk.11
Watch for anticonvulsant-related adverse events in patients with hepatic insufficiency because hepatitis might hinder anticonvulsant metabolism.20 Other medical comorbidities—such as HIV infection and systemic lupus erythematosus—also could increase the risk of antiepileptic-induced rash.10
Have you had fever, chills, or other symptoms? Patients with SJS and TEN usually present with systemic symptoms such as malaise, rash, lymphadenopathy, mucosal lesions, and/or symptoms such as photophobia, difficulty swallowing, rectal erosions, or dysuria. Patients with anticonvulsant hypersensitivity syndrome typically have fever and associated arthralgias, skin pain, lymphadenopathy, or a burning sensation on their skin. These symptoms generally are absent in localized cutaneous infections.
STEP 2: Examine the eruption
Cutaneous SJS and TEN findings usually include abrupt onset of erythematous macules—which progress to targetoid lesions containing central bullae—followed by extensive epidermal necrosis. Superficial lip and mouth necrosis occur early, leading to severe stomatitis.
TEN and SJS can appear similar clinically, but TEN
covers >30% of body surface area, whereas SJS covers <10%.
Rashes that cover 10% to 30% of body surface suggest SJS-TEN overlap syndrome.
Anticonvulsant hypersensitivity syndrome usually manifests as
a morbilliform eruption on the face, arms, and/or torso. The
lesions might become edematous and progress to exfoliation or vesiculobullae. Facial edema is a hallmark of anticonvulsant hypersensitivity,15,16 and pustules and/or erythroderma might also appear. Other warning signs include symmetrical widespread eruption and organomegaly.
STEP 3: Order laboratory tests
Check liver function and order a CBC with differential to measure eosinophils. Eosinophilia and abnormal LFT results can signal anticonvulsant hypersensitivity.
Eosinophils. A normal eosinophil count ranges between 0% and 5% of peripheral blood leukocytes in adults, at a count of 350 to 650/cm. Although upper limits of normal vary, values >500/cm suggest hypereosinophilia.21
LFTs. Normal aspartate aminotransferase and alanine aminotransferase levels are 0 to 42 U/L and 0 to 48 U/L, respectively. Any LFT elevation could signal anticonvulsant hypersensitivity syndrome.
STEP 4: Closely monitor the patient
Discontinue the anticonvulsant if findings suggest a cutaneous drug reaction, and contact the patient’s primary care physician or dermatologist immediately. Early consultation with a dermatologist can help determine the eruption’s cause and reveal therapeutic options.
Dr. Pejic is chief resident in the adult psychiatry residency program, Louisiana State University Health Sciences Center and Ochsner Clinic Foundation, New Orleans.
Dr. Klinger is a third-year dermatology resident, Dr. Conrad is assistant professor of clinical psychiatry, and Dr. Nesbitt is chairman, department of dermatology, Louisiana State University Health Sciences Center.
Related Resources
- High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. UpToDate Online (version 15.1); June 9, 2007. www.uptodate.com.
- Martin KA, Krahn LE, Rosati MJ, Balan V. Hepatitis C: How to manage mood during interferon treatment. Current Psychiatry 2006;5(11):69-80. http://www.currentpsychiatry.com/article_pages.asp?AID=4553.
Drug Brand Names
- Bupropion • Wellbutrin
- Buspirone • BuSpar
- Carbamazepine • Tegretol, Equetro, others
- Ciprofloxacin • Cipro, Proquin
- Escitalopram • Lexapro
- Hydrochlorothiazide • various
- Lamotrigine • Lamictal
- Lithium • Eskalith, others
- Olanzapine • Zyprexa
- Peginterferon alfa-2B • PEG-Intron
- Phenytoin • Dilantin
- Ribavirin • Copegus, Rebetol, others
- Valproic acid • Depakote
Disclosure
Dr. Conrad receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, and Wyeth.
Drs. Pejic, Nesbitt, and Klinger report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004;71(suppl 3):S27-S32.
2. Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord 2006;92:141-8.
3. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006;67(suppl 4):S28-S33.
4. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-52.
5. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;3:172-91.
6. Keck PE, Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2006;67(suppl 1):S8-S15.
7. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guidelines: medication treatment of bipolar disorder 2000. A postgraduate medicine special report. New York: McGraw-Hill; 2000:24.
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-8.
9. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;29(suppl 7):S22-S26.
10. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-19.
11. Physicians’ desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:1483-4, 1488.
12. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
13. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
14. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
15. Chang DK, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol 1992;12:329-7.
16. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
17. Callot V, Roujeau JC, Bagot M, et al. Drug induced pseudo-lymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996;132:1315-21.
18. Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000;43:898-9.
19. Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
20. McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry 2004;3:7.-
21. Valencak J, Ortiz-Urda S, Heere-Ress E, et al. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol 2004;43:51-4.
HISTORY: Depressed and sick
Mr. T, age 53, was diagnosed last year with hepatitis C and for 20 years has battled recurrent major depression with euthymia between episodes. His hepatologist asks us to evaluate his recent depressed mood and erratic behavior.
Less than 2 months ago, the hepatologist prescribed ribavirin, 1,000 mg bid, and peginterferon alfa-2B, 10 million IU/1.0 mL weekly, for hepatitis C. Soon afterward, Mr. T became irritable, especially toward his wife. He now refuses to leave his house most days because of overwhelming sadness and hopelessness. Once an avid motorcycle enthusiast, Mr. T has stopped riding and complains of fatigue, “fuzzy” thinking, and diminished concentration, but he denies suicidal thoughts or intent. He weighs 232 lb but has lost 15 lb in the last 6 weeks.
Five weeks ago, the hepatologist added bupropion XL, 150 mg/d, for Mr. T’s depressive symptoms, but the patient complained that the antidepressant “amped me up” and “made my mind race.” After 3 weeks, the hepatologist switched to escitalopram, 10 mg/d, but Mr. T’s agitation continued.
Several days after starting escitalopram, Mr. T experienced what he calls a “pink cloud” period—intensely pleasurable episodes that he says began in late childhood, usually last about 4 days, and occur 6 times annually. During these episodes, his thoughts race, his speech is mildly pressured, and he sleeps 5 hours or less nightly. While euphoric, he drives his motorcycle at 100 mph, starts several projects at once, and is distractible.
Once the “pink clouds” clear, Mr. T feels fatigued and “let down” as he does now. He says he has never reported these euphoric periods because he usually enjoys them.
Mr. T also has longstanding anxiety. Most days he is “on edge” and restless, feels muscle tension in his neck, and has trouble falling and staying sleep. After changing jobs last year, he began having panic attacks triggered by excessive worry. He denies anticipatory fear or avoidance, so we rule out panic disorder.
Additionally, Mr. T has been engaging in weekly binge-eating episodes during which he consumes nearly 50 large-sized cookies and 2 to 3 2-ounce bags of potato chips in 2 hours. He is wracked with guilt after bingeing and often feels embarrassed about being overweight (body mass index, 31 kg/m2). He does not purge but moderately restricts his diet between binges. He says he started bingeing at age 20, and at one point was bingeing 3 times a week.
Mr. T also complains that ribavirin and peginterferon are causing headaches, fatigue, and myalgias. He also takes hydrochlorothiazide, 25 mg/d, for hypertension, and is allergic to sulfonamides. He denies using alcohol and drugs but smokes 2 packs of cigarettes per day.
We diagnose bipolar II disorder based on Mr. T’s extreme mood shifts, history of major depressive episodes, recent hypomania, lack of manic or mixed episodes, and significant distress. His hypomania episodes last <1 week; episodes that last ≥1 week or require hospitalization would signal bipolar I disorder.
We rule out interferon-induced depression and hypomania1 because Mr. T showed signs of mood dysfunction long before he contracted hepatitis C. We also diagnose generalized anxiety disorder and eating disorder, not otherwise specified.
The authors’ observations
Diagnosing and managing bipolar disorder is challenging, especially when hypomania is not readily apparent.2
After we discuss treatment options with Mr. T, he chooses lamotrigine because it causes relatively few side effects and is less likely than valproic acid and other mood-stabilizing anticonvulsants to cause hepatotoxicity or pancreatitis.3 Lamotrigine also might reduce Mr. T’s anxiety.4
We do not try lithium because Mr. T is taking a diuretic (hydrochlorothiazide), which can cause lithium toxicity when used concomitantly. Also, lithium requires close laboratory monitoring, interacts with many medications, and can cause drowsiness, dry mouth, blurry vision, and fatigue.5 These
factors contraindicate lithium for Mr. T, who is taking several medications and suffers side effects from ribavirin and interferon.
Olanzapine might control Mr. T’s mood swings, but the neuroleptic can cause weight gain and metabolic syndrome6 and might complicate his eating disorder.
TREATMENT: A ‘rash’ reaction
We add lamotrigine, 25 mg/d, for 2 weeks and then increase to 50 mg/d.
Two days after the lamotrigine increase, Mr. T reports a rash on the left side of his trunk and left hip, buttock, and elbow (Figure). He also complains of mild chills and night sweats, although these symptoms emerged several weeks ago. He denies blistering, fevers, dysuria, nausea, or vomiting. We see no signs of lymphadenopathy, and mucosae are unaffected. Since he started lamotrigine, he says, he has not tried unfamiliar brands of shampoos, laundry detergents, or shower gels that might irritate his skin.
Figure: Did lamotrigine cause Mr. T’s rash?
Folliculocentric pustules around patient’s left elbow and throughout his left side.We have Mr. T come in that day for an emergency physical examination. At presentation, the rash appears infectious with isolated pustules throughout. We refer him to a dermatologist for same-day evaluation.
The authors’ observations
A rash is an immunologic reaction to an offending agent. If lamotrigine were causing the rash, lowering the dosage would not mitigate it.
We continued lamotrigine because the dermatologist could examine the rash within 24 hours of Mr. T’s complaint. Also, the agent was decreasing the patient’s mood, irritability, and anger. If we believed lamotrigine was causing the rash and could not obtain an immediate dermatology consult, we would have stopped the medication.
FOLLOW-UP: ‘Hot’ findings
During the patient history interview, the dermatologist discovers that Mr. T recently installed a whirlpool bath, and that the eruption occurred 3 to 5 days after the patient first used it. Physical examination shows groups of discrete folliculocentric pustules with surrounding erythema mainly on his extensor surfaces and left buttock. These findings and Mr. T’s history suggest a skin infection.
The dermatologist diagnoses hot tub folliculitis, an infection caused by exposure to contaminated whirlpools, hot tubs, or water slides. Cultures obtained that day grow Pseudomonas aeruginosa, confirming the diagnosis. The dermatologist tells Mr. T to stop using his whirlpool bath and prescribes topical gentamicin and ciprofloxacin, 500 mg bid for 10 days. We continue lamotrigine based on the dermatologist’s recommendation.
Two weeks later, Mr. T’s eruption resolves, and we increase lamotrigine to 100 mg/d, which improves his mood and achieves steady-state effectiveness.7 We continue escitalopram, 10 mg/d, then increase to 20 mg/d to treat his generalized anxiety. Mr. T begins experiencing anorgasmia 1 week after the escitalopram increase, so we switch to buspirone, 15 mg bid. After another 4 weeks, his anger, irritability, panic attacks, anxiety, and depression have diminished.
After 3 months, Mr. T’s hepatologist stops ribavirin and peginterferon because they are not helping his hepatitis C infection. Days later, Mr. T’s chills, sweats, and fatigue remit.
The hepatologist considers an experimental hepatitis C
medication.
We see Mr. T once monthly for supportive psychotherapy and medication management. Despite divorce proceedings and persistent mild depression he is optimistic, enjoys work, and rides his motorcycle safely twice a week.
The authors’ observations
Although Mr. T’s presentation and patient history clearly suggested an independent skin infection, distinguishing between an infection and anticonvulsant-induced rash can be difficult.
Lamotrigine and other antiepileptics (Table 1)8 have been associated with morbilliform eruptions, anticonvulsant hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), a severe form of SJS with a 20% to 30% mortality rate.9,10
Table 1
Estimated risk of severe rash among first-time antiepileptic users*
Drug | Total new users† | Total SJS/TEN cases | Risk per 10,000 new users |
---|---|---|---|
Carbamazepine | 286,360 | 39 | 1.4 |
Lamotrigine | 55,154 | 14 | 2.5 |
Phenobarbital | 8,659 | 7 | 8.1 |
Phenytoin | 36,171 | 30 | 8.3 |
Valproic acid | 103,150 | 4 | 0.4 |
* Researchers reviewed records of patients hospitalized between 1998 and 2001 with SJS or TEN after using an anticonvulsant. | |||
† Estimates based on number of dispensed prescriptions, average prescribed dosages, and duration of anticonvulsant use as recorded in Germany’s Mediplus database. | |||
SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis | |||
Source: Adapted from reference 8 |
Although most lamotrigine-induced cutaneous eruptions are mild or self-limited, some are severe and potentially fatal. In clinical trials, approximately 10% of patients receiving lamotrigine for epilepsy developed cutaneous reactions.11 Among 3,348 patients with epilepsy who received lamotrigine, 11 (0.3%) required hospitalization for SJS or TEN.11
Anticonvulsant hypersensitivity syndrome, estimated to occur once per 1,000 to 10,000 exposures to anticonvulsants,12 can lead to fever, lymphadenopathy, hepatomegaly, and arthralgias. Although hypersensitivity to aromatic anticonvulsants such as phenytoin, carbamazepine, or phenobarbital is most common, hypersensitivity to lamotrigine also has been reported.13,14
Roughly 90% of patients with anticonvulsant hypersensitivity syndrome develop leukocytosis with eosinophilia, and some develop leukocytosis with agranulocytosis.15-17 Fulminant hepatitis can occur, which leads to most deaths associated with this syndrome.
4 steps to gauging rash
Taking a thorough history, examining the eruption, ordering liver function tests (LFTs) and a complete blood count (CBC), and referring the patient to a dermatologist are key to determining the seriousness of an eruption and planning treatment in patients taking anticonvulsants (Table 2). See the patient within 12 hours after he reports the rash, as SJS and TEN often progress rapidly.
Table 2
4 steps to determining rash severity and cause
Take a thorough history | Find out when eruption occurred and when patient started the anticonvulsant |
Ask about past rashes, other medicines, and family history of reactions to medications | |
Find out if patient has had fever/chills, malaise, lymphadenopathy, or mucosal symptoms such as photophobia or dysuria | |
Examine the eruption | Examine for mucosal involvement, facial edema, and blistering; describe the symmetry and extent of involvement |
Look for systemic findings such as fever, chills, lymphadenopathy, and organomegaly | |
Photograph the eruption for the dermatologist if possible | |
Order laboratory tests | Order liver function tests and complete blood count with differentials; assess for eosinophilia |
Closely monitor patient | Stop anticonvulsant if history, physical findings suggest a drug-induced eruption |
Refer patient to a dermatologist |
STEP 1: Take a thorough history
Ask the patient:
What medications are you taking? Because more than 100 medications could cause SJS or TEN, a detailed drug history is critical to determining whether a medication has induced the eruption.
When did you start taking the potentially offending medication? True lamotrigine-induced eruptions usually occur 5 days to 8 weeks after the first dose.10 SJS and TEN generally take 1 to 2 weeks to develop.
What is your current dosage? Has it increased or decreased recently? Rapid lamotrigine dosage escalations or use of lamotrigine with valproic acid can cause severe rash.9,10,18 Valproic acid increases serum lamotrigine by inhibiting its hepatic metabolism, thereby raising side-effect risk. In clinical trials, 30% of patients who received both anticonvulsants developed a rash.10
Have any family members had rashes after taking an anticonvulsant? Compared with the general population, siblings and first-degree relatives of patients with anticonvulsant-related eruptions are at higher risk for this complication.19 Decreased epoxide hydrolase activity might negate these patients’ ability to detoxify the arene oxide metabolite, which can cause adverse effects if it accumulates.
Do you have other medical problems? Hepatitis C, for example, can theoretically increase lamotrigine’s half-life, thereby elevating side-effect risk.11
Watch for anticonvulsant-related adverse events in patients with hepatic insufficiency because hepatitis might hinder anticonvulsant metabolism.20 Other medical comorbidities—such as HIV infection and systemic lupus erythematosus—also could increase the risk of antiepileptic-induced rash.10
Have you had fever, chills, or other symptoms? Patients with SJS and TEN usually present with systemic symptoms such as malaise, rash, lymphadenopathy, mucosal lesions, and/or symptoms such as photophobia, difficulty swallowing, rectal erosions, or dysuria. Patients with anticonvulsant hypersensitivity syndrome typically have fever and associated arthralgias, skin pain, lymphadenopathy, or a burning sensation on their skin. These symptoms generally are absent in localized cutaneous infections.
STEP 2: Examine the eruption
Cutaneous SJS and TEN findings usually include abrupt onset of erythematous macules—which progress to targetoid lesions containing central bullae—followed by extensive epidermal necrosis. Superficial lip and mouth necrosis occur early, leading to severe stomatitis.
TEN and SJS can appear similar clinically, but TEN
covers >30% of body surface area, whereas SJS covers <10%.
Rashes that cover 10% to 30% of body surface suggest SJS-TEN overlap syndrome.
Anticonvulsant hypersensitivity syndrome usually manifests as
a morbilliform eruption on the face, arms, and/or torso. The
lesions might become edematous and progress to exfoliation or vesiculobullae. Facial edema is a hallmark of anticonvulsant hypersensitivity,15,16 and pustules and/or erythroderma might also appear. Other warning signs include symmetrical widespread eruption and organomegaly.
STEP 3: Order laboratory tests
Check liver function and order a CBC with differential to measure eosinophils. Eosinophilia and abnormal LFT results can signal anticonvulsant hypersensitivity.
Eosinophils. A normal eosinophil count ranges between 0% and 5% of peripheral blood leukocytes in adults, at a count of 350 to 650/cm. Although upper limits of normal vary, values >500/cm suggest hypereosinophilia.21
LFTs. Normal aspartate aminotransferase and alanine aminotransferase levels are 0 to 42 U/L and 0 to 48 U/L, respectively. Any LFT elevation could signal anticonvulsant hypersensitivity syndrome.
STEP 4: Closely monitor the patient
Discontinue the anticonvulsant if findings suggest a cutaneous drug reaction, and contact the patient’s primary care physician or dermatologist immediately. Early consultation with a dermatologist can help determine the eruption’s cause and reveal therapeutic options.
Dr. Pejic is chief resident in the adult psychiatry residency program, Louisiana State University Health Sciences Center and Ochsner Clinic Foundation, New Orleans.
Dr. Klinger is a third-year dermatology resident, Dr. Conrad is assistant professor of clinical psychiatry, and Dr. Nesbitt is chairman, department of dermatology, Louisiana State University Health Sciences Center.
Related Resources
- High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. UpToDate Online (version 15.1); June 9, 2007. www.uptodate.com.
- Martin KA, Krahn LE, Rosati MJ, Balan V. Hepatitis C: How to manage mood during interferon treatment. Current Psychiatry 2006;5(11):69-80. http://www.currentpsychiatry.com/article_pages.asp?AID=4553.
Drug Brand Names
- Bupropion • Wellbutrin
- Buspirone • BuSpar
- Carbamazepine • Tegretol, Equetro, others
- Ciprofloxacin • Cipro, Proquin
- Escitalopram • Lexapro
- Hydrochlorothiazide • various
- Lamotrigine • Lamictal
- Lithium • Eskalith, others
- Olanzapine • Zyprexa
- Peginterferon alfa-2B • PEG-Intron
- Phenytoin • Dilantin
- Ribavirin • Copegus, Rebetol, others
- Valproic acid • Depakote
Disclosure
Dr. Conrad receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, and Wyeth.
Drs. Pejic, Nesbitt, and Klinger report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
HISTORY: Depressed and sick
Mr. T, age 53, was diagnosed last year with hepatitis C and for 20 years has battled recurrent major depression with euthymia between episodes. His hepatologist asks us to evaluate his recent depressed mood and erratic behavior.
Less than 2 months ago, the hepatologist prescribed ribavirin, 1,000 mg bid, and peginterferon alfa-2B, 10 million IU/1.0 mL weekly, for hepatitis C. Soon afterward, Mr. T became irritable, especially toward his wife. He now refuses to leave his house most days because of overwhelming sadness and hopelessness. Once an avid motorcycle enthusiast, Mr. T has stopped riding and complains of fatigue, “fuzzy” thinking, and diminished concentration, but he denies suicidal thoughts or intent. He weighs 232 lb but has lost 15 lb in the last 6 weeks.
Five weeks ago, the hepatologist added bupropion XL, 150 mg/d, for Mr. T’s depressive symptoms, but the patient complained that the antidepressant “amped me up” and “made my mind race.” After 3 weeks, the hepatologist switched to escitalopram, 10 mg/d, but Mr. T’s agitation continued.
Several days after starting escitalopram, Mr. T experienced what he calls a “pink cloud” period—intensely pleasurable episodes that he says began in late childhood, usually last about 4 days, and occur 6 times annually. During these episodes, his thoughts race, his speech is mildly pressured, and he sleeps 5 hours or less nightly. While euphoric, he drives his motorcycle at 100 mph, starts several projects at once, and is distractible.
Once the “pink clouds” clear, Mr. T feels fatigued and “let down” as he does now. He says he has never reported these euphoric periods because he usually enjoys them.
Mr. T also has longstanding anxiety. Most days he is “on edge” and restless, feels muscle tension in his neck, and has trouble falling and staying sleep. After changing jobs last year, he began having panic attacks triggered by excessive worry. He denies anticipatory fear or avoidance, so we rule out panic disorder.
Additionally, Mr. T has been engaging in weekly binge-eating episodes during which he consumes nearly 50 large-sized cookies and 2 to 3 2-ounce bags of potato chips in 2 hours. He is wracked with guilt after bingeing and often feels embarrassed about being overweight (body mass index, 31 kg/m2). He does not purge but moderately restricts his diet between binges. He says he started bingeing at age 20, and at one point was bingeing 3 times a week.
Mr. T also complains that ribavirin and peginterferon are causing headaches, fatigue, and myalgias. He also takes hydrochlorothiazide, 25 mg/d, for hypertension, and is allergic to sulfonamides. He denies using alcohol and drugs but smokes 2 packs of cigarettes per day.
We diagnose bipolar II disorder based on Mr. T’s extreme mood shifts, history of major depressive episodes, recent hypomania, lack of manic or mixed episodes, and significant distress. His hypomania episodes last <1 week; episodes that last ≥1 week or require hospitalization would signal bipolar I disorder.
We rule out interferon-induced depression and hypomania1 because Mr. T showed signs of mood dysfunction long before he contracted hepatitis C. We also diagnose generalized anxiety disorder and eating disorder, not otherwise specified.
The authors’ observations
Diagnosing and managing bipolar disorder is challenging, especially when hypomania is not readily apparent.2
After we discuss treatment options with Mr. T, he chooses lamotrigine because it causes relatively few side effects and is less likely than valproic acid and other mood-stabilizing anticonvulsants to cause hepatotoxicity or pancreatitis.3 Lamotrigine also might reduce Mr. T’s anxiety.4
We do not try lithium because Mr. T is taking a diuretic (hydrochlorothiazide), which can cause lithium toxicity when used concomitantly. Also, lithium requires close laboratory monitoring, interacts with many medications, and can cause drowsiness, dry mouth, blurry vision, and fatigue.5 These
factors contraindicate lithium for Mr. T, who is taking several medications and suffers side effects from ribavirin and interferon.
Olanzapine might control Mr. T’s mood swings, but the neuroleptic can cause weight gain and metabolic syndrome6 and might complicate his eating disorder.
TREATMENT: A ‘rash’ reaction
We add lamotrigine, 25 mg/d, for 2 weeks and then increase to 50 mg/d.
Two days after the lamotrigine increase, Mr. T reports a rash on the left side of his trunk and left hip, buttock, and elbow (Figure). He also complains of mild chills and night sweats, although these symptoms emerged several weeks ago. He denies blistering, fevers, dysuria, nausea, or vomiting. We see no signs of lymphadenopathy, and mucosae are unaffected. Since he started lamotrigine, he says, he has not tried unfamiliar brands of shampoos, laundry detergents, or shower gels that might irritate his skin.
Figure: Did lamotrigine cause Mr. T’s rash?
Folliculocentric pustules around patient’s left elbow and throughout his left side.We have Mr. T come in that day for an emergency physical examination. At presentation, the rash appears infectious with isolated pustules throughout. We refer him to a dermatologist for same-day evaluation.
The authors’ observations
A rash is an immunologic reaction to an offending agent. If lamotrigine were causing the rash, lowering the dosage would not mitigate it.
We continued lamotrigine because the dermatologist could examine the rash within 24 hours of Mr. T’s complaint. Also, the agent was decreasing the patient’s mood, irritability, and anger. If we believed lamotrigine was causing the rash and could not obtain an immediate dermatology consult, we would have stopped the medication.
FOLLOW-UP: ‘Hot’ findings
During the patient history interview, the dermatologist discovers that Mr. T recently installed a whirlpool bath, and that the eruption occurred 3 to 5 days after the patient first used it. Physical examination shows groups of discrete folliculocentric pustules with surrounding erythema mainly on his extensor surfaces and left buttock. These findings and Mr. T’s history suggest a skin infection.
The dermatologist diagnoses hot tub folliculitis, an infection caused by exposure to contaminated whirlpools, hot tubs, or water slides. Cultures obtained that day grow Pseudomonas aeruginosa, confirming the diagnosis. The dermatologist tells Mr. T to stop using his whirlpool bath and prescribes topical gentamicin and ciprofloxacin, 500 mg bid for 10 days. We continue lamotrigine based on the dermatologist’s recommendation.
Two weeks later, Mr. T’s eruption resolves, and we increase lamotrigine to 100 mg/d, which improves his mood and achieves steady-state effectiveness.7 We continue escitalopram, 10 mg/d, then increase to 20 mg/d to treat his generalized anxiety. Mr. T begins experiencing anorgasmia 1 week after the escitalopram increase, so we switch to buspirone, 15 mg bid. After another 4 weeks, his anger, irritability, panic attacks, anxiety, and depression have diminished.
After 3 months, Mr. T’s hepatologist stops ribavirin and peginterferon because they are not helping his hepatitis C infection. Days later, Mr. T’s chills, sweats, and fatigue remit.
The hepatologist considers an experimental hepatitis C
medication.
We see Mr. T once monthly for supportive psychotherapy and medication management. Despite divorce proceedings and persistent mild depression he is optimistic, enjoys work, and rides his motorcycle safely twice a week.
The authors’ observations
Although Mr. T’s presentation and patient history clearly suggested an independent skin infection, distinguishing between an infection and anticonvulsant-induced rash can be difficult.
Lamotrigine and other antiepileptics (Table 1)8 have been associated with morbilliform eruptions, anticonvulsant hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), a severe form of SJS with a 20% to 30% mortality rate.9,10
Table 1
Estimated risk of severe rash among first-time antiepileptic users*
Drug | Total new users† | Total SJS/TEN cases | Risk per 10,000 new users |
---|---|---|---|
Carbamazepine | 286,360 | 39 | 1.4 |
Lamotrigine | 55,154 | 14 | 2.5 |
Phenobarbital | 8,659 | 7 | 8.1 |
Phenytoin | 36,171 | 30 | 8.3 |
Valproic acid | 103,150 | 4 | 0.4 |
* Researchers reviewed records of patients hospitalized between 1998 and 2001 with SJS or TEN after using an anticonvulsant. | |||
† Estimates based on number of dispensed prescriptions, average prescribed dosages, and duration of anticonvulsant use as recorded in Germany’s Mediplus database. | |||
SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis | |||
Source: Adapted from reference 8 |
Although most lamotrigine-induced cutaneous eruptions are mild or self-limited, some are severe and potentially fatal. In clinical trials, approximately 10% of patients receiving lamotrigine for epilepsy developed cutaneous reactions.11 Among 3,348 patients with epilepsy who received lamotrigine, 11 (0.3%) required hospitalization for SJS or TEN.11
Anticonvulsant hypersensitivity syndrome, estimated to occur once per 1,000 to 10,000 exposures to anticonvulsants,12 can lead to fever, lymphadenopathy, hepatomegaly, and arthralgias. Although hypersensitivity to aromatic anticonvulsants such as phenytoin, carbamazepine, or phenobarbital is most common, hypersensitivity to lamotrigine also has been reported.13,14
Roughly 90% of patients with anticonvulsant hypersensitivity syndrome develop leukocytosis with eosinophilia, and some develop leukocytosis with agranulocytosis.15-17 Fulminant hepatitis can occur, which leads to most deaths associated with this syndrome.
4 steps to gauging rash
Taking a thorough history, examining the eruption, ordering liver function tests (LFTs) and a complete blood count (CBC), and referring the patient to a dermatologist are key to determining the seriousness of an eruption and planning treatment in patients taking anticonvulsants (Table 2). See the patient within 12 hours after he reports the rash, as SJS and TEN often progress rapidly.
Table 2
4 steps to determining rash severity and cause
Take a thorough history | Find out when eruption occurred and when patient started the anticonvulsant |
Ask about past rashes, other medicines, and family history of reactions to medications | |
Find out if patient has had fever/chills, malaise, lymphadenopathy, or mucosal symptoms such as photophobia or dysuria | |
Examine the eruption | Examine for mucosal involvement, facial edema, and blistering; describe the symmetry and extent of involvement |
Look for systemic findings such as fever, chills, lymphadenopathy, and organomegaly | |
Photograph the eruption for the dermatologist if possible | |
Order laboratory tests | Order liver function tests and complete blood count with differentials; assess for eosinophilia |
Closely monitor patient | Stop anticonvulsant if history, physical findings suggest a drug-induced eruption |
Refer patient to a dermatologist |
STEP 1: Take a thorough history
Ask the patient:
What medications are you taking? Because more than 100 medications could cause SJS or TEN, a detailed drug history is critical to determining whether a medication has induced the eruption.
When did you start taking the potentially offending medication? True lamotrigine-induced eruptions usually occur 5 days to 8 weeks after the first dose.10 SJS and TEN generally take 1 to 2 weeks to develop.
What is your current dosage? Has it increased or decreased recently? Rapid lamotrigine dosage escalations or use of lamotrigine with valproic acid can cause severe rash.9,10,18 Valproic acid increases serum lamotrigine by inhibiting its hepatic metabolism, thereby raising side-effect risk. In clinical trials, 30% of patients who received both anticonvulsants developed a rash.10
Have any family members had rashes after taking an anticonvulsant? Compared with the general population, siblings and first-degree relatives of patients with anticonvulsant-related eruptions are at higher risk for this complication.19 Decreased epoxide hydrolase activity might negate these patients’ ability to detoxify the arene oxide metabolite, which can cause adverse effects if it accumulates.
Do you have other medical problems? Hepatitis C, for example, can theoretically increase lamotrigine’s half-life, thereby elevating side-effect risk.11
Watch for anticonvulsant-related adverse events in patients with hepatic insufficiency because hepatitis might hinder anticonvulsant metabolism.20 Other medical comorbidities—such as HIV infection and systemic lupus erythematosus—also could increase the risk of antiepileptic-induced rash.10
Have you had fever, chills, or other symptoms? Patients with SJS and TEN usually present with systemic symptoms such as malaise, rash, lymphadenopathy, mucosal lesions, and/or symptoms such as photophobia, difficulty swallowing, rectal erosions, or dysuria. Patients with anticonvulsant hypersensitivity syndrome typically have fever and associated arthralgias, skin pain, lymphadenopathy, or a burning sensation on their skin. These symptoms generally are absent in localized cutaneous infections.
STEP 2: Examine the eruption
Cutaneous SJS and TEN findings usually include abrupt onset of erythematous macules—which progress to targetoid lesions containing central bullae—followed by extensive epidermal necrosis. Superficial lip and mouth necrosis occur early, leading to severe stomatitis.
TEN and SJS can appear similar clinically, but TEN
covers >30% of body surface area, whereas SJS covers <10%.
Rashes that cover 10% to 30% of body surface suggest SJS-TEN overlap syndrome.
Anticonvulsant hypersensitivity syndrome usually manifests as
a morbilliform eruption on the face, arms, and/or torso. The
lesions might become edematous and progress to exfoliation or vesiculobullae. Facial edema is a hallmark of anticonvulsant hypersensitivity,15,16 and pustules and/or erythroderma might also appear. Other warning signs include symmetrical widespread eruption and organomegaly.
STEP 3: Order laboratory tests
Check liver function and order a CBC with differential to measure eosinophils. Eosinophilia and abnormal LFT results can signal anticonvulsant hypersensitivity.
Eosinophils. A normal eosinophil count ranges between 0% and 5% of peripheral blood leukocytes in adults, at a count of 350 to 650/cm. Although upper limits of normal vary, values >500/cm suggest hypereosinophilia.21
LFTs. Normal aspartate aminotransferase and alanine aminotransferase levels are 0 to 42 U/L and 0 to 48 U/L, respectively. Any LFT elevation could signal anticonvulsant hypersensitivity syndrome.
STEP 4: Closely monitor the patient
Discontinue the anticonvulsant if findings suggest a cutaneous drug reaction, and contact the patient’s primary care physician or dermatologist immediately. Early consultation with a dermatologist can help determine the eruption’s cause and reveal therapeutic options.
Dr. Pejic is chief resident in the adult psychiatry residency program, Louisiana State University Health Sciences Center and Ochsner Clinic Foundation, New Orleans.
Dr. Klinger is a third-year dermatology resident, Dr. Conrad is assistant professor of clinical psychiatry, and Dr. Nesbitt is chairman, department of dermatology, Louisiana State University Health Sciences Center.
Related Resources
- High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. UpToDate Online (version 15.1); June 9, 2007. www.uptodate.com.
- Martin KA, Krahn LE, Rosati MJ, Balan V. Hepatitis C: How to manage mood during interferon treatment. Current Psychiatry 2006;5(11):69-80. http://www.currentpsychiatry.com/article_pages.asp?AID=4553.
Drug Brand Names
- Bupropion • Wellbutrin
- Buspirone • BuSpar
- Carbamazepine • Tegretol, Equetro, others
- Ciprofloxacin • Cipro, Proquin
- Escitalopram • Lexapro
- Hydrochlorothiazide • various
- Lamotrigine • Lamictal
- Lithium • Eskalith, others
- Olanzapine • Zyprexa
- Peginterferon alfa-2B • PEG-Intron
- Phenytoin • Dilantin
- Ribavirin • Copegus, Rebetol, others
- Valproic acid • Depakote
Disclosure
Dr. Conrad receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, and Wyeth.
Drs. Pejic, Nesbitt, and Klinger report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004;71(suppl 3):S27-S32.
2. Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord 2006;92:141-8.
3. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006;67(suppl 4):S28-S33.
4. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-52.
5. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;3:172-91.
6. Keck PE, Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2006;67(suppl 1):S8-S15.
7. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guidelines: medication treatment of bipolar disorder 2000. A postgraduate medicine special report. New York: McGraw-Hill; 2000:24.
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-8.
9. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;29(suppl 7):S22-S26.
10. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-19.
11. Physicians’ desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:1483-4, 1488.
12. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
13. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
14. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
15. Chang DK, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol 1992;12:329-7.
16. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
17. Callot V, Roujeau JC, Bagot M, et al. Drug induced pseudo-lymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996;132:1315-21.
18. Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000;43:898-9.
19. Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
20. McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry 2004;3:7.-
21. Valencak J, Ortiz-Urda S, Heere-Ress E, et al. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol 2004;43:51-4.
1. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004;71(suppl 3):S27-S32.
2. Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord 2006;92:141-8.
3. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006;67(suppl 4):S28-S33.
4. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-52.
5. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;3:172-91.
6. Keck PE, Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2006;67(suppl 1):S8-S15.
7. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guidelines: medication treatment of bipolar disorder 2000. A postgraduate medicine special report. New York: McGraw-Hill; 2000:24.
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-8.
9. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;29(suppl 7):S22-S26.
10. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-19.
11. Physicians’ desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:1483-4, 1488.
12. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
13. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
14. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
15. Chang DK, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol 1992;12:329-7.
16. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
17. Callot V, Roujeau JC, Bagot M, et al. Drug induced pseudo-lymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996;132:1315-21.
18. Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000;43:898-9.
19. Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
20. McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry 2004;3:7.-
21. Valencak J, Ortiz-Urda S, Heere-Ress E, et al. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol 2004;43:51-4.
Unhappy feet: One woman’s severe akathisia
HISTORY: ‘Bizarre’ days
Ms. K, age 45, is brought to the ER by her brother, who reports she has been acting “bizarre and crazy” for 3 days. He says his sister—who has bipolar I disorder— has had trouble sleeping, is restless, hears voices, and is contemplating suicide. He adds she was discharged from a psychiatric hospital 2 weeks ago after a 3-month stay.
Risperidone, 2 mg nightly, was controlling Ms. K’s mania until this recent episode. According to her brother, she also has developed continuous involuntary leg and arm movements and cannot sit or stand still. When she tries to sleep, her feet sway back and forth in bed for hours.
We admit Ms. K to the psychiatric inpatient unit because of her suicidality and hallucinations. She is restless and agitated during initial evaluation, pacing around the room or rocking her feet while standing or sitting. Her speech is pressured and the “voices” are urging her to kill herself.
Ms. K is dysphoric and severely distraught about her “nervousness” and continuous urges to move. She says she would rather die than live with incessantly “jittery” legs and arms, yet she wants to be discharged and denies that she is mentally ill. She believes decreased sleep is causing her symptoms and requests a “sleeping pill.”
she habitually views her medications as useless and stops taking them.
The patient has been hospitalized at least 4 times with severe manic and psychotic symptoms. She does not use illicit drugs and is medically healthy.
The authors’ observations
Ms. K’s involuntary movements suggest akathisia, a common extrapyramidal side effect of antipsychotics and other psychotropics (Table).1
Akathisia is characterized by strong feelings of inner restlessness that manifest as excessive walking or pacing and difficulty remaining still. Ms. K’s movements met at least 2 of 5 DSM-IV-TR criteria for acute akathisia (Box). ,2
Akathisia is characterized by at least 5 subtypes: 3
- Acute akathisia begins hours or days after starting the offending medication and lasts
- Tardive is similar to acute akathisia but can arise within 3 to 4 months of starting the offending medication and persists for years.
- Chronic akathisia lasts ≥3 months and usually has no temporal correlation with antipsychotic initiation or dosage increase.4
- Withdrawal akathisia begins within 6 weeks of discontinuing a medication or significantly reducing the dosage.
- Pseudo akathisia consists of objective symptoms of movement without subjective awareness or distress. This subtype usually is seen in older patients.
history of medication nonadherence strongly suggest akathisia secondary to risperidone withdrawal.5 Several
cases of akathisia after risperidone cessation have been reported.5
We know risperidone is not causing acute akathisia because Ms. K responded well to the medication during her last hospitalization with no adverse effects. Also, her family confirmed that she stopped taking risperidone after her most recent discharge.
Mania also can fuel incessant movement and increase physical activity, but patients often do not realize they have a problem while in a manic phase. Also, swinging and rocking of legs is rarely seen in mania. By contrast, Ms. K was morbidly distraught over her akathisia.
Table
Drugs that can cause akathisia
|
The authors’ observations
Numerous treatments are available for akathisia:
Beta blockers such as propranolol are most widely used because of their rapid onset of action and overall effectiveness in akathisia.3 Researchers believe these drugs reduce extrapyramidal symptoms (EPS) by blocking the adrenergic system. Propranolol can be used at a maximum 120 mg/d in divided doses.
Beta blockers, however, can cause bradycardia, hypotension, or respiratory distress. Use beta blockers with caution, and monitor for these adverse effects.
Benzodiazepines. Clonazepam, which enhances the inhibitory effect of GABA in the brain, is commonly used for akathisia because of its effectiveness and long elimination half-life3 (30 to 40 hours), which decreases the risk of medication withdrawal.
and disinhibition-induced aggression in all patients.
Anticholinergics such as trihexyphenidyl are more commonly used for EPS associated with parkinsonian symptoms or side effects but can be partially effective for akathisia.3 Anticholinergics block the CNS cholinergic activity that causes parkinsonian symptoms.
Cyproheptadine, clonidine, and mianserin have shown some positive results against akathisia in clinical trials.6-8 Iron, nicotine patches, and amantadine have shown limited effectiveness against akathisia in research studies and case reports.3,9
Restarting risperidone at a lower dosage—rather than adding a medication— might have resolved Ms. K’s akathisia, but because she was morbidly despondent over her akathisia, we felt we had no time to experiment. We also believed Ms. K’s would respond well to a neuroleptic with a lower EPS risk—such as quetiapine.1,10
A. Subjective complaints of restlessness after exposure to neuroleptics
B. At least 1 of the following is observed:
- Fidgety movements or swinging of the legs
- Rocking from foot to foot while standing
- Pacing to relieve restlessness
- Inability to sit or stand still for at least several minutes
C. Symptoms develop within 4 weeks of starting or raising the dosage of a neuroleptic or after reducing a medication used to treat extrapyramidal symptoms
D. Criterion A symptoms are not better accounted for by a mental disorder
E. Criterion A symptoms are not caused by a nonneuroleptic or a general medical condition
Source: Adapted from reference 2 with permission
TREATMENT: Trying trials
We perform a complete medical workup to rule out an underlying medical problem. We then start valproic acid, 500 mg bid, for Ms. K’s mania; quetiapine, 50 mg bid, for psychosis and mania; and propranolol, 30 mg bid, for akathisia.
We titrate quetiapine by 100 mg/d every 2 days to 400 mg/d, but after 10 days her akathisia, irritable mood, decreased sleep, and suicidal thoughts persist. We cannot increase propranolol because her blood pressure is 90/60 mm Hg, and adding lorazepam, 0.5 mg tid, does not control her movements. Three days later, we add trihexyphenidyl, 5 mg bid.
Fifteen days after admission, Ms. K remains akathisic, dysphoric, and suicidal despite a 5-drug regimen. Her “nervousness” prevents her from attending groups or other unit activities, and her uncontrollable foot swaying still keeps her awake at night.
The authors’ observations
Neither propranolol, clonazepam, nor trihexyphenidyl alleviated Ms. K’s akathisia. Switching to another neuroleptic with a relatively low EPS risk—such as olanzapine—might help. Olanzapine reduced akathisia in 3 case reports,11 and we hope its strong anticholinergic and antiserotonergic action will help resolve Ms. K’s akathisia.
with patients receiving therapeutic dosages of risperidone.12 In another study, olanzapine showed anticholinergic activity at therapeutic doses but risperidone did not.13 Researchers believe these features reduce olanzapine’s EPS risk compared with other antipsychotics.
TREATMENT: Drug works, but …
Three weeks after Ms. K’s presentation, we stop all psychotropics, start olanzapine, 10 mg nightly, for psychosis and mania, and continue propranolol, 30 mg bid, for akathisia. Within 2 days, Ms. K’s akathisia improves significantly.
We also start lithium, 150 mg bid, for mania, and increase it 4 days later to 300 mg bid to maintain serum lithium at approximately 1 mEq/L. We check serum lithium every 3 days after dosage adjustment. Although lithium can induce akathisia, we thought it would most effectively control her mania.
Six days after we started the new medications, Ms. K’s mania and psychosis begin to improve and she becomes euthymic. She is able to sit calmly during group therapy and community meetings.
Ten days after we start olanzapine and lithium, Ms. K appears bloated. Weight check shows an approximate 5-lb weight gain since starting the medications, both of which can cause weight gain and other metabolic side effects.
At Ms. K’s request, we stop olanzapine and start aripiprazole, 5 mg/d, to try to control her weight gain. We continue lithium and propranolol, which have been controlling her mood and akathisia. The next day—after 1 dose of aripiprazole—her akathisia returns.
The authors’ observations
Because aripiprazole was started as soon as olanzapine was discontinued, it is unclear which action aggravated Ms. K’s akathisia or if both were to blame.
Akathisia’s underlying cause is uncertain. Researchers believe dopamine receptor blockade in the mesocortical dopamine system might be responsible.3 Positron-emission tomography studies suggest that D2 receptor occupancy in the striatum contributes to akathisia, and noradrenergic and serotonergic systems also play a role.3,14
Antipsychotics, antidepressants, and sympathomimetics all have been implicated in akathisia, but antipsychotics that are potent serotonin (5HT) receptor antagonists—such as olanzapine and clozapine—show a lower incidence compared with other psychotropic agents.3
Aripiprazole—a partial D2 and 5HT1A receptor agonist and 5HT2 receptor antagonist—could have caused Ms. K’s akathisia. In 1 study, 11% of patients receiving aripiprazole, 15 to 30 mg/d, for acute mania reported akathisia symptoms.15
Olanzapine cessation could have caused Ms. K’s akathisia, although no cases of akathisia secondary to olanzapine withdrawal have been reported. Alternatively, olanzapine could have interacted with lithium to block lithium’s ability to induce akathisia.
TREATMENT: Back to olanzapine
After we thoroughly discuss olanzapine’s risks and benefits with Ms. K, she consents to switch back to olanzapine, 10 mg/d. We also instruct her to exercise daily and strictly control her diet after discharge.
Ms. K’s akathisia improves dramatically within 1 to 2 days, and her psychosis and mania improve gradually. Her persistent delusions and hallucinations are less intense, although she is still concocting grandiose get-rich-quick schemes.
Ten days after this latest dosage change, we discharge Ms. K on olanzapine, 10 mg/d, and lithium, 300 mg bid. She has no akathisia symptoms, and we arrange placement in an adult home where a psychiatrist sees her regularly. Three years later, she has been lost to follow-up.
Related resource
- AkathisiaSupport.org. Online resource offers links to articles describing causes of and treatments for akathisia subtypes. www.akathisiasupport.org.
- Aripiprazole • Abilify
- Carbidopa/levodopa • Stalevo, Parcopa
- Clonazepam • Klonopin
- Clonidine • Catapres
- Cyproheptadine • Periactin
- Ethosuximide • Zarontin
- Lithium • Eskalith, others
- Lorazepam • Ativan
- Metoclopramide • Reglan
- Olanzapine • Zyprexa
- Quetiapine • Seroquel
- Reserpine • various
- Risperidone • Risperdal
- Trihexyphenidyl • Artane
- Valproic acid • Depakote
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Sadock BJ, Sadock VA. Biological therapies (chapter 36). Kaplan & Sadock’s synopsis of psychiatry: behaviorial sciences/clinical psychiatry, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:1110.
2. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
3. Nelson DE. Akathisia—a brief review. Scott Med J 2001;46:133-4.
4. Sachdev P. The epidemiology of drug-induced akathisia: part II. Chronic, tardive and withdrawal akathisias. Schizophr Bull 1995;21:451-60.
5. Bertolín Guillén JM, Martínez Franco L, Juni Anahuja J. Akathisia due to risperidone withdrawal: two clinical cases [in Spanish]. Actas Esp Psiquiatr 2002;30:195-7.
6. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-6.
7. Poyurovsky M, Kreinin A, Modai I, Weizman A. Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmacol 1995;10:261-3.
8. Poyurovsky M, Shardorodsky M, Fuchs C, et al. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 1999;174:238-42.
9. Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 1997;134:153-6.
10. Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): not different from placebo for EPS or prolactin. Biol Psychiatry 1996;39:598.-
11. Yousaf F, Fialho A, Warden M. Akathisia treated with olanzapine: three case reports. Int J Psychiatry Clin Pract 2004;8:123-5(3).
12. Lavalaye J, Booij J, Linszen DH, et al. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001;156:53-7.
13. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.
14. Chung WS, Chiu HP. Drug-induced akathisia revisited. Br J Clin Pract 1996;50:270-8.
15. Keck P, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripriprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
HISTORY: ‘Bizarre’ days
Ms. K, age 45, is brought to the ER by her brother, who reports she has been acting “bizarre and crazy” for 3 days. He says his sister—who has bipolar I disorder— has had trouble sleeping, is restless, hears voices, and is contemplating suicide. He adds she was discharged from a psychiatric hospital 2 weeks ago after a 3-month stay.
Risperidone, 2 mg nightly, was controlling Ms. K’s mania until this recent episode. According to her brother, she also has developed continuous involuntary leg and arm movements and cannot sit or stand still. When she tries to sleep, her feet sway back and forth in bed for hours.
We admit Ms. K to the psychiatric inpatient unit because of her suicidality and hallucinations. She is restless and agitated during initial evaluation, pacing around the room or rocking her feet while standing or sitting. Her speech is pressured and the “voices” are urging her to kill herself.
Ms. K is dysphoric and severely distraught about her “nervousness” and continuous urges to move. She says she would rather die than live with incessantly “jittery” legs and arms, yet she wants to be discharged and denies that she is mentally ill. She believes decreased sleep is causing her symptoms and requests a “sleeping pill.”
she habitually views her medications as useless and stops taking them.
The patient has been hospitalized at least 4 times with severe manic and psychotic symptoms. She does not use illicit drugs and is medically healthy.
The authors’ observations
Ms. K’s involuntary movements suggest akathisia, a common extrapyramidal side effect of antipsychotics and other psychotropics (Table).1
Akathisia is characterized by strong feelings of inner restlessness that manifest as excessive walking or pacing and difficulty remaining still. Ms. K’s movements met at least 2 of 5 DSM-IV-TR criteria for acute akathisia (Box). ,2
Akathisia is characterized by at least 5 subtypes: 3
- Acute akathisia begins hours or days after starting the offending medication and lasts
- Tardive is similar to acute akathisia but can arise within 3 to 4 months of starting the offending medication and persists for years.
- Chronic akathisia lasts ≥3 months and usually has no temporal correlation with antipsychotic initiation or dosage increase.4
- Withdrawal akathisia begins within 6 weeks of discontinuing a medication or significantly reducing the dosage.
- Pseudo akathisia consists of objective symptoms of movement without subjective awareness or distress. This subtype usually is seen in older patients.
history of medication nonadherence strongly suggest akathisia secondary to risperidone withdrawal.5 Several
cases of akathisia after risperidone cessation have been reported.5
We know risperidone is not causing acute akathisia because Ms. K responded well to the medication during her last hospitalization with no adverse effects. Also, her family confirmed that she stopped taking risperidone after her most recent discharge.
Mania also can fuel incessant movement and increase physical activity, but patients often do not realize they have a problem while in a manic phase. Also, swinging and rocking of legs is rarely seen in mania. By contrast, Ms. K was morbidly distraught over her akathisia.
Table
Drugs that can cause akathisia
|
The authors’ observations
Numerous treatments are available for akathisia:
Beta blockers such as propranolol are most widely used because of their rapid onset of action and overall effectiveness in akathisia.3 Researchers believe these drugs reduce extrapyramidal symptoms (EPS) by blocking the adrenergic system. Propranolol can be used at a maximum 120 mg/d in divided doses.
Beta blockers, however, can cause bradycardia, hypotension, or respiratory distress. Use beta blockers with caution, and monitor for these adverse effects.
Benzodiazepines. Clonazepam, which enhances the inhibitory effect of GABA in the brain, is commonly used for akathisia because of its effectiveness and long elimination half-life3 (30 to 40 hours), which decreases the risk of medication withdrawal.
and disinhibition-induced aggression in all patients.
Anticholinergics such as trihexyphenidyl are more commonly used for EPS associated with parkinsonian symptoms or side effects but can be partially effective for akathisia.3 Anticholinergics block the CNS cholinergic activity that causes parkinsonian symptoms.
Cyproheptadine, clonidine, and mianserin have shown some positive results against akathisia in clinical trials.6-8 Iron, nicotine patches, and amantadine have shown limited effectiveness against akathisia in research studies and case reports.3,9
Restarting risperidone at a lower dosage—rather than adding a medication— might have resolved Ms. K’s akathisia, but because she was morbidly despondent over her akathisia, we felt we had no time to experiment. We also believed Ms. K’s would respond well to a neuroleptic with a lower EPS risk—such as quetiapine.1,10
A. Subjective complaints of restlessness after exposure to neuroleptics
B. At least 1 of the following is observed:
- Fidgety movements or swinging of the legs
- Rocking from foot to foot while standing
- Pacing to relieve restlessness
- Inability to sit or stand still for at least several minutes
C. Symptoms develop within 4 weeks of starting or raising the dosage of a neuroleptic or after reducing a medication used to treat extrapyramidal symptoms
D. Criterion A symptoms are not better accounted for by a mental disorder
E. Criterion A symptoms are not caused by a nonneuroleptic or a general medical condition
Source: Adapted from reference 2 with permission
TREATMENT: Trying trials
We perform a complete medical workup to rule out an underlying medical problem. We then start valproic acid, 500 mg bid, for Ms. K’s mania; quetiapine, 50 mg bid, for psychosis and mania; and propranolol, 30 mg bid, for akathisia.
We titrate quetiapine by 100 mg/d every 2 days to 400 mg/d, but after 10 days her akathisia, irritable mood, decreased sleep, and suicidal thoughts persist. We cannot increase propranolol because her blood pressure is 90/60 mm Hg, and adding lorazepam, 0.5 mg tid, does not control her movements. Three days later, we add trihexyphenidyl, 5 mg bid.
Fifteen days after admission, Ms. K remains akathisic, dysphoric, and suicidal despite a 5-drug regimen. Her “nervousness” prevents her from attending groups or other unit activities, and her uncontrollable foot swaying still keeps her awake at night.
The authors’ observations
Neither propranolol, clonazepam, nor trihexyphenidyl alleviated Ms. K’s akathisia. Switching to another neuroleptic with a relatively low EPS risk—such as olanzapine—might help. Olanzapine reduced akathisia in 3 case reports,11 and we hope its strong anticholinergic and antiserotonergic action will help resolve Ms. K’s akathisia.
with patients receiving therapeutic dosages of risperidone.12 In another study, olanzapine showed anticholinergic activity at therapeutic doses but risperidone did not.13 Researchers believe these features reduce olanzapine’s EPS risk compared with other antipsychotics.
TREATMENT: Drug works, but …
Three weeks after Ms. K’s presentation, we stop all psychotropics, start olanzapine, 10 mg nightly, for psychosis and mania, and continue propranolol, 30 mg bid, for akathisia. Within 2 days, Ms. K’s akathisia improves significantly.
We also start lithium, 150 mg bid, for mania, and increase it 4 days later to 300 mg bid to maintain serum lithium at approximately 1 mEq/L. We check serum lithium every 3 days after dosage adjustment. Although lithium can induce akathisia, we thought it would most effectively control her mania.
Six days after we started the new medications, Ms. K’s mania and psychosis begin to improve and she becomes euthymic. She is able to sit calmly during group therapy and community meetings.
Ten days after we start olanzapine and lithium, Ms. K appears bloated. Weight check shows an approximate 5-lb weight gain since starting the medications, both of which can cause weight gain and other metabolic side effects.
At Ms. K’s request, we stop olanzapine and start aripiprazole, 5 mg/d, to try to control her weight gain. We continue lithium and propranolol, which have been controlling her mood and akathisia. The next day—after 1 dose of aripiprazole—her akathisia returns.
The authors’ observations
Because aripiprazole was started as soon as olanzapine was discontinued, it is unclear which action aggravated Ms. K’s akathisia or if both were to blame.
Akathisia’s underlying cause is uncertain. Researchers believe dopamine receptor blockade in the mesocortical dopamine system might be responsible.3 Positron-emission tomography studies suggest that D2 receptor occupancy in the striatum contributes to akathisia, and noradrenergic and serotonergic systems also play a role.3,14
Antipsychotics, antidepressants, and sympathomimetics all have been implicated in akathisia, but antipsychotics that are potent serotonin (5HT) receptor antagonists—such as olanzapine and clozapine—show a lower incidence compared with other psychotropic agents.3
Aripiprazole—a partial D2 and 5HT1A receptor agonist and 5HT2 receptor antagonist—could have caused Ms. K’s akathisia. In 1 study, 11% of patients receiving aripiprazole, 15 to 30 mg/d, for acute mania reported akathisia symptoms.15
Olanzapine cessation could have caused Ms. K’s akathisia, although no cases of akathisia secondary to olanzapine withdrawal have been reported. Alternatively, olanzapine could have interacted with lithium to block lithium’s ability to induce akathisia.
TREATMENT: Back to olanzapine
After we thoroughly discuss olanzapine’s risks and benefits with Ms. K, she consents to switch back to olanzapine, 10 mg/d. We also instruct her to exercise daily and strictly control her diet after discharge.
Ms. K’s akathisia improves dramatically within 1 to 2 days, and her psychosis and mania improve gradually. Her persistent delusions and hallucinations are less intense, although she is still concocting grandiose get-rich-quick schemes.
Ten days after this latest dosage change, we discharge Ms. K on olanzapine, 10 mg/d, and lithium, 300 mg bid. She has no akathisia symptoms, and we arrange placement in an adult home where a psychiatrist sees her regularly. Three years later, she has been lost to follow-up.
Related resource
- AkathisiaSupport.org. Online resource offers links to articles describing causes of and treatments for akathisia subtypes. www.akathisiasupport.org.
- Aripiprazole • Abilify
- Carbidopa/levodopa • Stalevo, Parcopa
- Clonazepam • Klonopin
- Clonidine • Catapres
- Cyproheptadine • Periactin
- Ethosuximide • Zarontin
- Lithium • Eskalith, others
- Lorazepam • Ativan
- Metoclopramide • Reglan
- Olanzapine • Zyprexa
- Quetiapine • Seroquel
- Reserpine • various
- Risperidone • Risperdal
- Trihexyphenidyl • Artane
- Valproic acid • Depakote
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
HISTORY: ‘Bizarre’ days
Ms. K, age 45, is brought to the ER by her brother, who reports she has been acting “bizarre and crazy” for 3 days. He says his sister—who has bipolar I disorder— has had trouble sleeping, is restless, hears voices, and is contemplating suicide. He adds she was discharged from a psychiatric hospital 2 weeks ago after a 3-month stay.
Risperidone, 2 mg nightly, was controlling Ms. K’s mania until this recent episode. According to her brother, she also has developed continuous involuntary leg and arm movements and cannot sit or stand still. When she tries to sleep, her feet sway back and forth in bed for hours.
We admit Ms. K to the psychiatric inpatient unit because of her suicidality and hallucinations. She is restless and agitated during initial evaluation, pacing around the room or rocking her feet while standing or sitting. Her speech is pressured and the “voices” are urging her to kill herself.
Ms. K is dysphoric and severely distraught about her “nervousness” and continuous urges to move. She says she would rather die than live with incessantly “jittery” legs and arms, yet she wants to be discharged and denies that she is mentally ill. She believes decreased sleep is causing her symptoms and requests a “sleeping pill.”
she habitually views her medications as useless and stops taking them.
The patient has been hospitalized at least 4 times with severe manic and psychotic symptoms. She does not use illicit drugs and is medically healthy.
The authors’ observations
Ms. K’s involuntary movements suggest akathisia, a common extrapyramidal side effect of antipsychotics and other psychotropics (Table).1
Akathisia is characterized by strong feelings of inner restlessness that manifest as excessive walking or pacing and difficulty remaining still. Ms. K’s movements met at least 2 of 5 DSM-IV-TR criteria for acute akathisia (Box). ,2
Akathisia is characterized by at least 5 subtypes: 3
- Acute akathisia begins hours or days after starting the offending medication and lasts
- Tardive is similar to acute akathisia but can arise within 3 to 4 months of starting the offending medication and persists for years.
- Chronic akathisia lasts ≥3 months and usually has no temporal correlation with antipsychotic initiation or dosage increase.4
- Withdrawal akathisia begins within 6 weeks of discontinuing a medication or significantly reducing the dosage.
- Pseudo akathisia consists of objective symptoms of movement without subjective awareness or distress. This subtype usually is seen in older patients.
history of medication nonadherence strongly suggest akathisia secondary to risperidone withdrawal.5 Several
cases of akathisia after risperidone cessation have been reported.5
We know risperidone is not causing acute akathisia because Ms. K responded well to the medication during her last hospitalization with no adverse effects. Also, her family confirmed that she stopped taking risperidone after her most recent discharge.
Mania also can fuel incessant movement and increase physical activity, but patients often do not realize they have a problem while in a manic phase. Also, swinging and rocking of legs is rarely seen in mania. By contrast, Ms. K was morbidly distraught over her akathisia.
Table
Drugs that can cause akathisia
|
The authors’ observations
Numerous treatments are available for akathisia:
Beta blockers such as propranolol are most widely used because of their rapid onset of action and overall effectiveness in akathisia.3 Researchers believe these drugs reduce extrapyramidal symptoms (EPS) by blocking the adrenergic system. Propranolol can be used at a maximum 120 mg/d in divided doses.
Beta blockers, however, can cause bradycardia, hypotension, or respiratory distress. Use beta blockers with caution, and monitor for these adverse effects.
Benzodiazepines. Clonazepam, which enhances the inhibitory effect of GABA in the brain, is commonly used for akathisia because of its effectiveness and long elimination half-life3 (30 to 40 hours), which decreases the risk of medication withdrawal.
and disinhibition-induced aggression in all patients.
Anticholinergics such as trihexyphenidyl are more commonly used for EPS associated with parkinsonian symptoms or side effects but can be partially effective for akathisia.3 Anticholinergics block the CNS cholinergic activity that causes parkinsonian symptoms.
Cyproheptadine, clonidine, and mianserin have shown some positive results against akathisia in clinical trials.6-8 Iron, nicotine patches, and amantadine have shown limited effectiveness against akathisia in research studies and case reports.3,9
Restarting risperidone at a lower dosage—rather than adding a medication— might have resolved Ms. K’s akathisia, but because she was morbidly despondent over her akathisia, we felt we had no time to experiment. We also believed Ms. K’s would respond well to a neuroleptic with a lower EPS risk—such as quetiapine.1,10
A. Subjective complaints of restlessness after exposure to neuroleptics
B. At least 1 of the following is observed:
- Fidgety movements or swinging of the legs
- Rocking from foot to foot while standing
- Pacing to relieve restlessness
- Inability to sit or stand still for at least several minutes
C. Symptoms develop within 4 weeks of starting or raising the dosage of a neuroleptic or after reducing a medication used to treat extrapyramidal symptoms
D. Criterion A symptoms are not better accounted for by a mental disorder
E. Criterion A symptoms are not caused by a nonneuroleptic or a general medical condition
Source: Adapted from reference 2 with permission
TREATMENT: Trying trials
We perform a complete medical workup to rule out an underlying medical problem. We then start valproic acid, 500 mg bid, for Ms. K’s mania; quetiapine, 50 mg bid, for psychosis and mania; and propranolol, 30 mg bid, for akathisia.
We titrate quetiapine by 100 mg/d every 2 days to 400 mg/d, but after 10 days her akathisia, irritable mood, decreased sleep, and suicidal thoughts persist. We cannot increase propranolol because her blood pressure is 90/60 mm Hg, and adding lorazepam, 0.5 mg tid, does not control her movements. Three days later, we add trihexyphenidyl, 5 mg bid.
Fifteen days after admission, Ms. K remains akathisic, dysphoric, and suicidal despite a 5-drug regimen. Her “nervousness” prevents her from attending groups or other unit activities, and her uncontrollable foot swaying still keeps her awake at night.
The authors’ observations
Neither propranolol, clonazepam, nor trihexyphenidyl alleviated Ms. K’s akathisia. Switching to another neuroleptic with a relatively low EPS risk—such as olanzapine—might help. Olanzapine reduced akathisia in 3 case reports,11 and we hope its strong anticholinergic and antiserotonergic action will help resolve Ms. K’s akathisia.
with patients receiving therapeutic dosages of risperidone.12 In another study, olanzapine showed anticholinergic activity at therapeutic doses but risperidone did not.13 Researchers believe these features reduce olanzapine’s EPS risk compared with other antipsychotics.
TREATMENT: Drug works, but …
Three weeks after Ms. K’s presentation, we stop all psychotropics, start olanzapine, 10 mg nightly, for psychosis and mania, and continue propranolol, 30 mg bid, for akathisia. Within 2 days, Ms. K’s akathisia improves significantly.
We also start lithium, 150 mg bid, for mania, and increase it 4 days later to 300 mg bid to maintain serum lithium at approximately 1 mEq/L. We check serum lithium every 3 days after dosage adjustment. Although lithium can induce akathisia, we thought it would most effectively control her mania.
Six days after we started the new medications, Ms. K’s mania and psychosis begin to improve and she becomes euthymic. She is able to sit calmly during group therapy and community meetings.
Ten days after we start olanzapine and lithium, Ms. K appears bloated. Weight check shows an approximate 5-lb weight gain since starting the medications, both of which can cause weight gain and other metabolic side effects.
At Ms. K’s request, we stop olanzapine and start aripiprazole, 5 mg/d, to try to control her weight gain. We continue lithium and propranolol, which have been controlling her mood and akathisia. The next day—after 1 dose of aripiprazole—her akathisia returns.
The authors’ observations
Because aripiprazole was started as soon as olanzapine was discontinued, it is unclear which action aggravated Ms. K’s akathisia or if both were to blame.
Akathisia’s underlying cause is uncertain. Researchers believe dopamine receptor blockade in the mesocortical dopamine system might be responsible.3 Positron-emission tomography studies suggest that D2 receptor occupancy in the striatum contributes to akathisia, and noradrenergic and serotonergic systems also play a role.3,14
Antipsychotics, antidepressants, and sympathomimetics all have been implicated in akathisia, but antipsychotics that are potent serotonin (5HT) receptor antagonists—such as olanzapine and clozapine—show a lower incidence compared with other psychotropic agents.3
Aripiprazole—a partial D2 and 5HT1A receptor agonist and 5HT2 receptor antagonist—could have caused Ms. K’s akathisia. In 1 study, 11% of patients receiving aripiprazole, 15 to 30 mg/d, for acute mania reported akathisia symptoms.15
Olanzapine cessation could have caused Ms. K’s akathisia, although no cases of akathisia secondary to olanzapine withdrawal have been reported. Alternatively, olanzapine could have interacted with lithium to block lithium’s ability to induce akathisia.
TREATMENT: Back to olanzapine
After we thoroughly discuss olanzapine’s risks and benefits with Ms. K, she consents to switch back to olanzapine, 10 mg/d. We also instruct her to exercise daily and strictly control her diet after discharge.
Ms. K’s akathisia improves dramatically within 1 to 2 days, and her psychosis and mania improve gradually. Her persistent delusions and hallucinations are less intense, although she is still concocting grandiose get-rich-quick schemes.
Ten days after this latest dosage change, we discharge Ms. K on olanzapine, 10 mg/d, and lithium, 300 mg bid. She has no akathisia symptoms, and we arrange placement in an adult home where a psychiatrist sees her regularly. Three years later, she has been lost to follow-up.
Related resource
- AkathisiaSupport.org. Online resource offers links to articles describing causes of and treatments for akathisia subtypes. www.akathisiasupport.org.
- Aripiprazole • Abilify
- Carbidopa/levodopa • Stalevo, Parcopa
- Clonazepam • Klonopin
- Clonidine • Catapres
- Cyproheptadine • Periactin
- Ethosuximide • Zarontin
- Lithium • Eskalith, others
- Lorazepam • Ativan
- Metoclopramide • Reglan
- Olanzapine • Zyprexa
- Quetiapine • Seroquel
- Reserpine • various
- Risperidone • Risperdal
- Trihexyphenidyl • Artane
- Valproic acid • Depakote
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Sadock BJ, Sadock VA. Biological therapies (chapter 36). Kaplan & Sadock’s synopsis of psychiatry: behaviorial sciences/clinical psychiatry, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:1110.
2. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
3. Nelson DE. Akathisia—a brief review. Scott Med J 2001;46:133-4.
4. Sachdev P. The epidemiology of drug-induced akathisia: part II. Chronic, tardive and withdrawal akathisias. Schizophr Bull 1995;21:451-60.
5. Bertolín Guillén JM, Martínez Franco L, Juni Anahuja J. Akathisia due to risperidone withdrawal: two clinical cases [in Spanish]. Actas Esp Psiquiatr 2002;30:195-7.
6. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-6.
7. Poyurovsky M, Kreinin A, Modai I, Weizman A. Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmacol 1995;10:261-3.
8. Poyurovsky M, Shardorodsky M, Fuchs C, et al. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 1999;174:238-42.
9. Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 1997;134:153-6.
10. Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): not different from placebo for EPS or prolactin. Biol Psychiatry 1996;39:598.-
11. Yousaf F, Fialho A, Warden M. Akathisia treated with olanzapine: three case reports. Int J Psychiatry Clin Pract 2004;8:123-5(3).
12. Lavalaye J, Booij J, Linszen DH, et al. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001;156:53-7.
13. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.
14. Chung WS, Chiu HP. Drug-induced akathisia revisited. Br J Clin Pract 1996;50:270-8.
15. Keck P, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripriprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
1. Sadock BJ, Sadock VA. Biological therapies (chapter 36). Kaplan & Sadock’s synopsis of psychiatry: behaviorial sciences/clinical psychiatry, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:1110.
2. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
3. Nelson DE. Akathisia—a brief review. Scott Med J 2001;46:133-4.
4. Sachdev P. The epidemiology of drug-induced akathisia: part II. Chronic, tardive and withdrawal akathisias. Schizophr Bull 1995;21:451-60.
5. Bertolín Guillén JM, Martínez Franco L, Juni Anahuja J. Akathisia due to risperidone withdrawal: two clinical cases [in Spanish]. Actas Esp Psiquiatr 2002;30:195-7.
6. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-6.
7. Poyurovsky M, Kreinin A, Modai I, Weizman A. Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmacol 1995;10:261-3.
8. Poyurovsky M, Shardorodsky M, Fuchs C, et al. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 1999;174:238-42.
9. Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 1997;134:153-6.
10. Hong WW, Arvanitis LA, Miller BG. ‘Seroquel’ (ICI 204,636): not different from placebo for EPS or prolactin. Biol Psychiatry 1996;39:598.-
11. Yousaf F, Fialho A, Warden M. Akathisia treated with olanzapine: three case reports. Int J Psychiatry Clin Pract 2004;8:123-5(3).
12. Lavalaye J, Booij J, Linszen DH, et al. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001;156:53-7.
13. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.
14. Chung WS, Chiu HP. Drug-induced akathisia revisited. Br J Clin Pract 1996;50:270-8.
15. Keck P, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripriprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.